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ABSTRACT
PCB-ASSOCIATED STEATOHEPATITIS AND THE ROLE OF NUCLEAR RECEPTORS
Heather B. Clair
May 17, 2017
Metabolic diseases, including fatty liver disease, hyperglycemia, and obesity, result when
body systems responsible for managing allostasis (dynamic homeostasis across systems) are
pressured beyond their collective compensatory reserve. Nutritional excess contributes to this
state, the capacity of which is limited by genetic variation, and failure of one system will gradually
lead to pathological overload in the others. Agents which act directly on the communication
machinery linking these connected systems can also change the point at which allostatic load
becomes allostatic overload. Environmental exposure to polychlorinated biphenyls (PCBs), a
class of persistent organic pollutant, is associated with a specific form of toxicant-associated
steatohepatitis, fatty liver disease with inflammatory infiltration. PCBs are known to be ligands
for the xenobiotic receptors, which, when activated, modulate the transcription of both xenobiotic
and intermediary metabolic targets. We investigated the prevalence and characteristics of liver
disease in a human population with high environmental PCB exposure, transcriptional changes in
the liver in a mouse model of PCB/high-fat diet coexposure, and transcriptional changes
attributable to xenobiotic receptors in a primary hepatocyte model.

v

TABLE OF CONTENTS
PAGE
ACKNOWLEDGEMENTS ........................................................................................................ X
ABSTRACT .............................................................................................................................. X
LIST OF TABLES ..................................................................................................................... X
LIST OF FIGURES................................................................................................................... X
BACKGROUND ....................................................................................................................... 1
CHAPTER ONE: PCBs are associated with toxicant-associated steatohepatitis,
inflammation, and metabolic dysregulation in an exposed human population ........................ 24
MATERIALS AND METHODS .................................................................................... 29
RESULTS.................................................................................................................... 36
DISCUSSION .............................................................................................................. 71
CHAPTER TWO: PCBs induce differential transcription in liver tissue from a mouse model of
chronic PCB/dietary coexposure.............................................................................................. 79
MATERIALS AND METHODS .................................................................................... 81
RESULTS.................................................................................................................... 86
DISCUSSION .............................................................................................................. 133
CHAPTER THREE: PCB exposure induces a differential transcriptome which
partially overlaps with that of prototypical xenobiotic receptor ligands in a mouse primary
hepatocyte model ..................................................................................................................... 138
MATERIALS AND METHODS .................................................................................... 140
RESULTS.................................................................................................................... 143
DISCUSSION .............................................................................................................. 156
CONCLUSIONS ....................................................................................................................... 162
REFERENCES......................................................................................................................... 181
APPENDIX
Appendix Table 1. Fold change and summary information for 123 targets differentially
transcribed with Aroclor 1260 exposure compared to prototypical ligand exposure .......... 213
CURRICULUM VITA ................................................................................................................ 237

vi

LIST OF TABLES
TABLE

PAGE

1. Composition of commercial Aroclor mixtures by PCB homolog group ................................ 5
2. Structural/functional groupings of PCB congeners measured in ACHS-II ........................... 11
3. 2003-2004 NHANES data – AOR for unexplained ALT elevation by
exposure quartile...................................................................................................................... 15
4. Criteria for the diagnosis of Metabolic Syndrome (MS/CVD and IR/T2DM) ....................... 21
5. PCB congeners associated with AOR for unexplained ALT elevations in
NHANES 2003-2004 ................................................................................................................ 28
6. Demographics in ACHS by liver disease status – continuous variables ............................. 37
7. Demographics in ACHS by liver disease status – biometric categorical variables .............. 38
8. Demographics in ACHS by liver disease status – lifestyle categorical variables. ............... 39
9. Demographics in ACHS-II by liver disease status – continuous variables. ......................... 40
10. Demographics in ACHS-II by liver disease status – biometric categorical variables ........ 41
11: Demographics in ACHS-II by liver disease status – health and lifestyle
categorical variables. ............................................................................................................... 42
12: Demographic characteristics and liver disease status of ACHS microRNA subcohort ..... 43
13: Univariate associations between demographic/exposure variables and the serum
cytokeratin 18 M65 and M30 biomarkers used to categorize liver disease status .................. 44
14: Unadjusted ACHS biomarker levels by liver disease status .............................................. 46
15: Adjusted beta coefficients of associations of ƩPCBs (wet weight) and liver
status with inflammatory biomarkers ....................................................................................... 48
16: Adjusted beta coefficients of associations of ƩPCBs (wet weight) and liver status
with metabolic biomarkers ...................................................................................................... 49
17: ACHS validation – miRNA data by CK18 liver disease group .......................................... 51
18: Adjusted beta coefficients of CK18 and miRNA levels ..................................................... 52
19: ACHS-II validation – LFTs by CK18 liver disease group .................................................. 53

vii

20: Cutoff values for upper limit of normal for the clinical liver injury biomarker alanine
aminotransferase (ALT) ........................................................................................................... 55
21: Effects of PCBs and BMI on liver disease status by multinomial logistic regression ........ 56
22: PCB groupings and CK18 liver disease status in ACHS and ACHS-II .............................. 57
23: Significant associations of ƩPCBs and miRNA species .................................................... 58
24: ACHS adjusted beta coefficients of significant associations of liver disease
status and CK18 biomarkers by individual PCB congeners .................................................... 60
25: TEQ for dioxin-like PCBs and other dioxin-like species and CK18-indicated
liver disease status in ACHS-II ................................................................................................ 62
26: Adjusted beta coefficients of significant associations of various TEQ summations
and CK18 biomarkers in ACHS-II ............................................................................................ 63
27: Unadjusted ACHS-II biomarker levels by sum of all PCBs (ƩPCBs) sum of
35 ortho-substituted congeners (ƩPCB-O) and all non-dioxin-like congeners (ƩNDL) ........... 65
28: Unadjusted ACHS-II biomarker levels by groups of ortho-substituted PCBs .................... 66
29: Unadjusted ACHS-II biomarker levels by groups of non-ortho-substituted
and dioxin-like PCBs ................................................................................................................ 67
30: ACHS adjusted beta coefficients of associations of ƩPCBs (wet weight)
with biomarkers ........................................................................................................................ 69
31: Adjusted beta coefficents of significant associations of PCB congeners with
biomarkers of glucose metabolism .......................................................................................... 70
32: in vivo experiment dataset properties ................................................................................ 85
33: Enrichments for genes differentially transcribed in comparison CVvsC20 ........................ 87
34: Enrichments for genes differentially transcribed in comparison CVvsC200 ...................... 88
35: Enrichments for genes differentially transcribed in comparison HVvsH20 ........................ 89
36: Enrichments for genes differentially transcribed in comparison HVvsH200 ...................... 90
37: Enrichments for genes differentially transcribed in comparison CVvsHV.......................... 91
38: Enrichments for genes differentially transcribed in comparison C20vsH20 ...................... 92
39: Enrichments for genes differentially transcribed in comparison C200vsH200 .................. 93
40: Common targets between moderate/high PCB exposure levels within the
control diet groups.................................................................................................................... 97

viii

41: Common targets between moderate/high PCB exposure levels within the
high-fat diet groups .................................................................................................................. 98
42: Common targets between all PCB exposure levels within diet comparisons .................... 101
43: Enrichments for liver and metabolic disease endpoints in comparison CVvsC20 ............. 102
44: Enrichments for liver and metabolic disease endpoints in comparison CVvsC200 ........... 103
45: Enrichments for liver and metabolic disease endpoints in comparison HVvsH20 ............. 104
46: Enrichments for liver and metabolic disease endpoints in comparison HVvsH200 ........... 105
47: Targets associated with liver disease enrichments and change vs. vehicle control by
comparison ............................................................................................................................... 106
48: Targets associated with metabolic disease enrichments (overnutrition/obesity)
and their change vs. vehicle control in each comparison ........................................................ 110
49: Targets associated with metabolic disease enrichments (Type 2 Diabetes Mellitus)
and their change vs. vehicle control in each comparison ........................................................ 113
50: Targets associated with metabolic disease enrichments (Metabolic Syndrome)
and their change vs. vehicle control in each comparison ........................................................ 116
51: Targets associated with metabolic disease enrichments (insulin resistance)
and their change vs. vehicle control in each comparison ........................................................ 118
52: Top ten transcription factor enrichments for condition CVvsC20 ...................................... 121
53: Top ten transcription factor enrichments for condition CVvsC200 .................................... 122
54: Top ten transcription factor enrichments for condition HVvsH20 ...................................... 123
55: Top ten transcription factor enrichments for condition HVvsH200 .................................... 124
56: Percent activation for engaged transcription factors identified in all conditions ................ 125
57: Percent activation for engaged transcription factors identified in 1-3 conditions ............... 126
58: Treatment summary ........................................................................................................... 141
59: Targets differentially regulated with Aroclor 1260 exposure .............................................. 145
60: Concordance in direction of differential transcription between PCB-DTGs
and prototypical ligand DTGs ................................................................................................... 150
61: Fold induction of protypical targets for AhR, PXR, and CAR with prototypical
ligand exposure ........................................................................................................................ 151
62: Enriched pathways for PCB-DTG set ................................................................................ 153

ix

63: Transcription factors with targets in the PCB-dependent differentiallytranscribed gene set................................................................................................................. 155
64: Differentially transcribed circadian-rhythm related targets from in vivo and
in vitro experiments .................................................................................................................. 169

x

LIST OF FIGURES
FIGURE

PAGE

1. Basic structure of a polychlorinated biphenyl ...................................................................... 4
2. Structural characteristics of PCBs compared to TCDD and other dioxin-like chemicals..... 9
3. Equations for calculated parameters in human epidemiological studies ............................. 14
4: Distribution of ortho/non-ortho structures within homolog groups ....................................... 17
5: Origin and detection of cytokeratin 18 in serum samples .................................................... 26
6: ƩPCBs were inversely associated with metabolic biomarkers in ACHS.............................. 64
7. Distribution of ALT levels in ACHS by liver disease category ............................................. 73
8. PCB exposure and high-fat diet induce phenotypic changes in C57/BL6 mice................... 82
9: Moderate and high PCB exposures produce overlapping DTG sets (vs. vehicle) .............. 95
10: Comparison of PCB/diet interactions ................................................................................. 99
11. IL-6-mediated acute-phase response in hepatocytes ........................................................ 107
12. IL-6/STAT-3 signaling pathways ........................................................................................ 108
13. Transcription factors regulated by PXR or PXR/RXR via protein-protein
interactions ............................................................................................................................... 127
14. Nipk/Trib3 signaling pathways downstream of PPAR-alpha ............................................. 129
15. Arnt/Bmal1 pathway related to circadian signaling ............................................................ 130
16. Claudin-1 and e-cadherin pathways related to EMT.......................................................... 132
17. Summary of transcriptional differences between groups ................................................... 134
18. Histograms of differential transcriptomes produced by PCB/prototypical
ligand exposure ........................................................................................................................ 144
19. Venn diagram showing the overlapping differential gene sets between PCB
and prototypical ligand exposures ........................................................................................... 147
20. A portion of the PCB-DTG overlapped with DTGs for AhR, PXR, CAR and
LXR prototypical ligands. ......................................................................................................... 148

xi

21. Pathways related to EMT were enriched in genes in the PCB-DTG set ........................... 154
22. Exposure to PCB with or without HFD coexposure alters transcription of
multiple components of IL-6 signaling...................................................................................... 165
23. Ephrin ligand A1 (Efna1) was differentially regulated in multiple comparisons ................ 172
24. Ephrin ligand A5 (Efna5) was differentially regulated in multiple comparisons ................. 173
25. Ephrin receptor B2 (EphB2) was differentially regulated in multiple comparisons ............ 174
26. in vivo comparison diagrams ............................................................................................. 179

xii

BACKGROUND

Toxicant-associated steatohepatitis (TASH) is a term applied to a unique subset of
nonalcoholic fatty liver disease (NAFLD) related to chemical exposures. Though the liver is
known to be a primary target in many industrial chemical exposures, environmental chemical
exposures represent a much more widespread and insidious threat to liver health. Persistent
organic pollutants (POPs) are lipophilic, and while some compounds are metabolized, relatively
unmetabolizable chemicals distribute to fat depots of exposed biota. Consumption of these
POPs-bearing biota represents the major route of environmental toxicant exposure for humans
and other apex consumers. Consequently, even though the same classes of chemicals may be
involved in industrial and environmental exposures, an environmental toxicant exposome is
acquired slowly throughout the life cycle and is enriched in less metabolizable chemicals, while
an industrially-acquired exposome more likely involves higher levels of more readily metabolized
chemicals acquired acutely by adults. This is an important consideration, because the same
endpoints are used to evaluate toxicity in either case, but the differences in acquisition timeframe
and composition may render the effects of chronic exposures subclinical and change toxicity
mechanisms. These differences can affect the biomarkers used for screening assays, hindering
diagnosis and treatment of TAFLD and TASH at earlier, more reversible stages and thereby
masking the extent of liver injury.
The class of POPs collectively referred to as polychlorinated biphenyls (PCBs) typify the
most challenging aspects of research in environmentally-acquired toxicant exposures. 1)
Because of their chemical stability, PCBs continue to persist in the environment and in the tissues
of humans decades after discontinuation of production. 2) PCBs are a class of chemicals
invariably encountered as mixtures both in industrial and environmental exposures, and the
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structures present within those mixtures are diverse enough that they are likely to have multiple
and potentially overlapping or competing mechanisms of toxicity. 3) Although compositions of
these mixtures have been exhaustively documented in production, the environment, and in the
tissues of biota including humans, for historical and political reasons, both the mixtures
themselves and their effects are still often summarized by a single component which assumes
one mechanism: in this case the subset of congeners bearing structural similarity to dioxins and
expected to act as arylhydrocarbon receptor (AhR) agonists. 4) The direct effects of chronic, lowlevel PCB exposures differ from the more thoroughly evaluated effects of high-level, industrial
exposures – likely because different distributions of congeners drive different engagement of
xenobiotic receptors. 5) The ultimate effects of chronic PCB exposure-related TASH have great
potential to be modulated or exacerbated by long-term nutritional coexposures, and race/ethnicity
and gender differences, and these differences are understudied. 6) PCBs, like other toxicants
associated with TASH, appear to cause a form of liver disease which is mechanistically and
diagnostically distinct from other forms of fatty liver disease, making its detection by typical
laboratory screening techniques difficult. These points may explain some characteristics which
frustrate the recognition of environmentally-acquired PCB impact on human health and hinder its
resolution.
PCBs remain a focus of environmental and human health research, occupying (in various
groupings) 3 out of the top 20 positions in the 2015 Substance Priority List published by the
Agency for Toxic Substances Disease Registry (ATSDR)1. We hypothesized that, in humans,
chronic environmental PCB exposure would be associated with increased liver injury biomarkers
indicating TASH. We furthermore hypothesized that PCB exposure in mice and primary mouse
hepatocytes would induce differential transcription of targets related to liver disease and that in
primary mouse hepatocytes, that differential transcription would overlap with the response to
prototypical ligands for specific xenobiotic receptors.
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Manufacture and chemical characteristics of PCBs
Every human health effect of PCBs must be evaluated in light of one critical
consideration: from the moment of manufacture to the moment of exposure, PCBs never exist as
a single chemical, but as a fluctuating mixture of related chemicals each with unique biological
and chemical properties. The basic structure of a PCB, shown in Figure 1, is that of a biphenyl
ring with as few as 1 or as many as 10 chlorine substitutions in various positions about the
molecule, leading to 209 potential congener configurations. PCBs were produced throughout the
world via ferric chloride-catalyzed chlorination of biphenyl. Three cities in the U.S. were sites for
commercial manufacture of PCBs: Anniston, AL from 1929-1930 (Swann Research, Inc.) and
1930-1971 (Monsanto, Inc.), Saguet, IL until 1977 (Monsanto, Inc.) and Houston, TX from 19721974 (Geneva Industries)2. PCBs were produced mainly for use as dielectric fluids in electrical
equipment, but were also used as lubricants, plasticizers, sealants and carriers in many products.
The desired material properties of chemical stability and low flammability offered by PCB mixtures
are related to the component structures and correspond roughly to the degree of chlorination.
PCBs produced by Monsanto, Inc. were marketed as mixtures called Aroclors, with a number
corresponding to the nominal average percent chlorine (e.g. Aroclor 1260 is approximately 60%
chlorine by weight)3.
This production and marketing methodology gives rise to one scheme for grouping PCBs:
PCB homologs are defined as sets of congeners with a common number of chlorine substitutions.
In addition to providing a way to estimate levels of total production, use and disposal of PCBs and
to equate these amounts with contamination levels, grouping by homologs allows the
appreciation of certain general characteristics and trends. More heavily substituted homologs
have higher average melting and boiling points, higher vapor pressure and are more miscible in
lipids (quantified as higher octanol-water partition coefficients) 3. Aroclor mixtures including
Aroclor 1260, 1254 and 1248 were composed mainly of higher-molecular weight homologs
(tetrachlorobiphenyl and above). Within each homolog group, PCB congeners with different
substitution patterns are referred to as isomers. The composition of commercial Aroclor mixtures
by PCB homolog group is shown in Table 1.
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Figure 1. Basic structure of a polychlorinated biphenyl.
The basic structure of a PCB is a biphenyl ring with 1-10 chlorine substitutions at carbons 2 (2’)
and 6 (6’). Substitutions in the ortho positions favor rotation of the rings relative to one another,
with the functional consequence of reduced coplanarity with each additional ortho substitution.
PCB congeners with less (tri, di, mono-ortho) or no ortho substitutions (non-ortho) assume an
increasingly more coplanar structure.
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Pentachlorobiphenyl
C12H4Cl6
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Serum (NHANES)

Composition of commercial Aroclor mixtures by PCB homolog group

Hexachlorobiphenyl
C12H3Cl7

Empirical
Formula

Heptachlorobiphenyl
C12H2Cl8
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2009), serum-ACHS(AA = African American/Black, NHW = Non-Hispanic White) (Pavuk et al., 2014), adipose (McFarland et al., 1989), liver,

muscle, kidney, and brain (Chu et al., 2003) by homolog is shown. The percent chlorine (by weight) is shown for each homolog group (column
3). The relative percent composition of several commercial Aroclor mixtures are shown in columns 4-10.
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PCB homolog group
name

Octachlorobiphenyl
C12H1Cl9

1221

71
1
2
2
1
Decachlorobiphenyl
C12Cl10
The composition of several commercial Aroclors (Erickson et al., 2015), and selected human tissues including serum-NHANES (Patterson et al.,

Nonachlorobiphenyl

% Chlorine (by weight)
In various homolog groups

Unsurprisingly, the environmental persistence of individual congeners within the mixture
is also related to structure. Weathering is a term applied to PCB mixtures undergoing profile
changes due to physical or chemical processes such as water washing, photodegradation,
volatilization, and evaporation. It can also refer to aerobic degradation due to microbial action.
Weathering disproportionately affects lighter molecular weight congeners, particularly mono-, di-,
and tri- substituted congeners, resulting in mixtures with proportionately more tetra- and pentasubstituted congeners4. Congeners bioaccumulating within the fatty tissue of exposed biota also
tend to be those with more chlorine substitutions, and are dependent on two properties related to
structure and influenced by degree of chlorination: resistance to non-metabolic clearance
(increased lipophilicity) and structural inaccessibility to metabolic machinery (substitution
pattern)5.
In summary, PCBs were manufactured to meet a demand for industrial fluids that were
highly stable, thermoresistant, and miscible in lipids, the same characteristics underlying the
persistence of PCBs in the environment. It is important to note, however, that PCB congeners
are not equally affected by processes of physical and chemical degradation, leading to changes
in the profile of PCB mixtures from manufacture to environmental substrates to eventual
bioaccumulation in humans. This is particularly critical to the design of models which reflect the
current PCB exposure conditions: uptake of weathered and pre-metabolized PCBs through
ingestion of contaminated biota.

Bioactivity of PCBs in mixtures with widespread relevance to human health
Over 80 years have elapsed since the initial reports of human toxicity from PCB
exposure3, 6, and in that time, substantial research efforts have been put toward understanding
the chemical composition and health effects of manufactured PCB mixtures and occupational
exposures7-12. While this work has been critical to characterizing human disease resulting from
industrial exposures, it has become somewhat obsolete for several reasons. First, except from a
standpoint of longitudinal health and mortality assessment, research modeled on occupational
PCB exposures is less relevant today because PCB production has been banned for 40 years,
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therefore, new occupational exposures no longer occur in the process of PCB manufacture.
Second, the most common route of exposure in humans is low-level, environmental acquisition
through ingestion of contaminated foodstuffs, and as congeners bioaccumulate at different rates,
PCBs which make up the current exposome are more likely to be higher-substituted, highlybioaccumulated and less metabolizable, generalizations which are reflected in assessments of
serum PCB levels in exposed populations. Third, emerging data on the impact of nutritional
coexposures suggests that the current obesity epidemic may significantly modulate the effects of
PCBs on human health. Thus, different PCBs may be exerting their effects in a different internal
environment currently than was explored in the original toxicity studies.
Early evaluation of the toxicity of PCBs focused on high-level exposures and acute
toxicity which modeled the human health effects seen in occupational exposures7-9, accidental
contamination from PCB-containing electrical equipment12, 13, and poisoning incidents such as the
Yusho and Yucheng9, 14, 15 events in which thousands of people in Japan and Taiwan
(respectively) were exposed to PCBs, dioxins and dibenzofurans through ingestion of rice oil
contaminated with a commercial PCB mixture. These incidents differ from the PCB exposure
experienced by most U.S. citizens in both scale and composition. Health consequences such as
chloracne (a noninflammatory skin condition characterized by cyst and closed comedone
development with sebaceous gland atrophy), immunosuppression, reproductive and
developmental effects, acute liver damage, and cancer were observed in some individuals within
these cohorts. Importantly, elevated liver enzyme activity and other biomarkers of these effects
were typically observed at very high exposures. This observation as well as a superficial
resemblance of this pattern of human health effects to the constellation of pathologies induced by
dioxins in laboratory animals16 led researchers to focus on a small subset of congeners within the
exposure mixture with a specific structural characteristic: absence of chlorine substitutions in the
four available ortho positions. This characteristic is related to but independent of the overall
degree of chlorination in the molecule. Chlorine substitutions at these ortho positions affect the
orientation of the rings relative to one another such that congeners with no substitutions in these
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positions are relatively coplanar, while increasing numbers of chlorine substitutions in these
positions increases the likelihood of a molecule with rings that are non-coplanar (perpendicular).
Coplanar PCBs share structural similarity to the molecule 2,3,7,8-tetrachlorodibenzo-pdioxin (TCDD), which is an extensively studied, potent agonist for the AhR. Structural
characteristics of PCBs compared to TCDD and other dioxin-like chemicals are shown in Figure
2. Coplanar PCBs, which can induce transactivation of targets under the control of a dioxin
response element (DRE), are considered dioxin-like (DL) PCBs, while increasing ortho
substitutions render a congener increasingly non-dioxin-like (NDL). The number of relatively
potent (non-ortho) dioxin-like congeners is constrained by the requirement for unsubstituted ortho
carbons (2, 2’, 4, and 4’) and becomes increasingly unlikely as the number of substitutions
increases, such that only 1 non-ortho congener (PCB 169) exists among hexachlorobiphenyls
and none exist among the higher molecular weight congeners.
Most research has focused on these dioxin-like congeners, which are present in only
trace amounts within most commercial PCB mixtures and found at extraordinarily low levels in the
tissues of exposed biota including humans. In rodent models, exposure to TCDD has been linked
to many of the disease endpoints listed above, including immunotoxicity, reproductive effects, and
cancer16, although the connection between TCDD and other dioxins and these effects in humans
is less clear17. Even chloracne, which is the only consistently-reported human health marker of
dioxin intoxication18, is not a clear outcome of AhR induction and does not follow AhR induction
by all ligands. Nevertheless, coplanar PCBs are also ligands for AhR, although they are much
less effective than prototypical ligand TCDD at inducing transcription of Cyp1a1, the prototypical
target of AhR, in vivo16.
NDL congeners are characterized by chlorine substitutions in the ortho positions, which
induce non-coplanarity. These congeners tend to be more resistant to degradation and
bioaccumulate to much higher levels. Historically, these congeners were dismissed as less toxic
to humans and of a lower priority in remediation and human health research16, however more
recently, the recognition that these congeners are ligand activators of other xenobiotic receptors
has led to a resurgence of interest. NDL congeners are direct ligands for the pregnane and
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Figure 2. Structural characteristics of PCBs compared to TCDD and other dioxin-like chemicals.
(Adapted from Int. J. Mol. Sci. 2014, 15(8), 14044‐14057.)

9

xenobiotic receptor (PXR) and the human constitutive androstane receptor isoforms 2 and 3
(hCAR2/3) but not human CAR isoform 1 (hCAR1), which is homologous to murine CAR
(mCAR)19. However, our laboratory recently reported that the both NDL and DL PCB congeners,
as well as the mixture Aroclor 1260, inhibit activation of the human and murine epidermal growth
factor receptor (EGFR), which provides an indirect mechanism for mCAR activation20, 21.
Importantly, though AhR, CAR, and PXR are considered xenobiotic receptors and most
research has focused on describing their role in the drug- or toxicant-dependent induction of
xenobiotic metabolic machinery, they are also involved in transcriptional control of intermediary
metabolism and inflammatory response. These functions may ultimately explain both the link
between PCB exposure and metabolic disruption and some complexities of diet/PCB
coexposures in metabolic disease. Our laboratory reported that, in mice, exposure to Aroclor
1260 alone was insufficient to induce a phenotype of steatohepatitis, and that a coexposure to
high fat diet was required to observe the phenotypes of fatty liver and diabetes22, 23.
Beyond the DL/NDL stratification, other groupings of PCB congeners reflect the ability of
individual congeners to alter the function of receptors such as the ryanodine receptor24-26,
estrogen receptor27, 28, and androgen receptor29, 30, shown in Table 2.
In summary, humans encounter PCBs not as individual chemicals, but as complex
mixtures of congeners, each of which has unique structural characteristics that influence stability
and bioaccumulation patterns as well as the mechanisms of biological effect. The composition of
PCB mixtures represented in historic occupational and accidental PCB intoxication events differs
significantly from the mixture accumulated slowly through chronic environmental exposure, and
this is likely to alter both the mechanism of effect and the phenotype. Therefore, experimental
designs which involve single congeners and risk-assessment algorithms which assume only one
mechanism are unlikely to realistically model the effect of environmental exposure.

Historic context for reliance on AhR induction estimates to define PCB toxicity
As stated above, although PCBs are encountered as complex mixtures with complex
effects, historically, the toxicity of PCBs was attributed entirely to AhR-mediated effects of dioxin-
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Table 2
Structural/functional groupings of PCB congeners measured in ACHS-II

Structural groupings
28, 44, 49, 52, 66, 74, 87, 99, 101, 105, 110,
118, 128, 138–158, 146, 149, 151, 153, 156,
157, 167, 170, 172, 177, 178, 180, 183, 187,
189, 194, 195, 196–203, 199, 206, 209
28, 44, 49, 52, 66, 74, 87, 99, 101, 105, 110,
118, 128, 138, 146, 149, 151, 153, 156, 157,
167,170, 172, 177, 178, 180, 183, 187, 189,
194, 195, 196, 199, 206, 209
149, 151, 177, 178, 183, 187, 195, 196-203,
199, 206, 209
44,49, 52, 87, 99, 101, 110, 128, 138-158, 146,
153, 170, 172, 180, 194
28, 66, 74, 105, 118, 156, 157, 167, 189
81, 126, 169

All (ƩPCB)

Ortho-Substituted (ƩPCB-O)

Tri- and Tetra-ortho (ƩPCB-TO)
Di-Ortho (ƩPCB-DO)
Mono-Ortho (ƩPCB-MO)
Non-Ortho (ƩPCB-NO)

Functional groupings
Dioxin-Like (ƩDL)

81, 105, 118, 156, 157, 167, 189, 126, 169

Non-Dioxin-Like (ƩNDL)

28, 44, 49, 52, 66, 74, 87, 99, 101, 110, 128,
138, 146, 149, 151, 153, 170, 172, 177, 178,
180, 183, 187, 194, 195, 196, 199, 206, 209

Estrogen receptor (estrogenic)

18, 28, 30, 44, 49, 52, 99, 101, 103, 110, 128

Estrogen receptor (anti-estrogenic)

118, 138, 163, 170, 180, 187, 194, 199, 203

Androgen receptor (anti-androgenic)

28, 49, 66, 74, 105, 118

Ryanodine receptor

95, 136, 149, 176, 84, 96, 52, 151, 183, 187,
170, 101, 132, 180, 18

PCBs are grouped by structural and structural/functional characteristics to assess relationships
between disease or biomarker parameters and the total serum levels of structures with common
characteristics (structural) or mechanisms (structural/functional). For dioxin-like/non-dioxin-like
congeners, the designation is based on the presence of ortho-substitutions (0 or 1 for dioxinlike, 2-4 for non-dioxin-like).
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like congeners. Both political and practical considerations motivated this focus. From a practical
standpoint, acute occupational exposures and high-level accidental poisoning with relatively
undegraded PCB mixtures were readily observable, and therefore exposure to mixtures
containing lower molecular weight and dioxin-like congeners was the primary PCB-related human
health concern at the time. Aggressive exploration of environmental PCB contamination began in
the 1970’s, following adoption of gas chromatography techniques which allowed identification of
PCBs (as well as chlorinated pesticides) in the environment3. In the same general time, political
pressure revolving around the use of Agent Orange in the Vietnam War steered a great deal of
research toward the health effects of dioxins and dioxin-like chemicals. The result of this was the
adoption of the TCDD-equivalent factor (TEF) protocol to determine the TCDD equivalency
(TEQ), a value normalizing any dioxin-like compound to TCDD based on its ability to induce AhRmediated response in an in vivo or in vitro system 31. Classes included in this protocol include
PCDDs, PCDFs and PCBs, the structures of which are shown in Figure 2. While this system
allows for the quick estimation of AhR-mediated toxicity in complex mixtures and clinical or
environmental samples by summing concentrations of individual compounds multiplied by their
respective TEQs, there are problems inherent in the concept.
First, the protocol presupposes that “Most, if not all, toxic and biological effects of
[PCDDs, PCDFs and PCBs] are mediated through the aryl hydrocarbon receptor”31. This is
certainly not true of mixtures such as PCBs in which all potential AhR ligands make up less than
1.5% of even unweathered commercial mixtures like 126032. Far from being inert, the remaining
98.5% of this mixture contains congeners which are known to induce other receptors, including
both classical xenobiotic nuclear receptors19, 33-35 and cell surface receptors20. Second, classic
assays based on induction or activity of xenobiotic metabolic targets of AhR presume that
exposure-dependent changes in AhR-mediated induction in this subset of targets can be
extrapolated to the entire complement of AhR targets. In fact, the transcriptional effects of AhR
are selectively modified by the ligand, with more widely conserved effects across ligands on
targets involved in xenobiotic metabolism or response to oxidative stress and more ligand-specific
modulation of targets involved in lipid carbohydrate metabolism36. Finally, the most powerful
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application of the TEQ protocol is the ability to quickly summarize the AhR-mediated effects of
various chemicals quantified by gas chromatography coupled to high-resolution mass
spectrometry (GC/HRMS) by normalizing the contribution of each compound to TCDD using the
TEF and then summing the resulting TEQs. This allows a total TEQ to be derived from multiple
dioxin-like classes of chemical, including PCDDs, PCDFs and PCBs (Figure 3). Perhaps most
pertinent to this particular study, although data from multiple human exposures to these
compounds, including Yusho and Yucheng poisoning events14 and exposed individuals residing
near the PCB manufacturing facility in Anniston, AL suggest that PCDDs and PCDFs contribute
more to the overall TEQ. However, our laboratory’s evaluation of the 2003-2004 NHANES data
showed that, among these classes, after adjustment for multiple comparisons, only PCBs were
positively associated with liver injury37 (shown in Table 3).
In summary, a need to prioritize exposures for reasons of risk assessment and
remediation led to methods, like the TEQ protocol, which weight the importance of one
mechanism over others, and the selection of dioxins/AhR as the flagship toxicant was driven by
both practical and political considerations. While this method may accurately represent the
likelihood that PCBs will have effects mediated by AhR, neither AhR activation nor modulation of
any other single mechanism can sufficiently describe the toxic/biological effects of complex
environmental exposures. This is particularly true in the case of PCBs, where both the overall
exposure level and the distribution of congeners comprising the mixture are known to differ
considerably between acute/occupational and chronic/environmental exposures.

Environmental PCB exposures vs. industrial PCB exposures
High-level exposures to industrial PCB mixtures are known to cause liver injury as well as
pathologies in other tissues in humans and other animals, as previously described. Although the
effects of chronic, environmental PCB exposures on the liver are less well characterized, some
conclusions can be drawn about the relationship between PCBs and liver injury based on the
results of several studies: the NHANES study described above, a longitudinal examination of the
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Equation 1. PCDD TEQ

Equation 2. PCDF TEQ

Equation 3. PCB TEQ

Equation 4. Total TEQ

Equation 5: HOMA‐IR
22.5
Equation 6: HOMA‐β
20
3.5

%

Equation 7: Total Lipids

2.27

62.3

/

Figure 3. Equations for calculated parameters in human epidemiological studies.
These equations are used to summarize and interpret differential biomarkers in human serum.
Equations 1-4 are used to calculate the effects of various PCB congener groupings on the
arylhydrocarbon receptor. Equations 5 & 6 are used the in homeostatic method of assessment
(HOMA) model to discriminate between different etiologies in abnormal glycemic control.
Equation 7 is used to estimate the total lipid content of serum from measured parameters of total
cholesterol and triglycerides. “Total lipids” is then used as a variable to correct serum content of
hydrophobic contaminants such as PCBs.
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Table 3
2003-2004 NHANES data – AOR for unexplained ALT elevation by exposure quartile

Pollutant
Subclass
Coplanar PCBs
Non-dioxin-like
PCBs
Total PCBs

Adjusted* Odds Ratios for
Unexplained ALT Elevation
by Exposure Quartile
ptrend†
st
nd
rd
th
1
2
3
4
adj
Ref
2.2
4.4
7.6 <0.001
Ref

0.8

2.4

4.5

0.001

Ref

0.8

2.2

4.3

0.010

The relationships between biomarker‐indicated liver disease and PCBs in the 2003‐2004
NHANES population are shown. Increased total PCB exposure was associated with an increased
adjusted odds ratio (AOR) for unexplained ALT elevation, attributable to nonalcoholic fatty liver
disease. From Cave et al, 2010x. Used with permission.
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historically exposed Yusho population12, PCB exposure in the Michigan fisheaters study38, and
data from exposed wildlife16, 39.
At higher molecular weights, the distribution of congeners heavily disfavors non-ortho,
strong AhR ligands. Bioaccumulation patterns favor higher molecular weight congeners, meaning
that, for humans acquiring PCBs through the ingestion of contaminated biota, the initial exposure
is to a higher average molecular weight, more ortho mixture (shown in Table 1), and the steady
state distribution of congeners further reinforces this pattern, shown in Figure 4 and Table 1.

Sex, genotype and diet interactions in PCB-exposed humans and animal models
From a standpoint of complexity, there is no more daunting area of human health
research than metabolic disease. The metabolic machinery of humans is both versatile and
robust. We can adapt to frequent physiological fluctuations in nutritional status, different food
sources, and varying demands from multiple tissues to support daily function, development, and
reproduction. In many cases, tissues can weather temporary metabolic disruption due to illness
or intoxication and eventually regain homeostasis. This process is described by the concept of
allostasis, or maintaining stability through change, an energy-dependent process involving
concerted actions between multiple tissues40. On the other hand, in the multistep and
multisystem process that converts nutrients into metabolites and energy, a mutation leading to
loss of function in one critical enzyme can eventually lead to failure in connected systems.
Complex disease etiologies occur where additive pressures across connected systems eventually
overwhelm compensatory processes. Eventually, component systems fail as additive pressures
overwhelm their capacity to adapt, meaning that pressure from different causes can converge on
shared pathological outcomes. Because of the multitude of processes in play, disease
progression may be slow and pleiotropic, and the direct effects of causal agents may be obscured
as the allostatic load is shunted to other systems.
In mammals, the liver is the primary biochemical interface between the environment and
the organism, transducing signals and substrates in multiple directions to sense and respond to
constantly-changing conditions. In terms of allostatic processes, this places the liver as both a
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Figure 4. Distribution of ortho/non-ortho structures within homolog groups.
As molecular weight and number of chlorine substitutions increases, ortho substitutions become
more likely. The four non-ortho substituted congeners which bioaccumulate to appreciable levels
in humans are PCBs 77, 81, 126 and 169.
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hub (because of its position in lipid and carbohydrate trafficking) and as a temporary terminus
(because of its capacity for lipid and carbohydrate storage). The adaptive capacity of the liver is
extraordinary, but not limitless. Lipid and carbohydrate uptake which chronically exceeds hepatic
metabolic/export capacity can lead to steatosis. This has been demonstrated experimentally,
using diets enriched in various fats or sugars to induce steatosis, (as well as obesity,
dyslipidemia, hyperglycemia and hyperinsulinemia) in laboratory animals41-44. The process is also
indicated in humans by epidemiological studies which show a strong relationship between BMI or
visceral obesity (proxy measurements for hypercaloric/high-fat/high-sugar diets) and metabolic
dysregulation. In addition to the higher PCB exposures found in Anniston and other exposed
human populations vs. the NHANES 2003-2004 population, the contributions of
overweight/obesity to steatohepatitis and other metabolic disease cannot be ignored. These
nutritional factors are additive stressors, increasing demand on tissues whose adaptive capacity
is compromised by the effects of sensing or responding to xenobiotics. The boundaries of that
capacity arise from genetic variation in the components of metabolic machinery and the
combination of endobiotic and xenobiotic molecules interpreted as a need for functional change.
Examples drawn from epidemiological studies include patatin-like phosphospholipase domaincontaining-protein 3 (PNPLA3), which has been shown to segregate with racial/ethnic variations
in NAFLD prevalence45 and the prevalent Q84R (missense) mutation in the human tribbles
pseudokinase 3 gene (TRIB3) which is associated with insulin resistance/T2DM46, 47,
cardiovascular risk46, and polycystic ovary syndrome in various human populations. Humans
homozygous for dominant-negative PPARγ (adipose-prevalent isoform) have reduced body fat
and greatly increased insulin resistance48. Sex effects are also clear in epidemiological studies
of PCB-associated disease. In exposed individuals from Anniston, AL, T2DM prevalence was
increased only in females49, a finding which echoed reports from a 24-year follow-up of the
historic Yucheng poisoning incident, which found a 2-fold increase in the prevalence of diabetes
among female but not male subjects50. Males in the Yucheng cohort had a higher prevalence of
mortality from liver cirrhosis and liver cancer51.
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In summary, additive pressures from chemical exposures and nutrition can combine with
sex- and genotype- specific variation in adaptive capacity to change the prevalence or the
manifestation of metabolic disease. Because of its central position in both allostatic maintenance
and metabolic and detoxification processes, the liver might be expected to show early and
extensive effects from the multiple “hits” of xenobiotic and dietary exposures.

PCBs and TASH
The extraordinary range of molecular structures which can be recognized and
successfully handled by one or more hepatic metabolic pathways is rivaled only by another
unique quality: the liver can really take a beating. The liver can successfully regenerate after
surgical removal more than 70% of its total mass52, 53, or the necrosis of 1/3 of the hepatic lobule
following exposure to toxicants such as acetaminophen or carbon tetrachloride54.
Nonalcoholic fatty liver disease (NAFLD) is a widespread metabolic disease of the liver,
affecting an estimated 25% of the population worldwide55. NAFLD is defined histologically by
steatosis (pathological accumulation of lipids) within 5% or more of hepatocytes in the absence of
excess alcohol consumption. First considering the liver as an isolated system, four general
mechanisms can initiate lipid accumulation: increased lipid transport into the hepatocyte,
increased de novo synthesis of lipids, decreased β-oxidation, or decreased lipid export56. As the
hub of both intermediary metabolism and xenobiotic metabolism, the liver is essential to systemic
homeostasis of both lipids and glucose as well as metabolism of endogenous and exogenous
toxicants. It therefore possesses highly concerted machinery for sensing xenobiotics and
systemic signaling molecules, and incorporating this context into programs that regulate
nutrient/energy balance and nutrient outflow. From this perspective, it is not difficult to
understand how a chemical could alter systemic lipid and glucose homeostasis through its direct
effects on the liver; that is the concept underlying the use of metabolism-altering drugs with
primary effects in the liver such as statins, fibrates, and metformin to affect systemic homeostasis
of cholesterol, lipids, and glucose, respectively57-59. Toxicants which exert effects in the liver
could be expected to have similar effects, depending on what combination of mechanisms they
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perturb. In addition, both intrinsic and idiosyncratic reactions to drugs or toxicants can result in
the development of steatosis60, highlighting the complexity of exposure-genotype or exposuregenotype-nutrient interactions.
NAFLD is recognized as the liver manifestation of metabolic syndrome (MS), a
constellation of metabolic alterations in multiple organ systems, including obesity, insulin
resistance, dyslipidemia and hypertension, that appear to be connected (appear together more
often than would be expected by chance). In 2004, the National Heart, Lung and Blood Institute
(NHLBI) and the American Heart Association (AHA) released recommendations for diagnosis of
MS with a primary outcome of cardiovascular disease. According to the Adult Treatment Panel-III
(ATP-III), MS may be diagnosed by the presence of abnormalities in three or more of the
following five criteria, shown in Table 461. With similar tools but a focus on insulin-resistant
diabetes as the pathological endpoint of interest, the International Diabetes Federation released
similar guidelines which require obesity as well as abnormality in two of the other criteria62.
Regardless of the exact cutoffs required for diagnosis, the criteria cluster around several
interrelated components: obesity, insulin resistance, dyslipidemia, and progressive
cardiovascular disease. NAFLD is not currently part of the criteria for MS diagnosis, however, it is
frequently found with other components of MS and the presence of NAFLD (by persistent
elevations in liver enzymes ALT using the lower, gender-specific ranges defined by Prati et al.,
200263) had a significantly higher positive predictive value for development of insulin resistance
than ATP-III in nonobese, nondiabetic subjects64. Multiple studies (reviewed in Anstee et al.,
2013) indicate that the presence of NAFLD/NASH can predict the development of cardiovascular
disease and T2DM after adjustment for obesity65. The significance of these findings is
straightforward: the liver is an early site of dysfunction in MS, and liver injury can predict both MS
and its component diseases early in the natural history of this complex syndrome.
The liver, therefore, is a central hub in the progression of MS, however, because fatty
liver disease may be a cause or effect of systemic metabolic dysfunction, there may be
differences in specific direct and compensatory responses of hepatocytes depending on the
initiating event(s). These differences in engaged pathways may also affect the mechanisms
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Table 4
Criteria for the diagnosis of Metabolic Syndrome (MS/CVD and IR/T2DM)
Component
Disease

Test Parameter

NHLBI/AHA:
ATP-III Criteria, CHF/CVD
primary outcome
(3 of the 5 required)

IDF:
IR/T2DM primary outcome
(Visceral obesity required + 2 of
the 4 remaining)

Obesity

Visceral obesity
(waist
circumference)

> 102 cm in men or
> 88 cm in women

For Europid, Sub-Saharan
African and Eastern
Mediterranean and Middle
Eastern
Men: ≥ 94cm
Women: ≥ 80cm
For South Asian, Chinese,
Ethnic south and central
American
Men: ≥ 90 cm
Women: ≥ 80 cm
For Japanese
Men ≥ 85 cm
Women ≥ 90 cm

Hypertension

Elevated blood
pressure
Hyperglycemia
(elevated fasting
plasma glucose)
Elevated
(fasting) serum
triglycerides
Low HDL
cholesterol

> 130⁄ 85 mm Hg

> 130⁄ 85 mm Hg
(or treatment history)
≥ 5.6 mmol/l

Insulin
Resistance
Atherogenic
dyslipidemia

> 6.1 mmol/L
> 1.7 mmol/L

≥ 1.7 mmol/l
(or treatment history)

< 1.04 mmol/L

< 1.03 mmol/l for men
< 1.29 mmol/l for women

Criteria for the diagnosis of metabolic syndrome are shown. Because the endpoints of interest
to the American Heart Association (column 3) and International Diabetes Foundation (column 4)
differ, slightly different criteria are used to define metabolic syndrome.
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which drive changes in circulating biomarkers, including mechanistic biomarkers of hepatocyte
death, transcription and release of microRNAs, and release of liver-specific functional enzymes
which can be used for liver injury screening. This is important, because while liver disease
occurs early in MS and can be causal, it is also generally asymptomatic, making non-invasive,
low-risk detection techniques imperative.
Imaging techniques are non-invasive and low-risk and may eventually (in combination
with serum biomarkers) provide sensitive and specific diagnosis and staging of fatty liver disease
to subclinical populations. At present, however, ultrasonography is both subjective and
qualitative, and X-ray computed tomography (CT), proton magnetic resonance spectroscopy (1HMRS), and magnetic resonance imaging (MRI) are all resource-intensive and still cannot reliably
distinguish simple steatosis from steatohepatitis65. Elevated liver transaminases are widely used
clinically for diagnosis of liver injury, but they are far more effective for indicating liver injury from
endogenous causes (cholestatic, vascular, or autoimmune injury) acute, severe intoxication (i.e.
occupational exposures to chemicals or alcohol-induced liver injury) overdose-related or
idiosyncratic drug-induced liver injury (DILI), or infectious hepatitis (Hepatitis A, B, C). TASH
related to chronic organochlorine exposure may be particularly problematic, as previous research
suggests that transaminase levels may remain subclinical even with severe injury66. For the
purposes of environmental health research, the use of transaminases as indicators of liver injury
presents an additional problem: transaminase activity is lost relatively quickly in stored blood or
serum, even under optimal storage conditions67, 68, reducing the ability of liver transaminase
panels to reflect injury in archived samples. Emerging serum biomarkers such as microRNA 122,
or the mechanistic biomarker cytokeratin 18 (CK18) may offer alternative methods to noninvasively detect subacute or chronic liver injury and liver injury of different etiologies, including
TASH. CK18, because it is relatively storage-stable66 and can be detected in both whole and
caspase-cleaved forms66, 69, 70, can discriminate hepatocyte death due to necrosis (the
predominant mechanism in TASH) from hepatocellular apoptosis (the predominant mechanism in
ASH, NASH, and viral hepatitis71-73), is a particularly appealing biomarker.
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In summary, NAFLD is recognized as a component of MS, and the functional role of the
liver in both intermediary and xenobiotic metabolism suggests that progressive hepatic
dysfunction could cause, contribute to, or derive from systemic metabolic dysfunction. TASH is a
subcategory of NAFLD which is histologically indistinguishable from NASH and ASH but
mechanistically and diagnostically unique. This difference presents an opportunity to distinguish
TASH from other forms of fatty liver disease using mechanistic biomarkers, but also hinders
diagnosis of liver injury due to chronic toxicant exposure because it is undetectable using typical
clinical laboratory screening techniques. This is important to the field of environmental health
science because exposures occurring incrementally through ingestion of contaminants are more
likely to be low-level and chronic, resulting in slowly-progressive subclinical disease.
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CHAPTER ONE: PCBS ARE ASSOCIATED WITH TOXICANT-ASSOCIATED
STEATOHEPATITIS, INFLAMMATION, AND METABOLIC DYSREGULATION IN AN
EXPOSED HUMAN POPULATION
Anniston, Alabama was the location of a chemical manufacturing plant where an estimated
400,000 metric tons of PCBs were produced between 1929 and the 197174. At least 20.5 metric
tons of PCBs were released into the atmosphere prior to plant closure in 1971, and nearly 19,000
metric tons of PCBs or PCB distillation residue were buried in unlined landfills near the plant site
before and after production was halted74. The environment near the manufacturing plant is highly
contaminated; assessment of tree bark in the area revealed PCB concentrations of 171.93 µg/g
lipid near the plant and landfills, which dropped dramatically to 35 ng/g lipid within 17 kilometers75.
In the late 1990s and early 2000s, several environmental assessments of contamination in Anniston
were published, renewing concern over exposures in the residential population and the potential
health effects. At that time, there existed over 6 decades of data indicating the status of PCBs as
human toxicants6, although the human health effects from environmental exposure were less well
characterized than industrial exposures.

Nevertheless, concerns from residents, university

collaborators and environmental groups initiated the Anniston Community Health Survey (ACHS)
in 2003, funded by the Agency for Toxic Substances Disease Registry (ATSDR)76, 77.
ACHS, and a follow-up study (ACHS-II, undertaken in 2014) are both large, crosssectional research projects which provided an opportunity to evaluate accumulation of
environmental pollutants (POPs, heavy metals, etc.) in a residential population, and to assess
health effects related to these exposures as well as the effects of coexposures/comorbid
conditions49, 76, 78-80. Important findings from the ACHS include increased mean PCB levels
compared to NHANES (2-3 fold), which are significantly different between non-Hispanic white and
African-American/black participants78. Importantly, laboratories working with serum samples and
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data from the ACHS project have independently reported elevated prevalence of diseases related
to metabolic syndrome including obesity (54%)81, hypertension76, diabetes49, and dyslipidemia79.
Blood pressure elevations (both in hypertensive and normotensive ranges), dyslipidemia, and
diabetes (particularly in women over 55 years of age) were significantly associated with the total
body burden of PCBs49, 76, 79, 82.
As previously stated, NAFLD is the liver manifestation of metabolic syndrome, therefore,
we undertook an investigation of liver disease in the Anniston cohorts. We hypothesized that
biomarker-indicated liver injury would be prevalent in the ACHS and ACHS-II populations, due to
the high prevalence of other metabolic disease. Because of the BMI-independent relationship
between liver injury and PCB load reported in our NHANES study37 and the specific hepatocyte
death mechanism detected in other studies of TASH66,

, we further hypothesized that PCB-

69

exposed individuals in Anniston would display a pattern of hepatocellular necrosis indicative of
TASH. Because steatohepatitis has previously been associated with insulin resistance and
systemic inflammation

, we anticipated that dysregulation in biomarkers of these conditions

83, 84

would be observed along with elevations in indicators of liver damage and death.
Our primary biomarker of hepatocyte injury was cytokeratin 18, an intermediate filament
enriched in epithelioid cells, especially hepatocytes (Figure 5). Early in apoptosis, CK-18 is
cleaved by caspases, producing a neoepitope, CK18-M30. Both total CK18-M65 and the
caspase-cleaved component CK18-M30 are released from dying cells and can be detected in
the serum, therefore, the relative levels of these two forms can provide insight as to whether
hepatocytes are undergoing predominantly apoptotic or predominantly necrotic cell death.
CK18-M30 is a well-characterized biomarker of hepatocellular apoptosis. Many groups have
demonstrated the utility of CK18-M30 as a diagnostic tool for steatohepatitis due to infection,
alcohol, and NASH. Our lab previously demonstrated that total CK18, but not caspase-cleaved
CK18, was elevated in individuals with severe liver damage due to vinyl chloride inhalation. We
recognized that the effect of PCBs on liver injury could be direct or indirect (by promoting
systemic metabolic dysfunction through some other mechanism or target). We
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Figure 5. Origin and detection of cytokeratin 18 in serum samples
(A) Cytokeratin 18 (CK18) is an intermediate filament enriched in hepatocytes and arranged in
filaments from the nuclear surface to the plasma membrane. (B) In cells undergoing apoptosis,
CK18 is cleaved by caspases and released from disintegrating apoptotic bodies. (C) In cells
undergoing necrosis, disintegration of the plasma membrane releases whole CK18. (D) Both
cleaved and uncleaved CK18 can be detected in the serum, using an antibody against an epitope
on all CK18 proteins (M65 – red stars) or an antibody against a neoepitope exposed by cleavage
(M30 – yellow stars). The predominance of each form indicates the primary mechanism of
hepatocyte death. Serum from individuals with NASH related to metabolic disease have a
primarily apoptotic CK18 profile, while serum from individuals exposed to vinyl chloride have a
primarily necrotic CK18 profile.
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hypothesized in the Anniston cohorts, a positive relationship would exist between serum
concentrations of PCBs and serum levels of total CK18 due to their toxicant exposure. We
hypothesized that a positive relationship between serum concentrations of PCBs and serum
levels of caspase-cleaved CK18 would exist if PCBs influenced liver injury indirectly through
effects on other organ systems, leading to NASH.
In addition, we evaluated the relationships between serum PCB levels and various other
biomarkers of liver pathology and systemic inflammation, as well as biomarkers and calculated
values reflecting metabolic function. The purpose of these evaluations was to determine the
relationship (if any) between serum PCB concentration and components of the metabolic
syndrome.
Lastly, because PCBs exist as a mixture, different congeners and/or groups of congeners
acting on shared mechanism(s) could have differential effects, depending on the mechanisms. In
the NHANES study, a significant association was found between liver injury and several individual
congeners (Table 5). We hypothesized that serum levels individual congeners and congener
groups would have differential associations with biomarkers of hepatocyte apoptosis and
necrosis, fibrosis, insulin resistance, pancreatic function, and systemic inflammation.
To investigate our hypotheses, we determined the prevalence of TASH in both populations
using the mechanistic hepatocyte death biomarker cytokeratin 18 (CK18) and other liver injury
biomarkers, as well as serologic biomarkers of systemic inflammation and metabolic function
(glucose and lipid metabolism).
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Table 5
PCB congeners associated with AOR for unexplained ALT elevations in NHANES 2003-2004.
Quartile
p-value
1st
2nd
3rd
4th
Ptrend
Ptrend-adj
Dioxin-like PCB congeners
0.6
2.9
1.9
66
referent
0.003
0.011
(0.2–1.5)
(1.6–5.4)
(0.9–4.0)
2.2
3.0
6.0
74
referent
<0.001 0.004
(1.0–5.1)
(1.5–6.0)
(2.4–14.9)
1.2
2.8
3.4
105
referent
0.015
0.031
(0.5–3.0)
(1.2–6.5)
(1.1–10.9)
1.8
3.8
4.4
118
referent
0.006
0.016
(0.7–4.8)
(1.3–11.1)
(1.4–13.7)
1.5
3.3
4.3
126
referent
< 0.001 < 0.001
(0.6–3.5)
(1.5–7.2)
(2.0–9.4)
1.8
3.4
5.0
9.4
156
<.001
0.004
(0.6–5.5)
(1.3–8.7)
(1.5–17.2)
(2.5–36.2)
1.5
4.1
2.1
7.1
157
0.006
0.016
(0.8–2.8)
(1.8–9.2)
(0.6–7.6)
(2.2–22.4)
0.9
2.2
2.7
5.0
167
0.032
0.011
(0.4–2.2)
(1.0–4.8)
(1.0–7.0)
(1.9–13.3)
2.4
3.5
5.0
2.4
169
0.032
0.061
(0.9–7.0)
(1.3–9.7)
(1.8–14.0)
(0.4–12.8)
Non-dioxin-like PCB congeners
1.9
2.5
6.7
138/158
referent
0.001
0.009
(0.8–4.1)
(1.0–6.0)
(2.1–21.5)
2.2
2.7
6.8
146
referent
0.004
0.019
(1.0–4.5)
(1.1–6.9)
(1.8–25.5)
1.1
0.8
1.0
2.6
151
0.030
0.068
(0.3–3.6)
(0.3–2.1)
(0.4–2.3)
(1.2–5.8)
1.5
2.3
7.2
153
referent
0.006
0.023
(0.6–3.6)
(0.7–7.4)
(1.7–29.9)
2.1
3.1
4.4
170
referent
0.015
0.042
(1.0–4.3)
(1.1–8.7)
(1.3–14.4)
1.4
2.1
2.7
3.4
172
0.007
0.023
(0.7–3.1)
(0.8–5.4)
(0.9–8.1)
(1.2–9.7)
0.7
2.0
4.2
6.5
177
<0.001 <0.001
(0.4–1.3)
(1.0–3.9)
(1.7–10.4)
(2.8–15.3)
1.7
2.1
4.6
4.8
178
0.014
0.042
(0.8–3.9)
(1.0–4.6)
(1.4–15.3)
(1.3–17.4)
2.4
4.0
3.1
7.8
183
0.017
0.042
(0.4–15.4)
(0.6–26.8)
(0.4–23.2)
(0.9–63.9)
2.8
4.6
10.5
187
referent
<0.001 0.002
(1.6–5.0)
(1.6–13.3)
(3.2–34.6)
3.6
4.1
8.2
14.7
196/203
<0.001 0.002
(0.9–13.8)
(1.1–16.0)
(1.7–39.3)
(3.3–65.3)
In the 2003-2004 NHANES study, individual PCB congeners associated with a significantly
increased odds ratio for unexplained ALT elevation. The adjusted p-trend adjusts for age, sex,
race/ethnicity, insulin resistance (HOMA-IR), income (PIR), and obesity (BMI). Adapted from
Cave, et al 2010x. Used with permission.
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CHAPTER ONE: MATERIALS AND METHODS

Study design and recruitment of the ACHS and ACHS-II Cohorts
ACHS
The ACHS cohort was assembled in 2003 and has been previously described49, 76. The
two-stage sampling procedure involved, first, the random selection of 3,320 households from a list
of all residences within the Anniston city limits. Residences in West Anniston, nearer to the PCB
manufacturing facility, were oversampled. ACHS staff visited each of the selected residences,
contacting 1,823 of the targeted households. One adult (>18 years of age) from each of 1,110
households agreed to participate and completed an exhaustive questionnaire covering
demographic, family history, health history, and specific exposure- and lifestyle-relevant questions.
The selected individual also completed a clinic visit, in which biometric measurements (height,
weight, blood pressure) were assessed and a fasting serum sample was submitted. The overall
completion rate was 61% (of targeted households).
The 738 serum samples represented in our ACHS mechanistic liver damage assessment
and cyto/adipokine evaluation are comprised of adults completing both the survey and a clinic visit,
in which a fasting blood sample was successfully submitted for analysis.

ACHS MicroRNA subcohort
152 ACHS samples submitted to the laboratory of Dr. Brian Chorley (US EPA) were
selected from a stratified subset of the original 738 in which the above parameters were assessed
(stratifications based on CK18 determined TASH/no liver disease, sex and race).
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ACHS-II
ACHS-II was designed to remedy limitations in the original ACHS study design and to
provide longitudinal data on exposures and health outcomes in this population. ACHS-II is a subset
of the original ACHS cohort, and was approached as an effort to recontact every surviving subject
from ACHS. Individuals were recruited to the ACHS-II cohort by a multi-stage and multi-platform
methodology described in detail by Birnbaum et al.80 Methods used by ACHS staff to initiate contact
or determine ineligibility were: recruitment letters (to all original ACHS participants at baseline
addresses) and a public meeting (advertised and covered by local media), further attempts via
phone contact (to last known phone numbers of ACHS participants), Social Security Death Index
searches. To determine the status and location of participants not reachable at their last listed
number, study staff searched the Social Security Death Index, and a second recruitment mailing to
all original and updated addresses. Through a combination of these approaches, 359 eligible
participants were enrolled in ACHS-II, and of these, the blood volumes of 345 subjects were of
adequate quantity for biomarker determination.
The University of Louisville Institutional Review Board approved the studies performed on
archived, de-identified samples from these cohorts.

Collection of samples and analysis of polychlorinated organic pollutant concentrations
The de-identified serum samples examined in these studies were collected during the
ACHS and ACHS-II studies and archived at -800C. Identification and quantification of the levels
of PCBs (35 ortho-substituted congeners in ACHS and 38 dioxin-like and non-dioxin-like congeners
for

ACHS-II)

and

other

contaminants

was

determined

by

high-resolution

gas

chromatography/isotope dilution high-resolution mass spectrometry performed at the National
Center for Environmental Health Laboratory of the Centers for Disease Control and Prevention
(Atlanta, GA)49, 76, 78, 79.
Serum concentrations of contaminants were compared to biomarkers and calculated
disease parameters both individually and based on several summation schemes based on
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previously reported risk assessment protocols and mechanistic studies. For ACHS, 35 orthosubstituted congeners were analyzed. In ACHS-II, 35 ortho-substituted congeners, 3 non-ortho,
and several other classes of chemical contaminants were analyzed, including the polychlorinated
dibenzo dioxin (PCDD) and polychlorinated dibenzofuran (PCDF) classes. Composition of these
groupings by individual congener are described in Table 2. Structural/functional groupings of PCB
congeners measured in ACHS-II.

Measurement of steatohepatitis biomarkers
CK18 is a structural protein enriched in hepatocytes which can be detected in both whole
and caspase-cleaved forms, allowing for the differentiation of hepatocellular apoptosis (caspasecleaved CK18 or M30) from necrosis (CK18 M65). Because the hepatocellular death mechanism
appears to vary by etiology of fatty liver disease 83, 84, the pattern of CK18 elevation has been used
to differentiate TASH (predominantly necrotic, elevations in CK18 M65 alone) from other fatty liver
diseases (predominantly apoptotic, elevated CK18 M30 and M65)69. Moreover, unlike
transaminases, which the detectable property of enzyme activity is not retained during long-term
storage67, CK18 levels are determined by immunoassay-based protein quantitation, detectable in
samples archived for several decades66, 69. This was an important consideration for biomarker
selection, as the original ACHS samples had been archived for 7-9 years prior to our analysis. In
both phases of the Anniston Community Health Survey, CK18 M65 and M30 (PEVIVA 10020 and
10010, Diapharma, Cincinnati, OH) were measured by separate enzyme-linked immunosorbent
assays each using a monoclonal antibody recognizing a different CK18 epitope.
Quantifiable variations in several serum microRNA are associated with liver injury and
other metabolic diseases. A subset of serum samples from the ACHS cohort representing subjects
randomly selected from groups stratified by sex, race and liver disease status (TASH vs. no liver
disease as determined by CK-18) were evaluated for serum levels of 60 liver-associated
microRNAs. These analyses were performed by firefly analysis through our collaborator Brian
Chorley of the EPA.
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Liver function tests including alanine transaminase (ALT), asparagine transaminase (AST),
alkaline phosphatase (ALP), bilirubin, and albumin are widely used non-invasive clinical screening
tools for the assessment of liver injury (of diverse origins).

Importantly, however, toxicant-

associated steatohepatitis usually presents without transaminitis, in contrast to other forms of liver
injury including NASH and ASH when commonly-used normal ranges are applied. A liver function
panel including ALT, AST, ALP, total and direct bilirubin and albumin was carried out on ACHS-II
samples at the University of Louisville Hospital Clinical Laboratory. Due to limited sample volumes
and long storage times, clinical liver function tests were not performed on serum from ACHS.

Evaluation of other serum biomarkers
Fasting insulin, adipokines, and pro-inflammatory cytokines were also measured in
archived samples from both phases of the Anniston Community Health Survey. Adipocytokines
were measured using two separate multiplex bead arrays run on a Luminex IS100 system (EMD
Millipore Corporation, Billerica, MA). The first array (HADK2MAG-61K) measured interleukin 6 (IL6), interleukin 8 (IL-8), monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor α (TNFα),
interleukin 1-β (IL-1β), insulin, and leptin. For the second array (HADK1MAG-61K), samples were
diluted 1:400 in the provided assay buffer, and adiponectin, resistin, and total plasminogen activator
inhibitor-1 (PAI-1) were measured. The homeostatic models of assessment (HOMA)85 were used
to evaluate insulin resistance (HOMA-IR) and pancreatic beta cell function (HOMA-B).
In ACHS-II, hyaluronic acid, an additional fibrosis biomarker was measured by ELISA
(#029-001, Corgenix, Inc., Broomfield, CO). Endotoxin was measured by limulus amoebocyte
assay (#50-650U, Lonza Walkersville, Inc., Walkersville, MD) and total antioxidant activity was
measured by chromogenic assay (#709001, Cayman Chemical Company, Ann Arbor, MI). Serum
levels of a wide range of cytokines were provided by collaborators at ATSDR and SUNY, and were
evaluated for associations with PCB exposures and TASH indicators.
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Derivation of calculated values
Substituted values for contaminant levels beyond the detectable range
Levels of individual congeners reported by the ATSDR laboratory as “undetectable” were
substituted with a value equal to the lower limit of detection for the specific congener divided by the
square root of 286. When measured concentrations below the stated lower limit of detection were
reported from the laboratory, those measurements (rather than substituted values) were used78.
This method was previously employed to analyze and report associations between serum PCB
level and diabetes49 and hypertension76 in the ACHS cohort.

Substituted values for serum biomarker levels beyond the detectable range
Biomarkers assessed in our laboratory which were below the level of detection (IL-1β < 1.3
pg/ml; IL-6 < 0.96 pg/ml; insulin < 9.6 pg/ml; IL-8 < 0.64 pg/ml; MCP-1 < 1.3 pg/ml; TNFα < 0.64
pg/ml) were set to half the lower limit of detection. Leptin levels greater than the upper limit of
quantification (leptin > 600 ng/ml, 1 record) were set to 600 ng/ml.

Total Lipids
Values for total lipids were calculated by a standard87 which has been used previously to report
findings in the ACHS cohort49, 76. The formula for total lipids is listed in Figure 3, Equation 7.

Lipid-adjusted PCB
PCBs are highly lipophilic and move between physiological compartments along with lipids.
Therefore, adjustment for the total lipid content of serum is used to normalize total PCB
concentrations in serum, and PCBs are expressed PCB wet weight per gram lipid.

HOMA-IR and HOMA-B
The homeostatic model of assessment uses weighted fasting serum glucose and insulin
measurements to assess adequacy of compensation mechanisms: insulin secretion in response to
glucose load and glucose disposal in response to insulin secretion. Together, they are models
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used to determine pancreatic dysfunction vs. insulin resistance as etiologies in hyperglycemia85, 88.
The results are dimensionless and represent insulin resistance and percent pancreatic function.
Formulae for calculating HOMA parameters are listed in Figure 3, Equations 5 and 6.

PCB groupings and TEQ
PCBs have been grouped in various ways by structure and function for purposes of risk
assessment and association studies.

We incorporated several of these techniques into our

analyses. Because only 35 ortho PCBs were quantified in serum samples from the ACHS cohort,
for purposes of evaluating significant associations with our measured parameters, we presented
the data as lipid-adjusted serum levels of individual congeners and lipid-adjusted levels of the sum
of all 35 congeners measured (ƩPCB-O). In ACHS-II, the panel of PCBs and other contaminants
was expanded, increasing the number of dioxin-like compounds measured. In this group, we were
therefore able to present associations between measured parameters and the lipid-adjusted serum
levels of individual congeners and various summations listed in Table 2. Structural/functional
groupings of PCB congeners measured in ACHS-II.
As discussed in the introduction, historic focus on toxicity mechanisms dependent on AhR
led to the adoption of the toxic equivalency, which is a measure of potency with regards to AhR
normalized to the effects of the AhR ligand TCDD. Toxic equivalency factors (TEFs) have been
established for some dioxin-like chemicals31. Besides PCBs, other chemical contributors to the total
dioxin equivalency (Total Dioxin TEQ) that were measured in ACHS2 included polychlorinated
dibenzo-p-dioxins

(PCDDs,

n=7),

polychlorinated

dibenzofurans

(PCDFs,

n=10)

and

polybrominated diphenyl ethers (PBDEs, n=12). Using the 2005 World Health Organization TEFs,
we established toxic equivalency (TEQ) values for each dioxin-like congener, as well as TEQ by
class (PCBs, PCDDs, PCDFs) and Total Dioxin TEQ for each sample within the ACHS-II cohort to
explore the relationship between AhR activation and biomarker/disease status. TEQs for each
congener were derived by multiplying the concentration in each sample by the TEF, and summation
of TEQ by class and for all dioxins was carried out by the formulae listed in Figure 3, Equations 13 and 4, respectively.
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Statistical Analysis
Stratification into liver disease categories
For each cohort, subjects were stratified into three groups based solely on the combination
of CK18 M65 and M30 levels: one group without evident liver disease (no liver disease, or NLD,
M30<200 U/L and M65<300 U/L) and two groups with liver disease. The two liver disease groups
differ by hepatocyte death mechanism: primarily necrotic hepatocyte death characteristic of TASH
(M30<200 U/L and M65>300 U/L), and primarily apoptotic hepatocyte death encompassing other
forms of liver disease (other liver disease, or OLD, M30>200 U/L). These cutoff values were based
on prior studies 69, 89.

Associations between liver disease category and demographic groups or biomarkers
Counts and percentages for the main predictors were determined in the entire ACHS
population and for each stratification based on liver disease category. Differences in means and
frequencies by liver disease category were tested with a one-way ANOVA or chi-square test,
respectively. The TASH and OLD liver disease categories were always compared against NLD.
For each biomarker, regression lines were plotted within each category of liver disease status to
generate a β coefficient describing the relationship between biomarker and status. Biomarkers
were analyzed with multivariable generalized linear models to assess the relationship between
serum PCB levels and each outcome including with or without confounders. Unless specified
elsewhere, PCB levels were adjusted for log-transformed lipid levels.
Using SAS version 9.4 (SAS Institute, Cary, NC), and a statistical significance level of 0.05,
Multinomial logistic regressions models were constructed to analyze the associations of PCB, BMI,
and an interaction between PCB levels and BMI adjusted with and without additional confounders.
Biomarkers, PCB levels, and total lipid levels were log-transformed. All models used wet-weight
(ng/g serum) log-transformed individual PCB congeners with total lipids (also log-transformed) as
a covariate. Unless noted elsewhere, all analyses were adjusted for age (years; continuous), body
mass index (BMI, kg/m2; continuous), gender (male vs. female), race (African-American vs. nonHispanic white), diabetes status (none, pre-diabetic, or diabetic), alcohol use and lipid levels.
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CHAPTER ONE: RESULTS

Liver injury is prevalent and persistent in a human population highly exposed to
environmentally-acquired PCBs
Summaries of population demographics for the three cohorts described are provided in
Tables 6-12. In ACHS, the 738-subject cohort was comprised of a high percentage of AfricanAmericans (46.8%), females (70.1%), subjects ≥50 years old (63.0%), non-drinkers (70.6%), and
non-smokers (69.0%). Most subjects (80.3%) were either overweight (BMI≥25 kg/m2) or obese
(BMI≥30 kg/m2). Subjects were categorized by liver disease status based on elevated CK18 levels
consistent with either hepatocellular necrosis (TASH) – elevated CK18-M65 without CK18-M30
elevation, or apoptosis (OLD) with elevated CK18-M30. The prevalence of liver disease was 60.2%
including 48.6% with TASH and 11.5% with Other. Higher CK18 M65 levels were found in nonHispanic whites compared to African-Americans (p<0.001). A univariate sensitivity analysis
excluding thirteen subjects with total wet-weight PCB levels beyond four standard deviations of the
mean was performed (Table 13). This analysis showed that CK18 M65 was higher in non-Hispanic
whites (p<0.001) and in males (p=0.03); while CK18 M30 was higher in non-Hispanic whites
(p<0.001) and decreased with age (p=0.01).
In ACHS-II, the 345-subject cohort was comprised of a high percentage of AfricanAmericans (48.7%), females (73.0%), and subjects ≥50 years old (86.1%). As in ACHS, most of
the subjects were non-smokers (79.4%), however, more of the participants in ACHS-II consumed
alcohol (60.0%), with 51.3% drinking within defined limits and 8.7% drinking more than defined
limits. Most subjects (80.0%) were either overweight (25.5%) or obese (51.3%) by the criteria listed
above. Prevalence of liver disease in this cohort was 62.0%: 46% with TASH and 16% with OLD.
Participants with liver disease were more likely to be younger (p=0.03) and white (p=0.01).
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Table 6
Demographics in ACHS by Liver Disease Status – continuous variables
Liver disease status
Characteristic
Age (years)

None

TASH

Other

(n = 294)

(n = 359)

(n = 85)

54.1±15.7

56.0±16.3a

51.5±15.1

P-value

Total
(n = 738)

0.04

54.7±15.9

0.34
BMI (kg/m2)
31.5±7.8
30.9±7.7
32.1±7.7
31.25±7.7
∑PCBs (ortho,
0.40
6.4±9.1
7.2±14.4
5.4±10.3
6.7±12.1
whole weight)
Total lipids
0.01
656.9±192.4c
632.2±156.3
611.1±131.7
643.6±163.6b
(mg/dL)
Cytokeratin 18
792.5±584.9c
233.6±42.6
430.6±122.1a,b
<0.001 393.8±276.0
M65 (U/dL)
Cytokeratin 18
97.9±22.0
124.0±28.2a,b
407.6±324.6c
<0.001 146.3±147.1
M30 (U/dL)
Data are n(%) or mean±SD. Not all percents add to 100% due to rounding. Note that
cytokeratin 18 levels were used for categorization procedures.
P-value is one-way ANOVA (means) or Pearson chi-square test, across liver disease
categories.
a
adj-p<=0.05 in pair-wise comparison of TASH vs. Other liver disease category.
b
adj-p<=0.05 in pair-wise comparison of None vs. TASH liver disease category.
c
adj-p<=0.05 in pair-wise comparison of None vs. Other liver disease category.
d
Limits are <= 30 drinks for females and <=60 drinks for males.
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Table 7
Demographics in ACHS by Liver Disease Status – biometric categorical variables
Liver disease status
P-value
None
TASH
Other
Characteristic
(n = 294)
(n = 359)
(n = 85)
0.03
Gender
Male
72 (24.5)
26 (30.6)
123b (34.3)
Female
222 (75.5)
236 (65.7)
59 (69.4)
<0.001
Race/ethnicity

Total
(n = 738)
221 (30.0)
517 (70.1)

53c (62.4)
393 (53.3)
Non-Hispanic White
117 (39.8)
223b (62.1)
African/American
177 (60.2)
136 (37.9)
32 (37.7)
345 (46.8)
0.13
Age (years)
< 30
24 (8.2)
31 (8.7)
8 (9.4)
63 (8.5)
30-40
41 (14.0)
25 (7.0)
12 (14.1)
78 (10.6)
40-50
45 (15.3)
69 (19.2)
18 (21.2)
132 (17.9)
50-60
66 (22.5)
75 (20.9)
20 (23.5)
161 (21.8)
60-70
63 (21.4)
75 (20.9)
15 (17.7)
153 (20.7)
≥70
55 (18.7)
84 (23.4)
12 (14.1)
151 (20.5)
BMI (kg/m2)
0.40
0 (0.0)
5 (0.7)
< 18.5
3 (1.0)
2 (0.6)
18.5 - 24.9
61 (20.8)
67 (18.7)
14 (16.5)
142 (19.3)
25 - 29.9
62 (21.1)
109 (30.4)
20 (23.5)
191 (26.0)
30 - 34.9
77 (26.2)
90 (25.1)
22 (25.9)
189 (25.7)
35 -39.9
48 (16.3)
48 (13.4)
15 (17.7)
111 (15.1)
≥40
42 (14.3)
42 (11.7)
14 (16.5)
98 (13.3)
Missing
1 (0.3)
1 (0.3)
0 (0.0)
Data are n(%) or mean±SD. Not all percents add to 100% due to rounding. Note that
cytokeratin 18 levels were used for categorization procedures.
P-value is one-way ANOVA (means) or Pearson chi-square test, across liver disease
categories.
a
adj-p<=0.05 in pair-wise comparison of TASH vs. Other liver disease category.
b
adj-p<=0.05 in pair-wise comparison of None vs. TASH liver disease category.
c
adj-p<=0.05 in pair-wise comparison of None vs. Other liver disease category.

38

Table 8
Demographics in ACHS by Liver Disease Status – lifestyle categorical variables
Liver disease status
P-value
None
TASH
Other
Characteristic
(n = 294)
(n = 359)
(n = 85)
0.70
Number of drinks in last 30 days
No drinks
Within defined limits
More than limit
Missing
Current Smoker
No
Yes
West Anniston resident
No

d

Total
(n = 738)

205 (69.7)

254 (70.8)

62 (72.9)

521 (70.6)

63 (21.4)

73 (20.3)

14 (16.5)

150 (20.3)

16 (5.4)
10 (3.4)

23 (6.4)
9 (2.5)

8 (9.4)
1 (1.2)

47 (6.4)
20 (2.7)
0.69

208 (70.8)
86 (29.3)

243 (67.7)
116 (32.3)

58 (68.2)
27 (31.8)

509 (69.0)
229 (31.0)
0.25

43 (14.6)

62 (17.3)

12 (14.1)

117 (15.9)

Yes
251 (85.4)
297 (82.7)
73 (85.9)
621 (84.2)
Data are n(%) or mean±SD. Not all percents add to 100% due to rounding. Note that
cytokeratin 18 levels were used for categorization procedures.
P-value is one-way ANOVA (means) or Pearson chi-square test, across liver disease
categories.
a
adj-p<=0.05 in pair-wise comparison of TASH vs. Other liver disease category.
b
adj-p<=0.05 in pair-wise comparison of None vs. TASH liver disease category.
c
adj-p<=0.05 in pair-wise comparison of None vs. Other liver disease category.
d
Limits are <= 30 drinks for females and <=60 drinks for males.
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Table 9
Demographics in ACHS-II by Liver Disease Status – continuous variables
Liver disease status
Characteristic

None
(n = 131)

TASH
(n = 158)

Other
(n = 56)

P-value

Total
(n = 345)

Age (years)

63.8±12.7

63.4±13.3

59.1±12.9

0.06

62.9±13.1

32.0±9.5

31.2±7.2

32.2±7.2

0.59

31.7±8.1

6.0±6.4

5.4±7.2

5.6±9.8

0.20

5.7±7.4

231.8±46.0

436.7±142.9

624.8±368.1

<.001

389.4±226.5

84.1±26.5

111.6±36.3

380.1±269.8

<.001

144.7±153.1

611.1±143.7

632.5±162.1

622.1±154.8

0.47

622.7±154.0

2

BMI (kg/m )
∑PCBs (ortho and
non-ortho, whole
weight), ppb
Cytokeratin 18 M65
(U/dL)
Cytokeratin 18 M30
(U/dL)
Total lipids (mg/dL)
Gender

0.07

Male

26 (19.9)

49 (31.0)

18 (32.1)

93 (27.0)

Female

105 (80.2)

109 (69.0)

38 (67.9)

252 (73.0)

Race/ethnicity
0.01
Non-Hispanic
White
50 (38.2)
90 (57.0)
28 (50.0)
African/
American
81 (61.8)
68 (43.0)
28 (50.0)
Data are n(%) or mean±SD. Not all percents add to 100% due to rounding.

168 (48.7)
177 (51.3)

P-value is one-way ANOVA (means) or Pearson chi-square test, across liver disease
categories.
Abbreviations: BMI, body mass index; None, no liver disease; Other, other liver disease;
ΣPCB, sum of polychlorinated biphenyl congeners; TASH, toxicant associated steatohepatitis
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Table 10
Demographics in ACHS-II by Liver Disease Status – biometric categorical variables
Characteristic
Gender
Male
Female
Race/ethnicity
Non-Hispanic
White
African/American

Liver disease status
None
TASH
Other
(n = 131)
(n = 158)
(n = 56)

Total
(n = 345)

0.07
26 (19.9)
105 (80.2)

49 (31.0)
109 (69.0)

18 (32.1)
38 (67.9)

93 (27.0)
252 (73.0)
0.01

50 (38.2)

90 (57.0)

28 (50.0)

81 (61.8)

68 (43.0)

28 (50.0)

Age (years)
< 30

P-value

168 (48.7)
177 (51.3)
0.03

0

3 (1.9)

0

3 (0.9)

30-40

6 (4.6)

5 (3.2)

5 (8.9)

16 (4.6)

40-50

13 (9.9)

11 (7.0)

5 (8.9)

29 (8.4)

50-60

24 (18.3)

43 (27.2)

23 (41.1)

90 (26.1)

60-70

42 (32.0)

41 (26.0)

10 (17.9)

93 (27.0)

46 (35.1)

55 (34.8)

13 (23.2)

114 (33.0)

≥70
2

BMI (kg/m )
< 18.5
18.5 - 24.9
25 - 29.9

0.73
1 (0.8)

0

0

1 (0.3)

26 (20.0)

32 (20.8)

9 (16.1)

67 (19.5)

39 (30)

44 (28.6)

15 (26.8)

99 (28.8)

30 - 34.9

28 (21.5)

33 (21.4)

11 (19.6)

73 (21.2)

35 -39.9

16 (12.3)

28 (18.2)

9 (16.1)

54 (15.7)

≥40

20 (15.4)

17 (11.0)

12 (21.4)

50 (14.5)

Missing
1
1
Data are n(%) or mean±SD. Not all percents add to 100% due to
rounding.
P-value is one-way ANOVA (means) or Pearson chi-square test, across liver disease
categories.
Abbreviations: BMI, body mass index; None, no liver disease; Other, other liver disease;
ΣPCB, sum of polychlorinated biphenyl congeners; TASH, toxicant associated steatohepatitis
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Table 11
Demographics in ACHS-II by Liver Disease Status – health and lifestyle categorical variables
Liver disease status
Characteristic

None
(n = 131)

TASH
(n = 158)

Other
(n = 56)

Diabetes Status

Pvalue

Total
(n = 345)

0.19

Ever Diabetic

44 (33.6)

69 (43.7)

24 (42.9)

137 (39.7)

Non-diabetic
87 (66.4)
Typical Number of Drinks in Past 12
Months
No drinks
56 (42.8)

89 (56.3)

32 (57.1)

208 (60.3)

Within defined limits
More than limit

d

0.43
57 (36.1)

25 (44.6)

138 (40.0)

66 (50.4)

87 (55.1)

24 (42.9)

177 (51.3)

9 (6.9)

14 (8.9)

7 (12.5)

30 (8.7)

Current Smoker

0.88

No

105 (80.8)

124 (78.5)

44 (78.6)

273 (79.4)

Yes

25 (19.2)

34 (21.5)

12 (21.4)

71 (20.6)

Missing
1
Data are n(%) or mean±SD. Not all percents add to 100% due to
rounding.
P-value is one-way ANOVA (means) or Pearson chi-square test, across liver disease
categories.
d

1

Limits are <= 1 drink/day for females and <=2 drinks/day for males.

Abbreviations: BMI, body mass index; None, no liver disease; Other, other liver disease;
ΣPCB, sum of polychlorinated biphenyl congeners; TASH, toxicant associated steatohepatitis
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Table 12
Demographic characteristics and liver disease status of ACHS microRNA subcohort
Liver disease status
Characteristic
Age (years)
BMI (kg/m2)
∑PCBs (whole weight)
Total lipids (mg/dL)
Gender
Male
Female

None

TASH

(n = 76)

(n = 76)

56.5±13.8

55.3±14.5

0.62

30.2±6.0
6.8±8.6
605.8±139.0

32.6±8.1
11.3±26.6
658.6±173.5

0.045

38 (50.0)
38 (50.0)

38 (50.0)
38 (50.0)

Race/ethnicity

P-Value

0.16
0.04

0.03
Non-Hispanic
White
Nonwhite

31 (40.8)

44 (57.9)

45 (59.2)

32 (42.1)

Age (years)

0.32
< 30
30-40
40-50
50-60
60-70
≥70

2 (2.6)
10 (13.2)
11 (14.5)
16 (20.1)
22 (29.0)
15 (19.7)

4 (5.3)
6 (7.9)
16 (20.1)
22 (29.0)
13 (17.1)
15 (19.7)

BMI (kg/m2)

0.31

18.5 - 24.9
17 (22.7)
25 - 29.9
18 (24.0)
30 - 34.9
24 (32.0)
35 -39.9
9 (12.0)
≥40
7 (9.3)
Missing
1
Number of drinks in last 30 days
No drinks
53 (69.7)
Within defined
16 (20.1)
limits**
More than limit
5 (6.6)
Missing
2 (2.6)
Current Smoker
No
50 (65.8)
Yes
26 (34.2)
West Anniston resident
No
6 (7.9)
Yes
70 (92.1)
* Not all percents add to 100% due to rounding
** Limits are <= 30 drinks for females and <=60 drinks for males.
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9 (12.0)
20 (26.7)
21 (28.0)
13 (17.1)
12 (16.0)
1
0.80
53 (69.7)
13 (17.1)
8 (10.5)
2 (2.6)
0.49
54 (71.1)
22 (29.0)
0.29
10 (13.2)
66 (86.8)

Table 13

Cytokeratin 18 M65

Univariate associations between demographic/exposure variables and the serum cytokeratin 18 M65 and M30 biomarkers used to categorize
liver disease status.
Cytokeratin 18 M30

Estimate
0.34

SE

0.29

0.18

p-value

-21.82

-7.44

-0.43

Estimate

5.39

5.91

0.17

SE

<0.001

0.21

0.01

p-value

-103.06

-3.00

0.43

Estimate

24.66

27.21

0.78

SE

<0.001

0.91

0.59

p-value

-74.58

-33.32

0.42

Estimate

14.14

15.63

0.45

SE

<0.001

0.03

0.35

p-value

Sensitivity analysisa

Variable
-0.46
11.82
0.08

All data

Age
12.54
10.84

Sensitivity analysisa

Gender
-19.19

All data

Race

0.11

0.44

15.52

0.36

0.93

-24.49

0.007

0.41

0.73
0.26

-0.006

1.13

0.97
26.88

0.52

-0.92

1.62
-30.58

0.006

0.66

-0.06
0.53

-0.004

1.03

0.60
5.89

0.006

-0.46

0.35

3.68

0.003

0.003

0.19

0.16

-0.007

0.43

0.13

11.7

0.36

-1.27

0.71

16.32

0.003

0.46

1.07

Current
Smoker

-0.003
0.45

BMI

PCB,
lipidadjusted
-0.33

PCB, wet
weightb

a
Sensitivity analysis includes participants with total PCB wet weight values within four standard deviations of the mean. Thirteen participants of
738 were excluded.
b
Additionally adjusted for total lipids.
Results are presented as Estimate and Standard Error from a generalized linear model analysis.
Abbreviations: BMI, body mass index; PCB, polychlorinated biphenyls.
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Significant demographic differences were seen across liver disease categories with
respect to age, gender, and race/ethnicity. Males were more likely than females to have TASH
(55.7% vs. 45.6%, p<0.05) in ACHS, with gender differences found to be nonsignificant in ACHSII. In both studies, subjects with TASH were significantly more likely to be non-Hispanic white than
subjects without liver disease (62.1% vs. 39.8% in ACHS and 57.0% vs. 38.2% in ACHS-II). The
combined prevalence of liver disease was highest among males (67.4% in ACHS and 72.0% in
ACHS-II) and non-Hispanic whites (70.2% in both cohorts). These results are consistent with the
increased susceptibility to fatty liver disease in Caucasians (compared to African Americans) and
males as reported previously in other epidemiological studies90.

TASH was associated with

significantly increased age compared to Other in ACHS (56.0±16.3 vs. 51.5±15.1), but not in
ACHS-II. No intragroup differences were seen in other demographic or exposure variables
including total PCBs (wet weight) or West Anniston residence, body mass index, alcohol
consumption, or smoking status.
Total lipids were significantly increased in both TASH and Other in ACHS (Table 6) while
there were no significant intragroup differences for this parameter in ACHS-II (Table 9). Because
both necrotic and apoptotic (M30) hepatocyte death contribute to total CK18 (M65), it is not
surprising, based on the classification procedures, that CK18 M65 was significantly increased in
both liver disease groups compared to None. However, the absolute M65 level was increased to a
greater degree in Other compared to TASH, even though only M30 abnormality was used to
discriminate between the two.

Liver injury in Anniston is associated with increased pro-inflammatory cytokines and
metabolic abnormalities.
Steatohepatitis is associated with increased serum pro-inflammatory cytokines, which can
result from and/or lead to liver injury and metabolic disease91, 92. As shown in Table 14, IL-1β, IL6, IL-8, MCP-1, PAI-1, and TNFα were all numerically higher across liver disease categories
(graphs), but only MCP-1 (p=0.01) and PAI-1 (p=0.001) reached statistical significance in the
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Table 14
Unadjusted ACHS Biomarker levels by liver disease status.
Liver disease status

Adiponectin ng/ml
Mean±SD
Glucose, mg/dl
Mean±SD
HOMA-B
Mean±SD
HOMA-IR
Mean±SD
IL-1β pg/ml
Mean±SD
Not detectable
IL-6 pg/ml
Mean±SD
Not detectable
IL-8 pg/ml
Mean±SD
Not detectable
Insulin pg/ml
Mean±SD
Not detectable
LDL, mg/dl
Mean±SD
Leptin ng/ml
Mean±SD
Not detectable
MCP-1 pg/ml
Mean±SD
Not detectable
PAI-1 ng/ml
Mean±SD
Resistin ng/ml
Mean±SD
TNFα pg/ml
Mean±SD
Not detectable
Triglycerides, mg/dl
Mean±SD

Pvalue

None

TASH

Other

(n = 294)

(n = 359)

(n = 85)

17.2±12.4

18.3±19.1

15.1±10.2

0.22

17.5±15.8

105.1±40.4

108.2±40.9

115.7±53.9

0.13

107.8±42.5

164.2±223.7

183.5±334.3

219.6±306.7

0.29

180.0±291.9

3.9±5.4

5.1±8.4

6.4±8.3a

0.01

4.8±7.4

2.4±7.0
195

10.0±76.4
214

13.1±79.9
52

0.17

7.3±60.0
461

8.5±42.0
35

16.4±84.9
23

13.2±40.6
4

0.32

12.9±66.4
62

78.7±199.0
0

101.4±257.4
1

86.7±304.5
0

0.49

90.7±242.1
1

492.8±567.2
1

642.3±1067.2
1

757.7±918.7a
0

0.02

596.0±886.4
2

117.0±32.7

116.0±39.8

116.5±40.1

0.94

116.5±37.1

30.5±27.0
0

29.3±39.7
1

26.1±25.1
0

0.57

29.4±33.6
1

269.7±175.2
0

295.1±244.4b
1

314.9±193.6
0

0.01

294.6±194.1
1

49.0±19.4

54.9±21.4b

56.0±23.3a

0.001

52.7±21.1

41.0±31.7

44.1±29.8

37.8±19.1

0.15

42.1±29.6

6.4±5.5
3

9.2±24.2
2

7.0±7.1
0

0.11

7.8±17.4
5

119.3±75.5

147.0±107.5b

160.6±130.7a

0.0002

137.5±100.3

(n = 738)

P-value is one-way ANOVA, across all liver disease categories, unadjusted.
a adj-p<=0.05 in pair-wise comparison of None vs. Other liver disease category.
b adj-p<=0.05 in pair-wise comparison of None vs. TASH liver disease category.
c adj-p<=0.05 in pair-wise comparison of TASH vs. Other liver disease category.
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Total

unadjusted model. MCP-1 was higher in TASH than None (295.1±244.4 pg/ml vs. 269.7±175.2
pg/ml, p=0.009). PAI-1 was increased in both TASH (54.9±21.4 ng/ml, p=.001) and Other
(56.0±23.3 ng/ml, p=0.02) compared to None (49.0±19.4 ng/ml).
NAFLD is also commonly associated with insulin resistance and hypertriglyceridemia

.

93

The mean HOMA-IR for the overall cohort was elevated (4.8±7.4) beyond one proposed cutoff for
insulin resistance (HOMA-IR >4.65 or HOMA-IR >3.60 and BMI >27.5 kg/m2)94. HOMA-IR varied
significantly across liver disease groups (p=0.01), and it was increased in Other compared to None
(6.4±8.3 vs. 3.9±5.4, p=.017). While HOMA-IR was numerically higher in TASH (5.1±8.4) than
None, this trend did not reach statistical significance. Fasting insulin varied in a pattern like that
observed for HOMA-IR (Table 14), and likely accounted for the observed difference in HOMA-IR
as glucose levels were not different between groups. Triglycerides varied by liver disease category
(p=0.007) and were higher in both TASH (147.0±107.5 mg/dl, p=.001) and Other (160.6±130.7
mg/dl, p=.002) vs. None (119.3±75.5 mg/dl). In summary, both TASH and Other were associated
with increased PAI-1 and triglycerides. MCP-1 was also increased in TASH, while both HOMA-IR
and insulin were increased in Other.
In ACHS, TASH was associated with increased levels of IL-1β (p=0.04), IL-6 (p=0.03), and
PAI-1 (p=0.03) in our unadjusted model (Table 15). Beta coefficients for other pro-inflammatory
cytokines including IL-8, MCP-1, resistin, and TNFα were positive in TASH but did not reach
statistical significance. TASH was also associated with increased HOMA-IR (p=0.001) with
increased pancreatic insulin production (HOMA-B, p=0.003) and increased insulin levels (p=0.01)
(Table 16) Other was associated with increased IL-6 (p=0.01), HOMA-IR (p=0.02), insulin (p=0.04),
and decreased leptin (p=0.01). Thus, the liver disease categories remained associated with
increased pro-inflammatory cytokines and hepatic insulin resistance after adjustment for
confounders, although the specific cytokines varied slightly between models. This increases the
certainty that the categorization procedures correctly identified liver disease. TASH appeared more
pro-inflammatory than Other due to the greater number of associated cytokines.
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Table 15
Adjusteda beta coefficients of associations of ΣPCBs (wet weight) and liver status with
inflammatory biomarkers
IL-1β
PCB
TASH vs. None

0.01
0.18

0.05
0.09

0.90
0.04

Other vs. None
IL-6
PCB
TASH vs. None

0.25

0.14

0.07

0.05
0.27

0.05
0.09

0.33
0.003

Other vs. None

0.39

0.14

0.01

0.08
0.15
-0.04

0.07
0.12
0.18

0.25
0.20
0.83

0.02
0.01
-0.07

0.03
0.05
0.08

0.53
0.91
0.36

-0.01
0.07

0.02
0.03

0.51
0.03

0.07

0.05

0.15

0.04
0.07
-0.04

0.03
0.06
0.09

0.26
0.20
0.65

IL-8
PCB
TASH vs. None
Other vs. None
MCP-1
PCB
TASH vs. None
Other vs. None
PAI-1
PCB
TASH vs. None
Other vs. None
TNFα
PCB
TASH vs. None
Other vs. None
a

Adjustments were made for lipid levels, age, body mass index, gender, race/ethnicity,
diabetes, and alcohol use.
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Table 16
Adjusteda beta coefficients of associations of ΣPCBs (wet weight) and liver status with
metabolic biomarkers
Cytokine/Adipokine

β

Standard Error

p-Value

0.01
-0.04
-0.06

0.03
0.05
0.08

0.69
0.43
0.43

<0.001
0.00
0.03

0.01
0.02
0.03

1.00
0.90
0.18

-0.07
0.22

0.04
0.06

0.04
<0.001

Other vs. None

0.19

0.09

0.04

HOMA-B
PCB
TASH vs. None

-0.07
0.20

0.04
0.07

0.08
0.003

Adiponectin
PCB
TASH vs. None
Other vs. None
Glucose
PCB
TASH vs. None
Other vs. None
Insulin
PCB
TASH vs. None

Other vs. None
HOMA-IR
PCB

0.13

0.10

0.22

-0.08

0.04

0.03

TASH vs. None

0.21

0.06

0.001

Other vs. None

0.21

0.09

0.02

-0.14

0.04

<0.001

TASH vs. None
Other vs. None

-0.06
-0.24

0.06
0.09

0.32
0.01

Resistin
PCB
TASH vs. None
Other vs. None

0.01
0.06
-0.06

0.03
0.05
0.07

0.81
0.20
0.41

Leptin
PCB

a

Adjustments were made for lipid levels, age, body mass index, gender, race/ethnicity,
diabetes, and alcohol use.
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Liver injury in Anniston was validated by microRNA analysis and clinical liver function tests
Analysis of serum microRNA was used to validate the findings of ACHS in a subset of the
cohort, described as the ACHS miRNA cohort. Demographic findings for this population are shown
in Table 12. This semi-balanced subgroup differs from the other two in several demographic
characteristics. TASH participants tended to have higher BMI (kg/m2: 32.6 vs. 30.2, p = 0.045),
total lipids (mg/dL: 659 vs. 606, p = 0.04) and insulin/HOMA-B/HOMA-IR (p = 0.01, 0.045, 0.01).
They were more likely to be non-Hispanic white (58% vs. 41%, p = 0.03). Serum levels of 68
microRNAs related to liver and other metabolic disease were quantified by Firefly assay and
compared between CK18-defined TASH and NLD groups in this subcohort.
Differential levels of several microRNAs related to liver injury were seen between two liver
disease categories. The well-characterized biomarker of liver injury, microRNA 122 (miR-122-5p),
was significantly increased in the TASH group vs. the no liver disease (NLD) group. Several other
liver- and metabolic disease-associated microRNA were different between the two groups as well,
including miR-22-3p, miR-320a, and miR-375 (significantly increased), and miR-223-3p was
significantly decreased in TASH vs. NLD (Table 17).
Several microRNA showed significant positive and/or negative associations with the
individual isoforms of CK18, including miR-122, which was associated with an increase in CK18M30 and a smaller positive association with CK18-M65. Of the microRNA transcripts assayed, only
miR-877-5p displayed a similar pattern. Other microRNA showed either positive (hsa_miR_22_3p,
hsa_miR_320a, hsa_miR_375, or negative (hsa_miR_21_5p, hsa_miR_375, hsa_miR_92a_3p)
association with CK18-M65 alone.

Positive and negative associations (β-coefficients) for

microRNA vs. CK-18 isoforms are shown in Table 18.
Liver injury in ACHS-II was validated using clinical liver function tests (LFT). Clinical liver
function tests including ALT, AST, Alkaline phosphatase, and total bilirubin were significantly
elevated in the liver disease categories vs. control (Table 19). It is interesting to note, however,
that by standard cutoffs used by the NHANES laboratory, prevalence of ALT abnormality in ACHS2
for females and males (respectively) would be 7.6% and 3.9% in the NLD category, 42% and 56%
in the OLD category, and 22% and 8.2% in the TASH category, respectively. By the cutoffs
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Table 17
ACHS validation - miRNA data by CK18 liver disease group
Quantile-Normalized Data
Adjusted for age, race, bmi, log(10)-total PCB, log(10)-lipids, plate
Probe

Fold

Adj-P

FDR

Raw-P

NLD

TASH

hsa_miR_122_5p
hsa_miR_223_3p
hsa_miR_22_3p
hsa_miR_320a
hsa_miR_375
hsa_miR_92a_3p

1.58
0.91
1.09
1.09
1.18
0.93

0.02
0.33
0.26
0.04
0.12
0.02

0.01
0.06
0.05
0.01
0.03
0.01

0.003
0.047
0.04
0.01
0.02
0.003

83.37
533.99
865.24
1320.94
6.94
1457.91

132.13
485.08
941.12
1444.48
8.19
1357.75

A subset of samples from ACHS Phase 1 were analyzed for levels of specific microRNA
(miRNA) species associated with liver and/or metabolic disease. Individuals with CK18indicated TASH (TASH) were compared to individuals with CK levels indicating no liver disease
(NLD). Included in this table are those with a significant difference between groups (raw pvalue < .05).
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Table 18
Adjusted β-coefficients of CK-18 and miRNA levels.

Probe
hsa_miR_122_5p
hsa_miR_21_5p
hsa_miR_22_3p
hsa_miR_29a_3p
hsa_miR_29c_3p
hsa_miR_320a
hsa_miR_375
hsa_miR_503_5p
hsa_miR_877_5p
hsa_miR_92a_3p

β
1.00
0.01
0.09
-0.05
-0.10
0.09
0.09
-0.04
0.20
-0.08

CK18-M30
Standard
Error
Raw-P
0.33
0.13
0.09
0.08
0.10
0.07
0.15
0.10
0.10
0.05

0.003
0.94
0.31
0.52
0.36
0.19
0.55
0.70
0.04
0.15

β
0.20
-0.19
0.14
-0.10
-0.10
0.10
0.20
-0.12
0.14
-0.09

CK18-M65
Standard
Error
Raw-P
0.09
0.08
0.05
0.05
0.06
0.04
0.09
0.06
0.06
0.03

0.02
0.02
0.01
0.06
0.11
0.04
0.03
0.05
0.02
0.003

Several miRNA species showed significant positive or negative associations with either CK18
M30 level or CK18 M65 level.
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Table 19
ACHS-II validation – LFTs by CK18 liver disease group
Liver disease status
Characteristic

None

TASH

Other

(n = 131)

(n = 158)

(n = 56)

P-value

AST

25.9±8.1

29.0±12.1

42.2±27.4

<0.001

ALT

22.8±8.6

29.6±9.8

38.3±19.3

<0.001

Alk Phos

85.5±22.7

91.1±38.9

104.7±58.0

0.01

Albumin

4.2±0.4

4.2±0.4

4.2±0.5

0.85

Total Bilirubin

0.36±0.16

0.42±0.24

0.46±0.24

0.01

Liver injury was validated in ACHS 2 (Phase 2) using the clinical liver injury biomarkers
aspartate transaminase (AST), alanine transaminase (AST), alkaline phosphatase (Alk Phos),
albumin, and total bilirubin.
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suggested in Prati et al., (Table 20) prevalence of ALT abnormality in ACHS2 for females and males
(respectively) would be 61% and 15% in the NLD category, 76% and 94% in the other liver disease
(OLD) category, and 82% and 33% in the TASH category. By either set of definitions, ALT performs
better as a diagnostic tool for individuals with liver injury in which the predominant mechanism of
cell death is apoptosis.

Associations between ΣPCBs on Liver Disease as assessed by CK18, LFTs and miRNA 122
Previous epidemiologic studies have demonstrated dose responses for PCBs in liver
disease 95-99, and animal studies have demonstrated interactions between PCBs and diet-induced
obesity in steatohepatitis22,

.

23

Univariate analysis was performed in the ACHS-1 cohort to

determine associations between ƩPCBs and the liver injury biomarkers used to derive the liver
injury categories (Table 13). There were no significant associations between ƩPCB exposure
variables (lipid-adjusted or wet weight) and either CK18 M65 or M30 in the population overall.

A

sensitivity analysis was performed, excluding thirteen participants of 738 with total PCB wet weight
values within four standard deviations of the mean. In this sensitivity analysis alone, significant
negative associations were found between both lipid-adjusted and wet-weight serum PCB content
and CK18 M30, but not M65.
Multinomial logistic regression was performed using multivariate models adjusted with or
without additional confounders to investigate possible relationships between ƩPCBs and BMI and
liver disease status (Table 21). Liver disease status was not associated with either ƩPCB levels or
BMI whether alone or in combination. In both cohorts, there was no association between ƩPCBs
or ƩPCB-O on liver disease status as determined by CK-18 (Table 22). When taken together, these
results demonstrate that these two summation techniques, ƩPCBs and ƩPCB-O, were not
associated with CK-18-indicated liver disease status.
In the ACHS microRNA subcohort, after adjustment for age and race there was no
association between ƩPCB-O and miRNA 122. Two other miRNA were significantly positively
associated (hsa-let-7d-5p and hsa-miR-181d-5p) (Table 23). In ACHS-II, after adjustment, there
was were no associations between ƩPCB-O and clinical LFTs (data not shown).
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Table 20
Cutoff values for upper limit of normal for the clinical liver injury biomarker alanine
aminotransferase (ALT)
(2003-2004
NHANES study)
Men 18-21 ALT ≥ 37 IU/L
Men >21 ALT ≥ 48 IU/L
Women 18-21 ALT ≥ 30 IU/L
Women >21 ALT ≥ 31 IU/L

UofL upper limit
of reference
ALT ≥ 70 IU/L
ALT ≥ 70 IU/L
ALT ≥ 70 IU/L
ALT ≥ 70 IU/L

Prati, 2002
upper limits
30 U/L
30 U/L
19 U/L
19 U/L

Several cutoff values for the upper limit of normal have been proposed to define liver disease
based on serum alanine aminotransferase levels.
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Table 21
Effects of PCBs and BMI on liver disease status by multinomial logistic regression.

Multivariate Analysisb

0.095

Estimate
0.01

0.24

(SE)

0.004

0.003

-0.35

Estimate

0.55

0.01

0.02

0.37

(SE)

-0.006

-0.002

0.29

Estimate

0.01

0.01

0.27

(SE)

0.002

0.002

-0.01

Estimate

0.57
0.01
0.29
0.32
0.30
0.34

0.01

0.02

0.41

(SE)

Univariate Analysisa

PCBc
-0.009
0.01
1.23

0.70
-0.02
-0.32
-1.01
0.02
0.52

0.32

Other

BMI
-0.004
0.36

0.38
0.01
0.19
0.21
0.20
0.22

0.64

TASH

PCBc*BMI
0.93

0.51
-0.004
-0.46
-1.05
0.14
0.24

0.21

Other

Lipidc, ng/g
Age, years
Gender
Race
Alcohol Use
Pre-diabetic

0.42

TASH

Diabetic
Abbreviations: BMI, body mass index; PCB, Polychlorinated Biphenyl; SE, standard error.
Notes: Reference category is no liver disease.
Adjusted for lipid levels (natural log-transformed).
b

Natural log-transformed.

Adjusted for age, gender, race, diabetes status, alcohol use, and lipid levels (natural log-transformed).

a

c
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Table 22

None (n = 294)

TASH (n = 359)

5.4±10.3

Other (n = 85)

P-value

Total (n = 738)

7218.9

5599.6

2850.9

9810.0

0.15

0.49

0.20
0.20

720.9

3441.6

1337.7

5677.1

950.0

4367.6

2060.5

7398.7

6.7±12.1

7.2±14.4

None (n = 131)
Mean
SD
6.0
6.4
5411.0

1460.9

5642.8

0.04

0.40

6.4±9.1

Liver disease status

PCB groupings and CK-18 liver disease status in ACHS and ACHS-II
ACHS
Group
ƩPCB-O (whole weight)
ACHS-II

6402.1

1921.8

3277.8

1153.0

Liver disease status

6031.1

1272.1

4289.2

636.3

P-value

∑PCBs (whole weight), ppb
1822.9

3278.7

958.4

Group

ƩPCB-O
1364.0
3830.4

680.4

Total (n = 345)
Mean
SD
5.7
7.4

ƩPCB-TO
3708.2
838.9

Other (n = 56)
Mean
SD
5.6
9.8

ƩPCB-DO
805.9
1.4

0.7

5.8

1.5

0.9

4.9

1.2

0.6

6.5

1.7

0.9

5.1

1.1

0.6

9.0

2.2

1.3

0.23

0.04

5.1

1.3

0.7

6.7

1.7

1.0

TASH (n = 158)
Mean
SD
5.4
7.2

ƩPCB-MO

5.4

0.07

ƩDL

ƩPCB-NO
ƩNDL

0.06
303.2
338.2
257.6
366.2
258.4
471.2
275.0
374.7
ƩEL 1
0.09
1380.9
1466.2
1179.0
1570.0
1132.6
1877.3
1248.1
1584.9
ƩEL 2
0.04
692.0
743.7
583.0
856.7
525.9
939.9
615.1
830.2
ƩAE
0.03
561.9
637.4
457.0
715.5
432.8
866.9
492.9
714.4
ƩTLc
0.26
1534.9
1622.9
1420.2
1913.7
1515.5
2902.0
1479.3
2004.0
ƩRL
Data are n(%) or mean±SD. Not all percents add to 100% due to rounding. Note that cytokeratin 18 levels were used for categorization
procedures.
P-value is one-way ANOVA (means) or Pearson chi-square test, across liver disease categories.
adj-p<=0.05 in pair-wise comparison of None vs. Other liver disease category.
c
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Table 23
Significant associations of ∑PCBs and miRNA species
∑PCBs, whole weight
Standard
β
Error
miRNA species
0.07
0.03
hsa_let_7d_5p
0.08
0.03
hsa_miR_181d_5p

Raw-P
0.03
0.003

After adjustment for lipids, age, race, and inter-plate variation, no significant relationship was
found between the specific liver injury biomarker miRNA-122 and ∑PCBs . Two other miRNA
species, miRNA-let-7d and miRNA-181d, were positively associated with ∑PCBs.
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Associations between individual PCB congeners and CK18-indicated liver disease in ACHS
In the ACHS 1 cohort, TASH was positively associated with 10 PCB congeners (PCB 28,
44, 49, 52, 66 101, 110, 128, 149, 151). Three congeners associated with TASH were also
associated with Other (PCB 44, 49, 52). To explore the relationship between PCB levels and cell
death mechanism, we examined associations between levels of individual congeners and absolute
levels of CK18 M65 and M30. Thirteen congeners were positively associated with CK18 M65, while
four PCBs were positively associated with M30 (Table 24). In ACHS1, consistent with the concept
that TASH is ‘toxicant-associated’, more PCB congeners were associated with TASH than Other
(10 vs. 3). The relationships between serum PCB concentration and CK18 M65/M30 were different
for individual congeners than for summed groups. Although 13 congeners were positively
associated with CK18 M65, ƩPCBs was not associated with this hepatocellular necrosis biomarker.
While four congeners were positively associated with M30, ƩPCBs was inversely associated with
this hepatocyte apoptosis biomarker.
In the ACHS1 population, therefore, PCBs were associated with both liver disease status
and mode of hepatocyte death. Future experimental studies are required to evaluate the possible
mechanistic role of PCBs in liver cell death. While animal studies have reported interactions
between PCB exposures and diet-induced obesity in steatohepatitis 22, 23, no significant interaction
was found between ƩPCBs and BMI on liver disease status in this study. However, this analysis
may have been limited by the high prevalence of overweight/obesity and the elevated PCB levels
in this population.

Associations between TEQs for PCB congeners and other dioxin-like species on CK18indicated liver injury in ACHS-II
Within the ACHS-II population, we estimated effects of dioxin-like chemicals on liver
disease by using the TEQ protocol. As mentioned previously, the effects of dioxin-like chemicals
have historically been attributed to AhR-mediated mechanisms, and the TEQ, by estimating the
cumulative, weighted load of AhR ligands, can be used as an exposure variable to explore the
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Table 24

Estimate
0.03

p-value

0.01
0.01
0.001

p-value

Other vs. None
Estimate

0.73
0.71
0.59

0.01
0.01
0.001

M30b

0.11
0.10
0.09

0.04

p-value

0.05

Estimate

0.07

Estimate

0.01
0.01
<0.001
<0.001
0.02
0.03
0.04

<0.001

p-value

0.01
0.02
0.03
0.04
0.04

0.11
0.10
0.11
0.07
0.05
0.04
0.05

M65b

ACHS adjusted beta coefficients of significant associations of liver disease status and CK-18 biomarkers by individual PCB congeners

0.24
0.04
0.004
0.01
0.002
0.05

Liver Diseasea

0.45
0.66
0.37
0.29
0.20
0.004
0.02
0.02
0.01

TASH vs. None

0.36
0.22
0.24
0.25

0.05
0.04
0.04
0.04
0.04
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28
44
49
52
66
101
105
110
128
149
151
172
178
187
195

Note that all congeners given in this table had at least a 96.7% detection rate. No significant differences were seen for PCB congeners 74, 87,
99, 118, 138, 146, 153, 156, 157, 167, 170, 177, 180, 183, 189, 194, 196, 199, 206, 209.

a
Multinomial model adjusted for age, sex, race, alcohol use, log lipids, diabetes (pre- and any vs. none)
Regression model adjusted for age, sex, race, alcohol use, log lipids, diabetes.
b

PCB Congener

relationship between AhR induction and disease biomarkers. Associations between Total dioxin
TEQ, TEQ by individual class (PCDD, PCDF, PCB), and TEQ for each dioxin-like chemical with a
TEF available in the 2005 WHO evaluation were evaluated and are presented in Table 25. Adjusted
beta coefficients of significant associations of various TEQ summations and cytokeratin 18
biomarkers are shown in Table 26. We did not find significant associations between log transformed
mean of any TEQ sum and TASH status vs. None. Non-Ortho PCB TEQ and Total Dioxins TEQ
were significantly lower in the Other liver disease category compared to None.

Associations between PCBs and other serum biomarkers
PCB exposure has previously been associated with diabetes

. However, less is known
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regarding the potential impact of PCBs on adipocytokines. For ACHS, the effects of lipid-adjusted
ΣPCB levels on unadjusted adipocytokines and biomarkers of glucose and lipid metabolism are
given as beta coefficients in Table 16. The pro-inflammatory cytokines TNFα (p<0.001) and IL-6
(p=0.001), were positively associated with ΣPCBs in the unadjusted model. PCBs had no significant
effects on IL-1β, IL-8, MCP-1, PAI-1, or resistin. HOMA-B (p<0.001) and insulin (p=0.03) levels
were inversely associated with ΣPCB levels; while no effect was seen on HOMA-IR. Adiponectin
was positively associated with PCBs (p=0.01) while no difference was seen in leptin. Regression
curves presented in Figure 6 graphically depict the relationships between log-transformed insulin
and leptin levels with log-transformed ƩPCBs in ACHS.
For the ACHS-2 unadjusted model, biomarkers which varied significantly with changes to
serum concentrations of all PCBs measured (ΣPCB), 35 ortho-substituted congeners (ΣPCB-O),
or the non-dioxin-like congeners (ΣNDL) are shown in Table 27. In the same population and model,
the biomarkers which varied significantly with changes to serum concentrations of tri/tetra-ortho
substituted congeners (ΣPCB-TO), di-ortho substituted congeners (ΣPCB-DO), or mono-ortho
substituted congeners (ΣPCB-MO) are shown in Table 28, while those which varied significantly
with changes to serum concentrations of non-ortho substituted congeners (ΣPCB-NO), or dioxinlike (ΣDL) are shown in Table 29. A summary of the congeners represented in each grouping is
presented in Table 2.
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Table 25
TEQ for dioxin-like PCBs and other dioxin-like species and CK-18-indicated liver disease status in ACHS-II
Liver disease status
Mean
4.4
13.6

SD
4.3

1.0

6.7

Mean
3.6

13.9

1.0

13.3

SD
4.5

10.0

8.1

1.1

7.0

Mean
3.4

3.7

6.8

18.2

1.7

17.3

SD
5.3

0.09

0.23

0.08

0.04

0.17

0.24

0.03

14.0

2.8

11.2

8.7

1.1

7.6

Mean
3.8

9.6

2.3

7.7

14.8

1.2

14.1

SD
4.6

Total (n = 345)

8.9
1.0
7.7

7.8

3.1

9.9

P-value

PCB 126 TEQ, log-transformed
1.2
14.2

10.8

1.7

13.1

Other (n = 56)

PCB 169 TEQ, log-transformed
10.0
7.8

2.6

9.3

TASH (n = 158)

Non-ortho PCBs TEQ, logtransformedc
12.2
2.2

13.4

None (n = 131)

PCDD TEQ, log-transformed
3.0

9.7

Characteristic

PCDF TEQ, log-transformed
15.2

123678_HxCDD TEQ, log-transformed

12378_PeCDD TEQ, log-transformed

Total Dioxin TEQ, log-transformedc

PCDD, PCDF, cPCBs TEQ, logtransformed

2.0

3.2

5.9

29.2

25.2

1.4

1.9

3.6

24.3

20.8

1.7

3.0

5.2

24.1

21.1

1.3

2.1

3.7

24.0

20.0

2.1

2.7

5.0

24.2

21.1

3.2

1.8

3.3

28.5

23.5

0.45

0.10

0.09

0.02

0.047

1.9

3.0

5.4

26.0

22.7

1.8

2.0

3.6

24.9

20.9

Mono-ortho PCBs TEQ, log-transformed

PCDD and PCDF TEQ, log-transformed

23478_PeCDF TEQ, log-transformed

Data are n(%) or mean±SD. Not all percents add to 100% due to rounding. Note that cytokeratin 18 levels were used for categorization
procedures.
P-value is one-way ANOVA (means) or Pearson chi-square test, across liver disease categories.
adj-p<=0.05 in pair-wise comparison of None vs. Other liver disease category.
c
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Table 26
Adjusted beta coefficients of significant associations of various TEQ summations and CK-18 biomarkers in ACHS-II
Liver Diseasea
M30b

-0.28

0.20
0.26
0.55
0.57

0.13

0.11
-0.09
0.07
-0.03
0.45

-0.10
0.44
0.06
0.05

-0.11

0.91
0.89

0.59
0.79
0.86
0.95
0.16

0.78
0.19
0.77
0.78

0.66

0.02
0.01

0.004
-0.03
0.03
0.02
0.09

0.01
0.09
-0.02
0.01

-0.02

Estimate

0.76
0.82

0.92
0.67
0.65
0.78
0.17

0.86
0.16
0.69
0.82

0.61

p-value

-0.03
-0.01

0.01
0.01
-0.04
-0.03
0.01

-0.02
-0.002
-0.006
-0.01

-0.04

Estimate

0.59
0.85

0.67
0.81
0.43
0.60
0.87

0.66
0.96
0.85
0.79

0.28

p-value

M65b

Total TEQ

-0.34
-0.30
-0.10
-0.08

0.65
0.93
0.14
0.24
0.48

-0.04
0.04

Other vs.None
Estimate
p-value

By class
PCDD
PCDF
Mono-ortho PCBs
non-ortho PCBs

0.07
0.02
-0.44
-0.37
-0.18

0.20
0.50

TASH vs. None
Estimate
p-value

Individual congeners
PCB126
PCB 169
1,2,3,7,8 PeCDD
1,2,3,6,7,8 HxCDD
2,3,4,7,8 PeCDF TEQ

-0.36
-0.15

Exposure

Other summations
PCDD and PCDF
PCDD, PCDF, AND Non-ortho PCB

Exposure and CK18 values are log-transformed
a
Multinomial
model adjusted for age, sex, race, alcohol use, diabetes (and log-transformed total lipids for whole weight sum of PCBs).
Regression model adjusted for age, sex, race, alcohol use, diabetes (and log-transformed total lipids for whole weight sum of PCBs).
b
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Figure 6. ƩPCBs were inversely associated with metabolic biomarkers in ACHS. Regression
lines showing the change in insulin (Panel A) and leptin (Panel B) with increasing serum
PCB load are shown for each liver disease group.
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Table 27
Unadjusted ACHS-II biomarker levels by sum of all PCBs (∑PCBs ) sum of 35 orthosubstituted congeners (∑PCB-O), and all non-dioxin-like congeners (ƩNDL)
β
SE
P-value
Adiponectin (ug/ml)
0.07
0.03
0.03
∑PCBs
MCP-1
-0.07
0.03
0.01
TNFa
0.07
0.04
0.04
ALT (SGPT)
-0.06
0.02
<.001
ALK PHOS
0.04
0.01
0.02
Albumin
-0.01
0.00
0.04
Insulin pmol/L
-0.12
0.04
<.001
HOMA-IR
-0.10
0.04
0.01
HOMA-B
-0.13
0.05
0.01
Hyaluronic Acid (ng/ml)
0.36
0.04
<.001
Insulin
-0.12
0.04
<.001
CK18 M30
-0.08
0.03
0.00
Adiponectin (ug/ml)
0.08
0.03
0.02
ƩPCB-O
MCP-1
-0.08
0.03
0.00
ALT (SGPT)
-0.07
0.02
<.001
ALK PHOS
0.03
0.01
0.02
Albumin
-0.01
0.00
0.01
Insulin pmol/L
-0.13
0.04
<.001
HOMA-IR
-0.12
0.04
0.01
HOMA-B
-0.14
0.05
0.01
Hyaluronic Acid (ng/ml)
0.37
0.04
<.001
Insulin
-0.13
0.04
<.001
CK18 M30
-0.08
0.03
0.00
CK18 M65
-0.04
0.02
0.04
Adiponectin (ug/ml)
0.08
0.03
0.02
ƩNDL
MCP-1
-0.08
0.03
0.00
ALT (SGPT)
-0.06
0.02
<.001
ALK PHOS
0.03
0.01
0.02
Albumin
-0.01
0.00
0.02
Insulin pmol/L
-0.13
0.04
<.001
HOMA-IR
-0.12
0.04
0.00
HOMA-B
-0.14
0.05
0.01
Hyaluronic Acid (ng/ml)
0.37
0.04
<.001
Insulin
-0.13
0.04
<.001
CK18 M30
-0.08
0.03
0.00
CK18 M65
-0.04
0.02
0.04
For the ACHS-II unadjusted model, biomarkers which varied significantly with
changes to serum concentrations of all PCBs measured (ΣPCB), 35 ortho-substituted
congeners (ΣPCB-O), or the non-dioxin-like congeners (ΣNDL) are shown.
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Table 28
Unadjusted ACHS-II biomarker levels by groups of ortho-substituted PCBs
β
SE
Adiponectin (ug/ml)
0.08
0.03
ƩPCB-TO
MCP-1
-0.08
0.03
ALT (SGPT)
-0.07
0.02
ALK PHOS
0.03
0.01
Albumin
-0.01
0.00
Insulin pmol/L
-0.13
0.03
HOMA-IR
-0.13
0.04
HOMA-B
-0.13
0.05
Hyaluronic Acid (ng/ml)
0.34
0.04
Insulin
-0.13
0.03
CK18 M30
-0.07
0.03
Adiponectin (ug/ml)
0.07
0.03
ƩPCB-DO
MCP-1
-0.09
0.03
ALT (SGPT)
-0.07
0.02
ALK PHOS
0.03
0.01
Albumin
-0.01
0.00
Insulin pmol/L
-0.13
0.04
HOMA-IR
-0.12
0.04
HOMA-B
-0.13
0.05
Hyaluronic Acid (ng/ml)
0.37
0.04
Insulin
-0.13
0.04
CK18 M30
-0.09
0.03
CK18 M65
-0.05
0.02
Adiponectin (ug/ml)
0.08
0.03
ƩPCB-MO
MCP-1
-0.06
0.03
TNFa
0.08
0.04
ALT (SGPT)
-0.08
0.02
ALK PHOS
0.04
0.01
Albumin
-0.02
0.00
Insulin pmol/L
-0.11
0.04
HOMA-B
-0.14
0.05
Hyaluronic Acid (ng/ml)
0.33
0.04
Insulin
-0.11
0.04
Leptin
0.23
0.05
CK18 M30
-0.08
0.03
CK18 M65
-0.06
0.02
For the ACHS-II unadjusted model, biomarkers which varied significantly with

P-value
0.01
0.00
<.001
0.03
0.01
<.001
0.00
0.01
<.001
<.001
0.01
0.03
0.00
<.001
0.02
0.02
<.001
0.01
0.01
<.001
<.001
0.00
0.03
0.02
0.03
0.03
<.001
0.01
<.001
0.00
0.01
<.001
0.00
<.001
0.00
0.01

changes to serum concentrations of tri/tetra-ortho substituted congeners (ΣPCB-TO), di-ortho
substituted congeners (ΣPCB-DO), or mono-ortho substituted congeners (ΣPCB-MO) are
shown.
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Table 29
Unadjusted ACHS-II biomarker levels by groups of non-ortho-substituted and dioxin-like PCBs
β
SE
P-value
AST (SGOT)
-0.06
0.02
0.00
ALT (SGPT)
-0.08
0.02
<.001
Albumin
-0.02
0.01
<.001
Total Bilirubin
-0.07
0.03
0.02
Direct Bilirubin
-0.05
0.02
0.04
Hyaluronic Acid (ng/ml)
0.22
0.05
<.001
IL-6
0.14
0.06
0.01
Leptin
0.27
0.06
<.001
CK18 M30
-0.08
0.03
0.02
CK18 M65
-0.06
0.03
0.02
TNFa
0.09
0.03
0.01
ƩDL
AST (SGOT)
-0.04
0.02
0.03
ALT (SGPT)
-0.08
0.02
<.001
ALK PHOS
0.04
0.01
0.01
Albumin
-0.01
0.00
<.001
Insulin pmol/L
-0.10
0.03
0.00
HOMA-B
-0.14
0.04
0.00
Hyaluronic Acid (ng/ml)
0.31
0.04
<.001
Insulin
-0.10
0.03
0.00
Leptin
0.18
0.05
<.001
CK18 M30
-0.07
0.02
0.00
CK18 M65
-0.05
0.02
0.01
For the ACHS-II unadjusted model, biomarkers which varied significantly with changes to
ƩPCB-NO

serum concentrations of non-ortho substituted congeners (ΣPCB-NO), or dioxin-like (ΣDL) are
shown.
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In ACHS-II, significant positive relationships were observed between ƩPCBs and
adiponectin, TNFα, alkaline phosphatase, and hyaluronic acid, while significant negative
relationships were observed between ƩPCBs and MCP-1, ALT, Albumin, Insulin, HOMA-IR, and
HOMA-B. Interestingly, while most of these relationships were conserved between ƩPCBs and
other grouping structures, the positive relationship between summed PCBs and TNFα was
observed only in the comparison with mono-ortho (β=0.08±0.04, p=0.03) and dioxin-like
(β=0.09±0.03, p=0.01) PCBs, along with an additional positive relationship with IL-6 (β=0.14±0.06,
p=0.01) observed in the dioxin-like group (Tables 27-29). This suggests a relationship between
the inflammatory processes contributing to PCB-related TASH and the structural characteristics of
congeners within the exposure mixture.
In the adjusted model, ΣPCBs remained associated with abnormal glucose metabolism.
ΣPCBs were associated with decreased HOMA-IR (p=0.03) and insulin (p=0.04), with a trend
towards decreased HOMA-B (p=0.08) (Table 30). ΣPCBs were also associated with decreased
leptin (p<0.001). To investigate these associations further, we determined adjusted beta
coefficients for individual PCB congeners and these biomarkers (Table 31). Significant inverse
associations were seen between seven high molecular weight PCB congeners and both HOMA-IR
and insulin. Twenty-six congeners (both low and high molecular weight) were inversely associated
with leptin. Inverse associations were also found between HOMA-B and PCBs 180 and 194. ΣPCBs
was no longer associated with increased pro-inflammatory cytokines in the adjusted model. Thus,
PCBs appeared to modulate both liver cell death mechanism, intermediary metabolism, and
adipokines. The liver-specific impact of PCBs on inflammation was less certain due to variability
between the adjusted and unadjusted models.
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Table 30
ACHS adjusteda beta coefficients of associations of ΣPCBs (wet weight) with biomarkers
Cytokine/Adipokine

β

SE

p-Value

<0.001
-0.07
-0.07
-0.08

0.01
0.04
0.04
0.04

0.04
0.08

IL-1β
IL-6
IL-8
Leptin

0.01
0.05
0.08
-0.14

0.05
0.05
0.07
0.04

<0.001

MCP-1
PAI-1
Resistin
TNFα

0.02
-0.01
0.01
0.04

0.03
0.02
0.03
0.03

0.53
0.51
0.81
0.26

Glucose
Insulin
HOMA-B
HOMA-IR

a

1.00

0.03
0.90
0.33
0.25

Adjustments were made for lipid levels, age, body mass index, gender, race/ethnicity,
diabetes, and alcohol use.
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Table 31
Adjusted beta coefficients of significant associations of PCB congeners with

PCB Congener

biomarkers of glucose metabolism
HOMA-B
HOMA-IR
PCB
PCB
28
44
52
66
74
101
-0.07
110
128
138
146
151
153
156
157
-0.08
167
170
-0.08
172
177
178
180
-0.08
-0.08
183
187
189
-0.09
194
-0.07
-0.08
195
196
-0.08
199
-0.08
206
-0.06
209

Insulin
PCB

Leptin
PCB
-0.08
-0.16
-0.10
-0.06

-0.07
-0.13
-0.09
-0.07
-0.07

-0.08
-0.07

-0.08

-0.08
-0.08
-0.07

-0.09
-0.13
-0.13
-0.06
-0.15
-0.06
-0.14
-0.12
-0.16
-0.06
-0.10
-0.16
-0.17
-0.13
-0.13
-0.15
-0.13
-0.114

In ACHS-II, several individual congeners were associated with biomarkers or
assessments of metabolic disease. Leptin was negatively associated with most
congeners, while insulin and HOMA-IR were primarily negatively associated with
higher molecular weight congeners.
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CHAPTER ONE: DISCUSSION
To our knowledge, the 738 subjects in ACHS make this the largest environmental liver
disease study ever undertaken using sensitive mechanistic biomarkers. The overall liver injury
prevalence of over 60% is among the highest ever reported for a residential cohort, and is well
above estimates of NAFLD prevalence in the US and worldwide. Importantly, this high
prevalence was maintained across both phases, suggesting that the injury remains chronic and
the biomarkers of that injury are persistent. Positive associations between TASH categorization
and elevated pro-inflammatory cytokines, insulin resistance, and hypertriglyceridemia further
support our conclusion that chronic steatohepatitis has occurred and is persistent in these
subjects.
The individuals comprising the ACHS and ACHS-II cohorts are highly contaminated with
PCBs due to the proximity to a former PCB-manufacturing facility and exposure to PCBcontaining waste released into the environment. Most subjects within these cohorts were also
overweight or obese, and the ACHS cohort was previously reported to have elevated prevalence
of disease components of the metabolic syndrome, therefore, we expected to find increased
prevalence of NASH, consistent with these reports, and we hypothesized that mechanism of
hepatic injury would be consistent with TASH because of the toxicant exposure. Liver injury in
80% of ACHS and 73.8% of ACHS-II cases was associated with hepatocellular necrosis, a
characteristic of TASH83, 84 but not of NASH, or ASH, which are associated with increased
hepatocellular apoptosis91.
The liver is the principal target organ for organochlorine toxicants such as PCBs101-103.
Associations between PCBs and liver injury have been demonstrated in industrial exposures and
in cases of accidental poisoning in humans, and chronic PCB exposure has been shown to cause
steatohepatitis in laboratory animal models. Attempts to demonstrate a straightforward
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relationship between environmental PCB exposure and liver injury in humans, however, has been
frustrated, in part, by the lack of adequate biomarkers. In 2010, our laboratory published an
evaluation of the 2003-2004 NHANES data, which showed an association between serum levels
of PCBs and elevations of the clinical liver injury biomarker ALT. In this study, using upper limits
defined in the 2003-2004 NHANES laboratory protocol104, 10.6% of subjects had ALT elevation
not attributable to viral hepatitis, hemochromatosis, or alcohol abuse37. Odds of inclusion in this
group increased with increasing levels of serum PCBs, and inclusion was also associated with
overweight/obesity and Hispanic/non-Hispanic White ethnicity, both of which are associated with
increased NASH prevalence. The association between PCBs and liver injury in this population
persisted even after adjustment for BMI, however, the use of ALT in the NHANES population
does not allow discrimination between NASH and TASH as potential etiologies for liver injury37.
The use of CK18 M30 and M65 in the ACHS cohorts allowed dissection of these
etiologies based on cell death mechanism. Our validation studies using alternative (miRNA) or
approved clinical (ALT) diagnostic methods indicate significantly elevated markers of liver injury in
the CK18-designated liver injury groups vs. NLD indicate that CK18 can detect liver injury in a
population such as the ACHS cohorts, where TASH is suspected. This capability is particularly
important when one considers the findings of the ACHS-II clinical liver function tests, which
indicate statistically significant but clinically irrelevant elevations in mean ALT within the TASH
group. Mean values for both NLD and “TASH” groups are well below the clinical cutoffs used in
the 2003-2004 NHANES study as well as in most clinical applications. Using the upper limits
recommended in Prati et al., 200263 (shown in Table 20), which redefined the cutoffs using a
cohort at low risk for chronic HCV infection or NAFLD, a much larger proportion of the ACHS-II
cohort has ALT values in the abnormal range (Figure 7), however, even by the Prati definitions,
ALT abnormality was only detected in 33% of males within the TASH group. This contrasts with
females in the TASH group, 82% of whom had ALT abnormalities with the lower cutoff. Liver
injury due to chronic TASH or TASH superimposed on NASH may not be detected in a clinical
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ALT

Liver Disease Status

Figure 7. Distribution of ALT levels in ACHS by liver disease category.
Distribution of ALT levels for female (blue circles) and male (green squares) participants in the
three CK18-defined liver disease categories, with lines indicating upper limits of normal based on
the NHANES (black lines) or Prati definition (red lines). The upper limit of normal for females is
the lower line in each color, while the upper limit of normal for males is the upper line in each
color. Males tended to have higher ALT levels in all groups
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setting using common screening methods, and this could delay identification therapeutic
intervention.
Neither ƩPCBs nor BMI was associated with liver disease in the ACHS cohorts, though
ƩPCBs has been previously associated with liver disease in other epidemiologic studies

37, 95-99

.

Differences in methodologies and demographic/exposure variables might account for this
discrepancy. However, exposures to 13 specific PCB congeners were associated with TASH and/or
CK18 M65 elevation in the ACHS cohort. Of these, PCBs 66, 105, 149, 151, 172, 178, and 187
were previously associated with increased ALT in NHANES97. The present study using mechanistic
biomarkers greatly extends this prior work. Some of the thirteen identified PCB congeners (PCBs
28, 66, 105, and 128) have dioxin-like activity, while others have estrogenic (44, 49, 52, 101, 110)
or phenobarbital-like (44, 49, 52, 101, 128, 149, 151, 187, 195) effects

. Perhaps activation of

105

the AhR, estrogen receptor, or the constitutive androstane receptor (CAR) may be involved in PCBrelated TASH. While four congeners were associated with increased CK18 M30, an inverse
association was observed between ΣPCBs and this apoptosis biomarker. Notably, activation of
the PCB receptor CAR, was found to be anti-apoptotic in a mouse model of cholestatic liver disease
. This supports our clinical observation that some phenobarbital-like PCBs, which activate CAR,

106

were associated with TASH106. Although not directly tested in this study, it is conceivable that PCBs
could mediate a transition from NASH to TASH by decreasing apoptosis and promoting more proinflammatory necrotic hepatocyte death. While PCBs were a ‘second hit’ in the transition from dietinduced steatosis to more advanced liver disease in animal studies23, 107-109, a significant interaction
between PCBs and BMI on liver disease status was not observed in the present study. Perhaps
the high rates of overweight/obesity and elevated PCB levels in the cohort limited the ability to
detect interactions occurring at lower exposures and body weights.
In ACHS-II, the relationship between pro-inflammatory biomarkers and less orthosubstituted congener groupings again suggests receptor-mediated disease processes, although
the loss of significant relationships in the model adjusted for diabetes may indicate that modulation
of inflammatory response in TASH may be an extrahepatic effect.
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In ACHS, liver disease affected males (67.2%) and non-Hispanic whites (70.2%)
disproportionately. The sex difference is consistent with a recently published report documenting
increased mortality from hepatic disease in men exposed to PCB through ingestion of contaminated
rice oil110. Moreover, men and Caucasians have increased susceptibility to NAFLD90. Genetic
polymorphisms may contribute to ethnic differences in NASH90,

.

111, 112

For example, ethnic

differences in the distribution of null alleles in the NASH susceptibility gene (patatin-like
phospholipase domain containing protein 3 - PNPLA3), have been reported. We postulate that
gene-environment interactions may also influence TASH; and that these interactions may have
contributed to the ethnic differences observed in this study. In addition to PNPLA3, candidate
genes include the pregnane X receptor (PXR), which is a PCB receptor
polymorphisms previously associated with NAFLD severity

19

with at least two

. The observed gender differences
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could potentially be explained by estrogenic PCB congeners.
While steatohepatitis has long been associated abnormal adipocytokines

83, 84

relatively

less is known about the effects of PCBs on these biomarkers. In a cohort of 992 elderly Swedish
subjects, ƩPCBs was significantly associated with vascular cell adhesion protein 1 but not IL-6,
MCP-1, or TNFα 114. However, Aroclor 1260 increased TNFα, IL-6, and PAI-1 23, 108 in mice fed high
fat diet. Adiponectin was inversely associated with PCB 28, 138, and 153 in a study of 98 Koreans
; but ƩPCBs was not associated with adiponectin levels in the Great Lakes Sport Fish Caught
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Consumers Study (n=413)116. Leptin receptor expression was decreased in PCB-exposed children
; and PCB-exposures induced leptin resistance in the 3T3-L1 cell culture model while increasing
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both TNFα and IL-6 production

; In the present study, ƩPCBs was associated with increased
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TNFα and IL-6, but only in the unadjusted model. While ƩPCBs was associated with increased
adiponectin in the unadjusted model, it was associated with decreased leptin in the adjusted model.
Importantly, in the adjusted model twenty-six PCB congeners were individually associated with
decreased leptin. If PCBs decrease leptin expression while simultaneously inducing leptin
resistance, this could be an important potential mechanism for PCB-related metabolic dysfunction.
A high prevalence of diabetes (27%) has previously been reported in the ACHS49, and the
impact of PCBs on diabetes has recently been reviewed100. In the present study, ƩPCBs was
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associated with decreased HOMA-B in the unadjusted model with a trend (p=0.08) towards
decreased HOMA-B in the adjusted model. ƩPCBs and nine individual high molecular weight
congeners were associated with decreased HOMA-IR in the adjusted model. ƩPCBs were inversely
associated with insulin in both models. Adjustments were not made for diabetes medications, so it
is difficult to draw firm conclusions from these data. Nonetheless, these data are by and large
consistent with the findings from our recently published mouse model. In that experiment, C57Bl/6
male mice fed a 42% milk fat diet for 12 weeks with or without co-exposure to a high molecular
weight PCB mixture (Aroclor 1260) at a dose designed to model ACHS108. PCB treatment induced
steatohepatitis, decreased HOMA-B and HOMA-IR but did not change glucose tolerance. Hepatic
gluconeogenesis, glucose transporters, physical activity, food intake, and respiratory exchange
rate appeared to be regulated, in part, by interactions between PCBs and the nuclear receptors Pxr
and Car

. These studies clearly demonstrate significant derangements in glucose metabolism

108

occurring in the context of PCB-related liver disease. The mechanisms underpinning the
complicated effects of PCBs on intermediary metabolism in steatohepatitis require further
elucidation. However, based on the results of the present study, pancreatic β cell dysfunction,
rather than insulin resistance (e.g., not Type II diabetes), may be involved in the diabetes
associated with PCB exposures. Importantly, such dysfunction would appear to occur in the
absence of anti-islet antibodies (e.g. not Type I diabetes), suggesting the potential for Type 3c or
pancreatogenic diabetes119 among the mechanisms of PCB-associated liver disease.
CK18 is currently the most extensively validated serum biomarker for steatohepatitis as a
stand-alone test correlating with histology 89, 120; and the addition of transaminases to CK18 in order
to create a prediction model did not improve the diagnostic value of CK18 alone in NASH

. In a

89

multi-center validation study, the sensitivity and specificity of CK18 M30 for biopsy-proven NASH
(vs. steatosis alone) were as high as 77% and 92% respectively depending on the test threshold
. While CK18 correlated with ALT

89

, it offered improved diagnostic accuracy over ALT for

69, 89

histological NASH 89 and TASH 66. While CK18 is less well validated in TASH than NASH, it showed
superior performance to ALT in previously published studies 66, 69.
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This is the first analysis of liver disease in the ACHS, and the results have several
limitations. The demographic and exposure characteristics of the ACHS cohort are not
representative of the overall population, limiting the generalizability of the study results.
Furthermore, the ACHS cohort likely had elevated exposures to unmeasured environmental
chemicals, including additional dioxin-like PCBs, most notably PCB 126. In a pilot study of 65
ACHS participants, median concentrations of the dioxin-like congeners PCB 126 and 169
approached the 95th percentile reported for the same age group in the general U.S. population for
subjects age 40-59. Importantly, dioxin-like PCBs were among the most potent environmental
chemicals associated with the development of steatosis in rodent studies
like congeners were associated with TASH in ACHS.

, and several dioxin-

121

PCB exposures may also have been

accompanied by exposures to dioxins, dibenzofurans, metals, and other organics related to PCB
production or releases from the nearby Anniston Army Depot Superfund Site or local ferromanganese smelting operations. Although the potentially confounding effects of alcohol were taken
into consideration, viral hepatitis were not excluded. Although CK18 is validated clinically, this may
be the first application of CK18 in an epidemiological study.

The follow-up ACHS-II study

addresses some of these limitations. Additional measurements in ACHS-II will include evaluation
of the relationships between CK-18 and individual congeners. Future liver imaging and/or biopsies
would help to confirm the study results.
In summary, the 60.2% prevalence of liver disease in the PCB-exposed ACHS population
is among the highest ever reported for a residential cohort. Assessment of steatohepatitis in
ACHS/ACHS-II population using the mechanistic liver injury biomarker CK18 revealed increased
prevalence of hepatocellular necrosis, and clinical LFT analysis indicated the absence of
transaminitis. This pattern is characteristic of TASH, a specific subcategory of NAFLD
associated with chemical exposures. The observed hepatocellular necrosis was associated with
elevations in the pro-inflammatory cytokine IL-6 and metabolic abnormalities, also consistent with
TASH. Assessment of the relationship between liver injury biomarkers and PCB exposure in this
population indicated a relationship between total PCB load and biomarkers of metabolic
dysfunction and fibrosis, however, increasing total PCB load was not associated with increases in
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the liver injury biomarker CK18. Interestingly, positive relationships with pro-inflammatory
biomarkers IL-6 and TNFα were only seen with non-ortho and dioxin-like congener groupings.
Exposures to ten individual PCB congeners were also associated with TASH. This suggests that
congener structures within the mixture may contribute to TASH in different ways. Individuals in
this cohort are exposed to PCBs at a level 2-3 times higher than the general U.S. population, and,
importantly, acquire PCBs through environmental (rather than industrial) exposure.
We therefore conclude that environmental PCB exposure is associated with increased
liver injury. Individuals with TASH had corresponding elevations in other serum liver injury
biomarkers, including miR-122, as well as indications of increased fibrosis and systemic
inflammation. In the context of clinical hepatology practice, our findings suggest that a greater
focus on the contribution of environmental chemical diseases is warranted, and the lack of
correlation between clinical liver biomarkers and CK-18 and miR-122 findings suggests that
standard screening practices may be insufficient to diagnose liver injury in some chemicalexposed populations.
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CHAPTER TWO: PCBS INDUCE DIFFERENTIAL TRANSCRIPTION IN LIVER TISSUE FROM
A MOUSE MODEL OF CHRONIC PCB/DIETARY COEXPOSURE

The implied mechanistic differences between obesity-related NASH and TASH suggest
that widespread exposure to persistent organic pollutants may contribute to liver injury.
Importantly, both dioxin-like and non-dioxin-like congeners appear to drive this difference, making
it clear that an understanding of the underlying mechanism is needed make therapeutic decisions
and to revise risk assessment in populations exposed to related chemicals. The apparent multisystem effects of PCB exposure observed in the Anniston studies appear to converge on liver
injury, but as PCB exposure in Anniston occurred in a complex coexposure environment, in the
context of this epidemiological study, it is not straightforward to disentangle PCB effects from diet
or metabolic disruption originating in organ systems outside the liver. We hypothesized that
direct PCB effects in the liver would induce transcriptional changes that could be mapped to
pathways and processes related to NASH.
A mouse model of diet-induced obesity and PCB coexposure has been evaluated in our
laboratory, as previously reported23. Notable findings from this study included the fact that
exposure to PCBs decreased fasting glucose in control mice, but had had no discernable effect
on histological or serological liver damage without dietary coexposure (high-fat diet, HFD). With
dietary coexposure, there was more histologically evident liver damage at a moderate exposure
to PCBs (HFD-A20) than at high exposure (HFD-A200). High fat diet increased body weight and
fat pad weight at all three PCB exposure levels, though it was significantly less at the high dose.
Therefore, HFD and PCB exposure contribute to the phenotype of liver damage and
metabolic dysfunction in this mouse model. Moreover, because the Anniston populations were
observed to have high prevalence of obesity, serologic indicators of liver injury and elevations in
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IL-6 and tPAI1 at PCB exposures at least 10-fold lower than the 200 mg/kg dose, the
HFD+20mg/kg conditions most accurately models the PCB/dietary coexposures in Anniston. We
hypothesized, therefore, that HFD coexposures would modulate the PCB-dependent
transcriptome (or vice versa), producing transcriptional changes related to the phenotype in this
model and in ACHS. We performed RNAseq analysis on RNA isolated from liver tissue in these
animals, and performed in silico analysis of the differential transcriptome. Specifically, we
expected to find that the genes differentially transcribed between CD/vehicle and CD/PCB
treatment would be enriched in gene ontology terms related to insulin resistance, and genes
differentially transcribed between CD/PCB and HFD/PCB would be enriched in terms related to
liver diseases, metabolic diseases, and inflammation.
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CHAPTER TWO: MATERIALS AND METHODS

Design of the animal study
In this chronic (12-week) study, male C57Bl/6J mice (8 weeks old; The Jackson
Laboratory, BarHarbor,ME, USA) were assigned to 6 study groups (n=10) as summarized in
Figure 7. Beginning at week 0, each group received one of two diets: control diet (CD, 10.2%
kCal from fat; TD.06416 Harlan Teklad) or a high fat diet (HFD, 42% kCal from milk fat; TD.88137
Harlan Teklad), and were allowed one week to acclimate. Beginning at Week 1, each group
received one of 3 exposures administered in corn oil by oral gavage: corn oil vehicle, Aroclor
1260 (AccuStandard, CT, USA) (vs. corn oil alone) at 20 mg/kg or at 200 mg/kg. Importantly, the
20 mg/kg exposure was designed to mimic the highest human PCB exposures in the ACHS
cohort, while the 200 mg/kg exposure was similar to that used in rodent carcinogenesis
studies102. The two doses of Aroclor 1260 were administered over a different time period in order
to manage acute toxicity at the higher dose, with the 20 mg/kg dose administered once (Week 1)
and the 200 mg/kg dose administered as four 50 mg/kg doses (Weeks 1, 3, 5, and 7).
Mice were housed in a temperature- and light-controlled room (12 h light; 12 h dark) with
food and water ad libitum. The animals were euthanized (ketamine/xylazine, 100/20 mg/kg body
weight, i.p.) at the end of Week 12. Liver tissue was harvested and immediately disrupted in RNA
Stat-60 reagent (AMS Biotechnology Limited, Abingdon UK) and stored on ice.

Preparation of RNA samples and RNAseq analysis
RNA was extracted by the RNA Stat-60 protocol according to manufacturer directions.
For RNAseq analysis, RNA samples were multiplexed using sequence barcoding, and sequenced
single ended to 75 base pair reads using a NextSeq500 to an approximate read count of 40

81

Aroclor
1260
20 mg/kg

Vehicle

↓
fasting glucose

CD

↑↑
BW
and

↑↑
BW
and fat

Aroclor
1260

↓
fasting glucose

↑ BW
and fat

HFD
↑ALT
↑IL‐6
↑tPAI

Figure 8. PCB exposure and high-fat diet induce phenotypic changes in C57/BL6 mice.
Six conditions evaluated in our mouse study are shown above, along with major phenotypic
changes.
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million reads per sample. Base calling (assigning nucleobase identity to chromatogram peaks)
for these files was accomplished using Illumina’s bcl2fastq software. All sequences produced
were aligned to the mouse reference genome (GRCm38.83) using the alignment software
TopHat, and transcript expression levels were calculated in FPKM (fragments per kilobase of
transcript per million mapped reads) units using Cufflinks122. The quantification was guided by
transcriptome annotation for the mouse downloaded from NCBI. Records corresponding to both
mitochondrial and ribosomal RNA were removed (annotated as transcript_biotype rRNA or
Mt_tRNA) to improve the accuracy of the transcriptome quantification. Differential analyses
(FPKM units averaged from 4 replicates of each test vs. DMSO-treated controls) were performed
using CuffDiff.

qPCR validation of selected targets
Targets for validation were prototypical targets of the transcription factors AhR, CAR, and
PXR. From the isolated RNA samples, cDNA was generated using the QuantiTect Reverse
Transcription kit (Qiagen #205313) according to manufacturer recommendations. Multiplexed
qPCR (target and GAPDH) was carried out on BioRad CFX384 system using the following
TaqMan Gene Expression Array probes: Cyp1a2 (Applied Biosystems Mm00487224_m1/FAM),
Cyp3a11 (Applied Biosystems Mm00731567_m1/FAM), Cyp2b10 (Applied Biosystems
Mm01972453_s1/FAM) and GAPDH (Applied Biosystems, Mm99999915_g1/VIC).

Pathway and enrichment analyses
Initial analysis of the datasets were performed using the MetaCoreTM (Thompson
Reuters) software suite. For each treatment, the fold changes and p-values for each differentially
transcribed gene (indexed by Ensembl ID) were uploaded into MetaCoreTM and recognized genes
were associated with one or more MetaCoreTM-curated network objects. Prefilters were applied
to each dataset using a species (M. musculus) and tissue (liver) prefilter. Most of the raw
Ensembl IDs for targets identified as differentially transcribed in each experimental comparison
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were successfully mapped to network objects represented within the MetaCoreTM curated
database (Table 32). An additional species and tissue prefilter applied to each dataset resulted in
object sets that were approximately 70% of the original size. The number of objects which could
be incorporated into one or more enrichment categories are also shown in Table 32. The fewest
objects were represented within disease enrichments (2-5% of each set), with the most
represented in GO processes (approximately 90-95%). There were no major discrepancies
between groups in representation within specific MetaCoreTM ontologies.
The experiments listed above were analyzed individually using the MetaCoreTM Enrichment
Analysis Workflow tool. Vehicle vs. PCB exposure within diet groups are represented by Groups
1 and 2, while Group 3 compares CD to HFD at 0 (Vehicle), 20 mg/kg or 200 mg/kg.
The four PCB exposures vs. vehicle control experiments were analyzed using the Toxicity
Workflow (Liver Toxicity filter) and Biomarkers Analysis (Metabolic Disease filter) to explore
enrichments specific to liver toxicity and metabolic disease, respectively. Genomic data from
these experiments was matched to maps, networks and biomarker lists from the peer-reviewed
literature database manually curated by Thomson Reuters.
Because xenobiotic receptors such as PXR, CAR and AhR are transcription factors which
are expected to mediate the transcriptional response to PCBs, as well as other xenobiotic and
endobiotic molecules, we assessed the differential expression of MetaCoreTM-curated
transcriptional targets of these receptors and their heterodimer complexes (PXR/RXR-alpha,
CAR/RXR-alpha, and AhR/ARNT).
Using the Build Network tool within MetaCoreTM, we analyzed connectivity between
network objects in each dataset and specific transcription factors, with the ten transcription
factors which could be expected to modulate transcription of the largest number of targets within
each dataset ranked highest. Because the xenobiotic receptors and heterodimer complexes are
additionally expected to crosstalk with other transcription factors by protein-protein interactions,
we built shortest-path networks showing the relationships between xenobiotic receptors and their
binding partners which have defined relationships curated in MetaCoreTM.

84

Table 32
in vivo experiment dataset properties

GO processes

Comparison number *

Included in Metacore
groupings

Process
networks

diseases

Maps

MetaCore
#
Metacore
network
significant
network objects objects
Comparisons DTGs
(unfiltered)
(prefiltered)
Group 1 (Dose within CD)
1
CVvsC20
132
128
94
56
3
88
49
2
CVvsC200
1139
1088
825
327 17
736 306
Group 2 (Dose within HFD)
3
HVvsH20
793
750
544
262 12
520 219
4
HVvsH200
410
388
280
142 13
262 125
Group 3 (Diet within dose)
5
C20vsH20
1436
1365
996
456 27
899 406
6
C200vsH200 1446
1379
1007
487 30
936 419
7
CVvsHV
1877
1801
1376
620 38 1256 564
*The number associated with each comparison (column 1) is used throughout this section in the
pathway maps generated with MetaCore software.
The six comparisons listed in column 2 were used to generate datasets of significantly
differentially transcribed genes (column 3). Changes to the overall sizes of the datasets were
induced by import into the MetaCore pathway analysis software and reconciliation with the
MetaCore curated database (column 4), and the application of prefilters excluding targets not
associated with species (Mus musculus) or tissue (liver) (column 5). Numbers of objects
associated each of 4 core grouping mechanisms curated by MetaCore – maps, diseases, gene
ontology (GO) processes, and process networks – are shown for each dataset in columns 6-9.
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CHAPTER TWO: RESULTS

PCB exposure induced differential transcription with and without HFD coexposure
Seven comparisons were made between the aggregated RNAseq data from each
condition and its respective control using CuffDiff, as indicated in Table 32. MetacoreTM
enrichment analyses for the DTG sets resulting from each comparison are shown in Tables 3339.
Chronic PCB exposure in the control-diet-fed animals explored the effects of systemic
PCB exposure alone on liver tissue. In the CVvsC20 comparison, DTGs were enriched in
diseases related to nutritional and metabolic disease, obesity and overnutrition, although these
mice were fed regular synthetic diet (Table 33). Terms related to circadian rhythm were enriched
among maps, networks and processes within this DTG set as well.
The 200 mg/kg PCB exposure was a concentration based on rodent toxicity studies.
Compared to vehicle, DTGs in this exposure were unsurprisingly enriched in terms related to
previously reported sequelae of high-level PCB exposures: neoplastic disease biomarkers,
immune-system and inflammatory process maps and networks. Disruption of cell regulatory
processes was also indicated at this exposure level. Interestingly, processes and networks
related to epithelial-mesenchymal transition and cell identity which are involved in both
development and tissue remodeling (Wnt, TGFβ signaling), were over-represented in this dataset
and, to a lesser extent, in the lower PCB exposure (Table 34).
Our evaluation of chronic moderate and high PCB exposures in the high-fat diet fed
animals explored the interaction between diet and exposure, to more faithfully reconstruct
conditions in many human PCB exposures, including Anniston. In the HVvsH20 and HVvsH200
comparisons, we generated datasets with genes significantly differentially transcribed in
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Table 33
Enrichments for genes differentially transcribed in comparison CVvsC20
Diseases
p-value
FDR
Colonic Diseases
1.271E-11
1.169E-08
In-house Adverse Events
2.304E-11
1.169E-08
Drug-Related Side Effects and Adverse Reactions
2.949E-11
1.169E-08
Nutritional and Metabolic Diseases
3.875E-11
1.169E-08
Cardiovascular Diseases
7.116E-11
1.506E-08
Chemically-Induced Disorders
7.488E-11
1.506E-08
Obesity
1.554E-10
2.280E-08
Overnutrition
1.554E-10
2.280E-08
Vascular Diseases
1.712E-10
2.280E-08
Physiological Phenomena
2.045E-10
2.280E-08
Networks
p-value
FDR
Neurophysiological process_Circadian rhythm
2.999E-04
3.029E-02
Development_Hedgehog signaling
3.478E-03
1.756E-01
Proliferation_Negative regulation of cell proliferation
1.424E-02
2.721E-01
Regulation of metabolism_Bile acid regulation of lipid metabolism
and negative FXR-dependent regulation of bile acids concentration
1.795E-02
2.721E-01
Chemotaxis
2.210E-02
2.721E-01
Cell adhesion_Cell-matrix interactions
2.427E-02
2.721E-01
Cytoskeleton_Intermediate filaments
2.537E-02
2.721E-01
Reproduction_Progesterone signaling
2.560E-02
2.721E-01
Development_EMT_Regulation of epithelial-to-mesenchymal
transition
3.091E-02
2.721E-01
Development_Neurogenesis_Axonal guidance
3.354E-02
2.721E-01
Maps
p-value
FDR
Neurophysiological process_Circadian rhythm
1.656E-04
3.987E-02
Action of GSK3 beta in bipolar disorder
3.242E-04
3.987E-02
DNA damage_ATM/ATR regulation of G1/S checkpoint
8.741E-04
7.167E-02
Development_TGF-beta receptor signaling
3.202E-03
1.199E-01
Development_GM-CSF signaling
3.202E-03
1.199E-01
Development_WNT signaling pathway. Part 2
3.780E-03
1.199E-01
Development_YAP/TAZ-mediated co-regulation of transcription
4.416E-03
1.199E-01
Nicotine metabolism in liver
4.416E-03
1.199E-01
Immune response_IL-5 signaling via JAK/STAT
4.642E-03
1.199E-01
Effect of H. pylori infection on gastric epithelial cell proliferation
4.875E-03
1.199E-01
Processes
p-value
FDR
cellular response to chemical stimulus
4.435E-17
1.807E-13
circadian rhythm
1.032E-15
2.103E-12
rhythmic process
1.591E-15
2.161E-12
cellular response to oxygen-containing compound
6.827E-13
6.955E-10
regulation of developmental process
6.009E-12
3.794E-09
regulation of cell differentiation
6.012E-12
3.794E-09
response to chemical
6.518E-12
3.794E-09
cellular response to organic substance
1.324E-11
6.743E-09
regulation of circadian rhythm
1.493E-11
6.759E-09
response to oxygen-containing compound
1.939E-11
7.900E-09
Enrichment is based on the significantly differentially transcribed genes (p<.05) in a
comparison between control diet/vehicle and control diet/20 mg/kg PCB (CVvsC20). Top ten
enrichments for each grouping, ranked from most to least significant by p-value
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Table 34
Enrichments for genes differentially transcribed in comparison CVvsC200
Diseases
p-value
FDR
Neoplasms
1.106E-19
1.136E-16
Pathological Conditions, Signs and Symptoms
1.280E-19
1.136E-16
Gastrointestinal Neoplasms
4.616E-19
2.488E-16
Neoplasms by Site
6.790E-19
2.488E-16
Respiratory Tract Neoplasms
7.238E-19
2.488E-16
In-house Adverse Events
9.070E-19
2.488E-16
Gastrointestinal Diseases
9.810E-19
2.488E-16
Drug-Related Side Effects and Adverse Reactions
2.239E-18
4.968E-16
Lung Neoplasms
4.384E-18
8.646E-16
Chemically-Induced Disorders
5.316E-18
9.436E-16
Networks
p-value
FDR
Protein folding_Response to unfolded proteins
1.973E-08
3.058E-06
Protein folding_Folding in normal condition
1.576E-05
1.222E-03
Reproduction_Feeding and Neurohormone signaling
7.931E-05
3.470E-03
Development_EMT_Regulation of EMT
8.954E-05
3.470E-03
Signal transduction_WNT signaling
1.304E-04
4.041E-03
Inflammation_Amphoterin signaling
1.777E-04
4.207E-03
Cell cycle_G1-S Growth factor regulation
1.900E-04
4.207E-03
Apoptosis_Endoplasmic reticulum stress pathway
3.415E-04
6.617E-03
Signal Transduction_TGF-beta, GDF and Activin signaling
4.710E-04
8.112E-03
Inflammation_IL-6 signaling
6.253E-04
9.693E-03
Maps
p-value
FDR
Immune response_HMGB1/RAGE signaling pathway
1.601E-06
1.242E-03
Immune response_IL-33 signaling pathway
4.092E-06
1.564E-03
Development_GM-CSF signaling
6.840E-06
1.564E-03
Development_Gastrin in cell growth and proliferation
8.063E-06
1.564E-03
CFTR folding and maturation (normal and CF)
1.214E-05
1.884E-03
Immune response_IL-4 signaling pathway
2.083E-05
2.323E-03
Immune response_TLR2 and TLR4 signaling pathways
2.326E-05
2.323E-03
Development_TGF-beta-dependent induction of EMT via RhoA,
PI3K and ILK
2.395E-05
2.323E-03
Development_Growth factors in regulation of oligodendrocyte
precursor cell survival
3.183E-05
2.745E-03
Apoptosis and survival_p53-dependent apoptosis
4.710E-05
3.655E-03
Processes
p-value
FDR
negative regulation of biological process
6.174E-24
3.243E-20
regulation of response to stimulus
1.167E-23
3.243E-20
regulation of apoptotic process
1.725E-23
3.243E-20
regulation of programmed cell death
1.820E-23
3.243E-20
regulation of signal transduction
2.106E-23
3.243E-20
regulation of cell death
6.601E-23
8.472E-20
negative regulation of cellular process
8.781E-23
9.659E-20
response to organic substance
4.861E-22
4.679E-19
regulation of cell communication
1.172E-21
1.002E-18
regulation of signaling
3.931E-21
3.027E-18
Enrichment is based on the significantly differentially transcribed genes (p<.05) in a
comparison between control diet/vehicle and control diet/200 mg/kg PCB (CVvsC200). Top
ten enrichments for each grouping, ranked from most to least significant by p-value
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Table 35
Enrichments for genes differentially transcribed in comparison HVvsH20
Diseases
p-value
FDR
Drug-Related Side Effects and Adverse Reactions
1.034E-34 1.907E-31
Chemically-Induced Disorders
4.035E-34 3.721E-31
In-house Adverse Events
9.344E-33 5.744E-30
Pathologic Processes
4.832E-32 2.227E-29
Pathological Conditions, Signs and Symptoms
1.681E-31 6.122E-29
Ovarian Diseases
2.159E-31 6.122E-29
Adnexal Diseases
2.324E-31 6.122E-29
Gonadal Disorders
2.441E-30 5.627E-28
Ovarian Neoplasms
2.986E-30 6.117E-28
Phenomena and Processes
5.235E-30 9.653E-28
Networks
p-value
FDR
Inflammation_IL-6 signaling
7.402E-09 1.147E-06
Blood coagulation
3.335E-08 2.584E-06
Development_Blood vessel morphogenesis
2.242E-06 1.158E-04
Development_EMT_Regulation of EMT
1.976E-05 7.655E-04
Reproduction_Gonadotropin regulation
3.205E-05 9.937E-04
Cell adhesion_Attractive and repulsive receptors
1.921E-04 4.604E-03
Reproduction_FSH-beta signaling pathway
2.121E-04 4.604E-03
Cell cycle_G1-S Growth factor regulation
2.376E-04 4.604E-03
Signal transduction_ESR1-nuclear pathway
2.984E-04 5.138E-03
Inflammation_Kallikrein-kinin system
3.730E-04 5.781E-03
Maps
p-value
FDR
Immune response_IL-6-induced acute-phase response in
hepatocytes
5.092E-13 3.753E-10
Reproduction_Gonadotropin-releasing hormone (GnRH) signaling
9.800E-07 2.408E-04
Immune response_IL-6 signaling pathway via JAK/STAT
9.800E-07 2.408E-04
Blood coagulation_Blood coagulation
1.335E-06 2.460E-04
Immune response_IL-5 signaling via JAK/STAT
4.937E-06 7.277E-04
Mitogenic action of Estradiol / ESR1 (nuclear) in breast cancer
1.176E-05 1.444E-03
Signal transduction_mTORC2 downstream signaling
2.503E-05 2.636E-03
Blood coagulation_Platelet microparticle generation
4.165E-05 3.567E-03
Immune response_MIF-induced cell adhesion, migration and
angiogenesis
4.763E-05 3.567E-03
Development_Ligand-dependent activation of the ESR1/AP-1
pathway
4.840E-05 3.567E-03
Processes
p-value
FDR
response to organic substance
1.741E-44 1.269E-40
response to chemical
5.052E-38 1.841E-34
cellular response to chemical stimulus
9.611E-37 2.336E-33
response to oxygen-containing compound
6.073E-33 1.107E-29
response to stress
9.920E-28 1.446E-24
response to organic cyclic compound
1.411E-27 1.714E-24
response to hormone
3.131E-25 3.261E-22
positive regulation of multicellular organismal process
6.891E-25 6.279E-22
response to lipid
2.898E-24 2.348E-21
cellular response to organic substance
7.733E-24 5.637E-21
Enrichment is based on the significantly differentially transcribed genes (p<.05) in a
comparison between high-fat diet/vehicle and high-fat diet/20 mg/kg PCB (HVvsH20). Top ten
enrichments for each grouping, ranked from most to least significant by p-value.
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Table 36
Enrichments for genes differentially transcribed in comparison HVvsH200
Diseases
p-value
FDR
Pathologic Processes
1.902E-22 2.574E-19
Pathological Conditions, Signs and Symptoms
3.351E-20 2.267E-17
Neoplasms, Ductal, Lobular, and Medullary
9.171E-20 4.136E-17
Neoplasms, Glandular and Epithelial
6.602E-19 2.233E-16
Neoplasms, Neuroepithelial
3.418E-18 9.250E-16
In-house Adverse Events
1.007E-17 2.022E-15
Digestive System Neoplasms
1.046E-17 2.022E-15
Drug-Related Side Effects and Adverse Reactions
1.713E-17 2.639E-15
Carcinoma
1.986E-17 2.639E-15
Stomach Diseases
1.996E-17 2.639E-15
Networks
p-value
FDR
Reproduction_FSH-beta signaling pathway
1.355E-04 1.350E-02
Development_Regulation of angiogenesis
2.381E-04 1.350E-02
Development_EMT_Regulation of epithelial-to-mesenchymal
transition
2.736E-04 1.350E-02
Apoptosis_Anti-apoptosis mediated by external signals via NF-kB
5.384E-04 1.758E-02
Protein folding_Response to unfolded proteins
5.940E-04 1.758E-02
Protein folding_Folding in normal condition
8.931E-04 2.203E-02
Signal transduction_WNT signaling
1.266E-03 2.677E-02
Proliferation_Negative regulation of cell proliferation
1.731E-03 3.162E-02
Apoptosis_Apoptotic nucleus
1.923E-03 3.162E-02
Proliferation_Positive regulation cell proliferation
2.434E-03 3.602E-02
Maps
p-value
FDR
Development_Regulation of EMT
7.035E-06 3.737E-03
Immune response_IL-6-induced acute-phase response/hepatocytes
1.913E-05 3.737E-03
Development_Lipoxin inhibitory action on PDGF, EGF and LTD4
signaling
1.913E-05 3.737E-03
CFTR folding and maturation (normal and CF)
3.154E-05 4.620E-03
Impaired Lipoxin A4 signaling in CF
6.244E-05 7.318E-03
Immune response_IL-5 signaling via JAK/STAT
2.709E-04 2.645E-02
Immune response_Oncostatin M signaling via JAK-Stat
3.581E-04 2.998E-02
Development_Regulation of lung epithelial progenitor cell
differentiation
4.474E-04 3.277E-02
Regulation of Tissue factor signaling in cancer
5.602E-04 3.648E-02
Immune response_TNF-R2 signaling pathways
6.931E-04 3.750E-02
Processes
p-value
FDR
response to organic substance
6.419E-23 3.433E-19
cellular response to chemical stimulus
3.993E-21 1.068E-17
response to oxygen-containing compound
1.463E-19 2.608E-16
regulation of signal transduction
3.241E-19 4.333E-16
response to hormone
7.205E-19 7.707E-16
negative regulation of cellular process
2.385E-18 2.105E-15
negative regulation of biological process
3.113E-18 2.105E-15
regulation of response to stimulus
3.148E-18 2.105E-15
response to organic cyclic compound
3.973E-18 2.361E-15
regulation of cell communication
5.115E-18 2.735E-15
Enrichment is based on the significantly differentially transcribed genes (p<.05) in a
comparison between high-fat diet/vehicle and high-fat diet/200 mg/kg PCB (HVvsH200). Top
ten enrichments for each grouping, ranked from most to least significant by p-value.
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Table 37
Enrichments for genes differentially transcribed in comparison CVvsHV
Diseases
p-value
FDR
Pathological Conditions, Signs and Symptoms
1.668E-40
3.561E-37
Pathologic Processes
1.095E-38
1.169E-35
Nutritional and Metabolic Diseases
2.753E-37
1.959E-34
Drug-Related Side Effects and Adverse Reactions
4.662E-36
2.489E-33
In-house Adverse Events
9.122E-36
3.895E-33
Chemically-Induced Disorders
1.856E-34
6.605E-32
Metabolic Diseases
6.604E-32
2.014E-29
Respiratory Tract Neoplasms
3.016E-29
7.174E-27
Physiological Phenomena
3.024E-29
7.174E-27
Phenomena and Processes
1.560E-28
3.330E-26
Networks
p-value
FDR
Development_Regulation of angiogenesis
2.143E-05
3.387E-03
Cell adhesion_Platelet-endothelium-leucocyte interactions
4.700E-05
3.713E-03
Cell adhesion_Cell-matrix interactions
8.355E-05
4.400E-03
Chemotaxis
1.403E-04
5.542E-03
Cell adhesion_Leucocyte chemotaxis
4.519E-04
1.220E-02
Cell adhesion_Integrin-mediated cell-matrix adhesion
5.221E-04
1.220E-02
Cell cycle_G2-M
5.407E-04
1.220E-02
Apoptosis_Anti-Apoptosis mediated by external signals via
PI3K/AKT
6.200E-04
1.224E-02
Signal Transduction_TGF-beta, GDF and Activin signaling
9.318E-04
1.560E-02
Translation_Translation initiation
9.871E-04
1.560E-02
Maps
p-value
FDR
Transcription_Sirtuin6 regulation and functions
2.545E-09
2.146E-06
Immune response_IL-4-induced regulators of cell growth, survival,
differentiation and metabolism
4.351E-07
1.834E-04
Cell cycle_Regulation of G1/S transition (part 1)
3.614E-06
1.015E-03
Cell cycle_ESR1 regulation of G1/S transition
7.096E-06
1.495E-03
Development_TFs in segregation of hepatocytic lineage
1.382E-05
2.115E-03
Protein folding and maturation_Angiotensin system maturation \
Human version
1.505E-05
2.115E-03
Cell adhesion_ECM remodeling
3.057E-05
3.018E-03
Cell cycle_Chromosome condensation in prometaphase
3.389E-05
3.018E-03
Role of ZNF202 in regulating gene expression in atherosclerosis
3.389E-05
3.018E-03
Cell adhesion_Integrin inside-out signaling in neutrophils
3.580E-05
3.018E-03
Processes
p-value
FDR
response to organic substance
1.024E-38
9.358E-35
response to oxygen-containing compound
7.650E-31
3.335E-27
cellular response to chemical stimulus
1.095E-30
3.335E-27
single-organism metabolic process
8.462E-30
1.933E-26
response to endogenous stimulus
2.380E-28
4.349E-25
response to organic cyclic compound
7.309E-28
1.113E-24
response to stress
3.846E-27
5.021E-24
response to external stimulus
6.496E-27
7.419E-24
response to lipid
1.313E-26
1.333E-23
response to hormone
1.619E-26
1.391E-23
Enrichment is based on the significantly differentially transcribed genes (p<.05) in a
comparison between control diet/vehicle and high-fat diet/vehicle (CVvsHV). Top ten
enrichments for each grouping, ranked from most to least significant by p-value.
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Table 38
Enrichments for genes differentially transcribed in comparison C20vsH20
Diseases
p-value
FDR
Drug-Related Side Effects and Adverse Reactions
9.926E-38 2.026E-34
Chemically-Induced Disorders
4.539E-37 4.632E-34
In-house Adverse Events
8.728E-37 5.938E-34
Pathological Conditions, Signs and Symptoms
2.331E-36 1.189E-33
Pathologic Processes
3.434E-36 1.402E-33
Fibrosis
1.512E-34 5.142E-32
Phenomena and Processes
6.761E-34 1.971E-31
Physiological Phenomena
2.105E-33 5.371E-31
Body Weight
4.840E-32 1.098E-29
Nutritional and Metabolic Diseases
7.909E-32 1.614E-29
Networks
p-value
FDR
Development_Regulation of angiogenesis
1.829E-09 2.889E-07
Development_Blood vessel morphogenesis
8.673E-06 6.851E-04
Development_EMT_Regulation of epithelial-to-mesenchymal
transition
1.716E-05 9.036E-04
Inflammation_IL-6 signaling
1.992E-04 6.405E-03
Signal Transduction_BMP and GDF signaling
2.027E-04 6.405E-03
Inflammation_Amphoterin signaling
5.171E-04 1.191E-02
Regulation of metabolism_Bile acid regulation of lipid metabolism
and negative FXR-dependent regulation of bile acids concentration
5.276E-04 1.191E-02
Apoptosis_Endoplasmic reticulum stress pathway
1.562E-03 3.086E-02
Cell adhesion_Attractive and repulsive receptors
1.912E-03 3.357E-02
Blood coagulation
2.654E-03 3.839E-02
Maps
p-value
FDR
Transcription_Sirtuin6 regulation and functions
8.710E-09 7.003E-06
Immune response_IL-6-induced acute-phase response/hepatocytes
8.699E-08 3.497E-05
Development_β-adrenergic receptors/brown adipocyte
differentiation
1.118E-06 2.997E-04
Development_TGF-beta-dependent induction of EMT via MAPK
2.196E-06 4.414E-04
Role of ZNF202 in regulating gene expression in atherosclerosis
4.150E-06 6.673E-04
Protein folding/maturation_Angiotensin system maturation \ Human
5.728E-06 7.675E-04
Protein folding/maturation_Angiotensin system maturation \ Rodent
1.793E-05 2.060E-03
Signal transduction_mTORC1 downstream signaling
3.867E-05 3.526E-03
Immune response_IL-6 signaling pathway via JAK/STAT
4.800E-05 3.526E-03
Apoptosis and survival_Role of PKR in stress-induced apoptosis
4.824E-05 3.526E-03
Processes
p-value
FDR
response to oxygen-containing compound
1.007E-43 8.605E-40
response to organic substance
5.608E-42 2.397E-38
cellular response to chemical stimulus
1.522E-37 4.337E-34
response to organic cyclic compound
4.105E-34 8.772E-31
response to organonitrogen compound
2.307E-31 3.944E-28
response to chemical
2.647E-30 3.770E-27
response to external stimulus
3.106E-30 3.792E-27
response to nitrogen compound
4.595E-30 4.909E-27
single-organism metabolic process
1.205E-29 1.144E-26
response to lipid
2.262E-29 1.933E-26
Enrichment is based on the significantly differentially transcribed genes (p<.05) in a
comparison between control diet/20 mg/kg PCB and high-fat diet/20 mg/kg PCB (C20vsH20).
Top ten enrichments for each grouping, ranked from most to least significant by p-value.
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Table 39
Enrichments for genes differentially transcribed in comparison C200vsH200
Diseases
p-value
FDR
Pathologic Processes
2.843E-45 5.814E-42
Drug-Related Side Effects and Adverse Reactions
4.265E-40 4.139E-37
Pathological Conditions, Signs and Symptoms
6.071E-40 4.139E-37
In-house Adverse Events
4.134E-39 1.816E-36
Chemically-Induced Disorders
4.439E-39 1.816E-36
Nutritional and Metabolic Diseases
1.527E-31 5.204E-29
Metabolic Diseases
8.142E-31 2.379E-28
Vascular Diseases
2.710E-29 6.928E-27
Endocrine System Diseases
2.060E-28 4.681E-26
Cardiovascular Diseases
7.414E-28 1.516E-25
Networks
p-value
FDR
Development_Regulation of angiogenesis
5.068E-06 4.739E-04
Chemotaxis
6.115E-06 4.739E-04
Immune response_Phagocytosis
1.356E-05 7.005E-04
Inflammation_IL-6 signaling
6.717E-05 2.603E-03
Cell adhesion_Attractive and repulsive receptors
1.385E-04 3.664E-03
Development_Blood vessel morphogenesis
1.418E-04 3.664E-03
Cell adhesion_Leucocyte chemotaxis
2.759E-04 6.108E-03
Signal Transduction_Cholecystokinin signaling
1.198E-03 2.320E-02
Cell cycle_G1-S Interleukin regulation
1.407E-03 2.423E-02
Immune response_Phagosome in antigen presentation
1.960E-03 3.037E-02
Maps
p-value
FDR
Immune response_IL-4-induced regulators of cell growth, survival,
differentiation and metabolism
3.816E-07 3.114E-04
Immune response_IL-6-induced acute-phase response/hepatocytes 9.473E-07 3.865E-04
Immune response_IL-2 activation and signaling pathway
3.245E-06 6.912E-04
Development_Role of IL-8 in angiogenesis
3.388E-06 6.912E-04
Neurophysiological_Receptor-mediated axon growth repulsion
1.057E-05 1.539E-03
Immune response_Antigen presentation by MHC class II
1.161E-05 1.539E-03
Transcription_Role of AP-1 in regulation of cellular metabolism
1.320E-05 1.539E-03
Putative pathways for BPA-stimulated fat cell differentiation
1.999E-05 2.039E-03
Cell cycle_ESR1 regulation of G1/S transition
3.414E-05 3.095E-03
Signal transduction_mTORC1 downstream signaling
4.447E-05 3.629E-03
Processes
p-value
FDR
response to organic substance
1.995E-37 1.674E-33
single-organism metabolic process
1.987E-32 8.334E-29
small molecule metabolic process
2.501E-31 6.994E-28
response to stress
1.066E-29 1.913E-26
lipid metabolic process
1.140E-29 1.913E-26
response to oxygen-containing compound
5.001E-29 6.993E-26
cellular response to chemical stimulus
8.298E-29 9.946E-26
response to organic cyclic compound
2.895E-27 3.036E-24
response to chemical
8.844E-27 8.245E-24
response to hormone
1.217E-26 1.021E-23
Enrichment is based on the significantly differentially transcribed genes (p<.05) in a
comparison between control diet/200 mg/kg PCB and high-fat diet/200 mg/kg PCB
(C200vsH200). Top ten enrichments for each grouping, ranked from most to least significant
by p-value.
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HFD/PCB coexposure vs. HFD alone. In the HVvsH20 comparison, enriched diseases were
associated with gonadal and ovarian disease, including ovarian neoplasms. Enriched networks
and maps including both inflammatory and EMT-related categories (Table 35). The HVvsH200
comparison was notable for enrichments in inflammatory, immune-system and EMT-related
networks and maps, and neoplastic diseases (Table 36). Interestingly, both of the HFD+PCB
groups were highly enriched in multiple processes related to xenobiotic responses (Tables 3536), while the CD+PCB groups were enriched in categories related to regulation of physiological
processes (Tables 33-34).

Transcriptional effects of HFD exposure were modulated by coexposure to PCBs
Comparisons between CD and HFD at each level of PCB exposure (CVvsHV, C20vsH20,
C200vsH200 comparisons) explored the transcriptional effects of HFD exposure without or with
two levels of PCB coexposure (Tables 37-39). Unsurprisingly, nutritional and metabolic disease
biomarkers were over-represented in all three comparisons. Enriched processes for comparisons
at all levels were associated with changes in cellular response to endobiotic and xenobiotic
organic cyclic compounds, with responses to endogenous compounds (e.g., hormone, lipid, etc.)
featuring prominently in the CVvsHV comparison (Table 37), and responses to organonitrogens
and external stimulus encroaching in the moderate exposure (Table 38). In a comparison
between CD and HFD in the highest PCB exposure group, enrichments in process maps related
to pro-inflammatory and anti-inflammatory cytokine signaling were over-represented (Table 39).

The sets of genes differentially transcribed by moderate and high PCB exposures within each diet
partially overlapped
Figure 9 shows the relative size of the targets differentially transcribed in a comparison
between vehicle and moderate (gold) or vehicle and high (red) PCB exposure in animals on
control diet (Panel A) or HFD (Panel B). The overlapping areas indicate targets which are shared
between moderate and high PCB exposure levels within a single diet condition. On control diet, a
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Panel A – Control Diet

Panel B – High‐Fat Diet

Figure 9. Moderate and high PCB exposures produce overlapping DTG sets (vs. vehicle)
In an evaluation of PCB transcriptional effect, comparison between PCB exposure and control
(vehicle) produced sets of significantly differentially transcribed genes (DTGs), which are shown
for control diet (CD, Panel A) and high fat diet (HFD, Panel B). The number of targets which were
differentially affected at both 20 mg/kg Aroclor 1260 and 200 mg/kg Aroclor 1260 are shown in
the intersecting regions. Targets which were differentially regulated at only moderate (gold) or
high (red) dose are shown in the non-intersecting regions. For CD, high PCB exposure resulted
in a larger DTG set than moderate PCB exposure. For HFD, moderate PCB exposure resulted in
a larger DTG set than high PCB exposure.
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larger number of targets were significantly differentially transcribed in response to chronic high
PCB exposure (CVvsC200 comparison) than chronic moderate PCB exposure (CVvsC20
comparison). In the HFD groups, this pattern was reversed, with a smaller number of genes
(both absolute and relative) differentially transcribed with the high PCB exposure (HVvsH200
comparison) and a larger number in the moderate PCB exposure (HVvsH20 comparison).
Enrichment analysis of DTGs common between moderate and high PCB exposure within
the CD group are shown in Table 40. Targets perturbed in both exposures were overrepresented in circadian rhythm-related categories within networks and processes, while
processes involving response to endogenous and exogenous molecules comprised the
remainder of the most ten enriched processes. Interestingly, hedgehog signaling and WNT
signaling, both involved in development and remodeling, were differentially regulated in both
moderate and high PCB exposures within this diet group. In the HFD-fed groups, enrichment
analysis of DTGs common between both moderate and high PCB exposures were enriched in
several networks and maps involved in development and EMT, particularly WNT signaling (Table
41). Hormone signaling pathways including FSH, progesterone and gonadotropin were also
identified as commonly engaged networks.

HFD coexposure at different PCB doses resulted in DTG sets with large areas of overlap
When high fat diet was compared to control diet within each PCB exposure level
(CDvsHFD, C20vsH20, C200vsH200), three large sets of differentially transcribed genes were
identified, with substantial overlap (Figure 10). In the vehicle-treated comparison (black) the
entire DTG set can be described as diet-dependent, and the overlapping areas between this and
other sets can be described as targets which are differentially transcribed with HFD exposure in
the presence or absence of Aroclor 1260 coexposure. The top enrichments for the DTGs
produced are shown in Tables 42-46. The moderate (gold) and high (red) PCB coexposuredependent DTGs are represented by the sections of those sets that do not overlap with the
vehicle-treated comparison.
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Table 40
Common targets between moderate/high PCB exposure levels within the control diet groups
Diseases
p-value
FDR
In-house Adverse Events
3.271E-07
1.434E-12
Colonic Diseases
3.480E-07
9.982E-08
Drug-Related Side Effects and Adverse Reactions
3.774E-07
2.375E-12
Endocrine System Diseases
9.532E-07
2.795E-05
Chemically-Induced Disorders
1.422E-06
2.626E-12
Cardiovascular Diseases
1.731E-06
1.550E-08
Neoplasms, Bone Tissue
3.722E-06
2.101E-05
Vascular Diseases
4.292E-06
1.097E-08
Diabetes Mellitus, Type 2
4.349E-06
4.745E-04
Eye Diseases
6.021E-06
5.913E-04
Networks
p-value
FDR
Reproduction_Progesterone signaling
2.405E-03
1.465E-01
Regulation of metabolism_Bile acid regulation of lipid metabolism
and negative FXR-dependent regulation of bile acids concentration
3.806E-03
1.465E-01
Signal transduction_WNT signaling
7.644E-03
2.304E-02
Immune response_IL-5 signalling
1.238E-02
1.980E-01
Reproduction_Feeding and Neurohormone signaling
1.374E-02
1.489E-02
Development_Hedgehog signaling
2.575E-02
3.305E-01
Development_Ossification and bone remodeling
3.250E-02
3.387E-01
Cell adhesion_Glycoconjugates
3.519E-02
3.387E-01
Muscle contraction
4.152E-02
7.278E-02
Neurophysiological process_Circadian rhythm
4.519E-02
7.038E-02
Maps
p-value
FDR
Development_WNT signaling pathway. Part 2
6.710E-04
4.347E-02
Nicotine metabolism in liver
7.887E-04
4.347E-02
Immune response_IL-5 signaling via JAK/STAT
8.307E-04
4.347E-02
Action of GSK3 beta in bipolar disorder
2.524E-03
8.628E-02
Immune response_IL-27 signaling pathway
2.748E-03
8.628E-02
Regulation of lipid metabolism_FXR-dependent negative-feedback
regulation of bile acids concentration
4.564E-03
1.090E-01
DNA damage_ATM/ATR regulation of G1/S checkpoint
4.858E-03
9.421E-02
Development_EPO-induced Jak-STAT pathway
6.121E-03
1.201E-01
Regulation of metabolism_Bile acids FXR regulation/ glucose and
lipid metabolism
7.886E-03
1.376E-01
Regulation of GSK3 beta in bipolar disorder
9.852E-03
8.940E-02
Processes
p-value
FDR
cellular response to chemical stimulus
1.811E-12
6.576E-12
cellular response to organic substance
1.056E-09
1.657E-09
response to stimulus
5.204E-09
1.921E-06
cellular response to oxygen-containing compound
5.723E-09
4.689E-06
circadian rhythm
1.362E-08
1.522E-06
response to chemical
2.079E-08
8.674E-07
response to organic substance
5.529E-08
2.305E-14
rhythmic process
9.143E-08
4.206E-07
response to organic cyclic compound
1.641E-07
2.153E-10
cellular response to organic cyclic compound
2.955E-07
8.475E-05
Top ten enrichments for each grouping, ranked from most to least significant by p-value
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Table 41
Common targets between moderate/high PCB exposure levels within the high-fat diet groups
Diseases
p-value
FDR
Hypoxia
1.987E-16 2.285E-13
Neoplasms, Ductal, Lobular, and Medullary
4.844E-16 2.785E-13
Physiological Phenomena
1.831E-15 7.121E-15
Ovarian Neoplasms
1.840E-15 2.478E-15
Ovarian Diseases
2.609E-15 3.432E-16
Adnexal Diseases
2.675E-15 3.432E-16
In-house Adverse Events
2.932E-15 2.308E-17
Vascular Diseases
3.321E-15 5.733E-15
Drug-Related Side Effects and Adverse Reactions
4.143E-15 7.903E-19
Signs and Symptoms, Respiratory
4.344E-15 4.996E-13
Networks
p-value
FDR
Reproduction_FSH-beta signaling pathway
2.903E-05 3.056E-03
Reproduction_Progesterone signaling
5.023E-05 3.056E-03
Proliferation_Positive regulation cell proliferation
6.596E-05 3.056E-03
Inflammation_IL-6 signaling
1.805E-04 9.444E-04
Signal transduction_ESR1-membrane pathway
2.894E-04 6.880E-03
Development_Regulation of angiogenesis
3.587E-04 6.880E-03
Signal transduction_WNT signaling
3.775E-04 6.880E-03
Development_EMT_Regulation of EMT
3.960E-04 6.880E-03
Cell cycle_G1-S Growth factor regulation
7.198E-04 1.112E-02
Reproduction_Gonadotropin regulation
8.224E-04 1.143E-02
Maps
p-value
FDR
IL-6-induced acute-phase response/hepatocytes
7.330E-06 3.084E-05
Lipoxin inhibitory action-PDGF/EGF/LTD4 signaling
7.330E-06 1.646E-03
Impaired Lipoxin A4 signaling in CF
2.013E-05 3.013E-03
Development_WNT signaling pathway. Part 2
5.040E-05 5.658E-03
Effect of H. pylori infection on gastric epithelial cell proliferation
7.811E-05 7.015E-03
Development_Gastrin in cell growth and proliferation
1.077E-04 7.580E-03
Development_Regulation of EMT
1.254E-04 7.580E-03
Ovarian cancer (main signaling cascades)
1.351E-04 7.580E-03
Development_Beta-adrenergic receptors transactivation of EGFR
1.753E-04 8.333E-03
Development_Ligand-dependent activation/ESR1/AP-1 pathway
1.856E-04 8.333E-03
Processes
p-value
FDR
response to organic substance
2.006E-20 5.752E-23
cellular response to chemical stimulus
2.280E-20 4.951E-17
regulation of signal transduction
4.488E-19 6.498E-16
regulation of cell communication
1.713E-18 1.860E-15
regulation of signaling
3.782E-18 3.286E-15
regulation of response to stimulus
1.437E-17 1.041E-14
response to chemical
2.895E-17 8.033E-20
response to oxygen-containing compound
3.049E-17 1.468E-15
positive regulation of cell communication
2.363E-16 1.140E-13
positive regulation of signaling
2.696E-16 1.171E-13
Top ten enrichments for each grouping, ranked from most to least significant by p-value
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Figure 10. Comparison of PCB/Diet interactions.
For each PCB exposure, control and high fat diet were compared to generate a differentially
regulated target set. These differentially regulated target sets are compared in the figure above.
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Enrichment analysis of common targets for all PCB exposure levels within diet
comparisons (Table 42) showed nutritional, metabolic, and endocrine-related diseases among the
highly-enriched disease biomarkers, and IL-6 signaling among the engaged maps and processes.
Processes related to lipid and steroid metabolism, endobiotic and xenobiotic response were also
commonly engaged in these comparisons.

Differentially regulated targets within vehicle vs. PCB comparisons were enriched in liver and
metabolic disease biomarkers
Because the animal model phenotype suggested liver and metabolic disease processes
at work, we further explored liver toxicity analysis and biomarker analysis for nutritional and
metabolic disease within these datasets. In an evaluation of liver toxicity endpoints in the control
diet groups, there were no significantly enriched pathways for the moderate exposure group
(Table 43), however, the high exposure was significantly (FDR < 0.05) enriched in pathways
related to ischemia and hypoxia (Table 44). In the high fat diet groups, significantly enriched
categories within the liver toxicity analysis were cholestasis and steatosis pathways for moderate
exposure (Table 45) and steatosis, fibrosis, and liver hypertrophy in the high exposure group
(Table 46). Targets affected within the steatosis category are shown in Table 47, and included
LIPE, ELOVL6, FADS3, GPAM, and several cytochrome P450s including members of the Cyp4A
and Cyp2C subfamilies.
One liver injury pathway map which was highly enriched in DTGs from several of the
conditions was IL-6-mediated acute-phase response in hepatocytes (Figure 11). Several
immediate effectors of acute phase response down-stream of IL-6 signaling were up-regulated,
particularly in the HVvsH20 condition, including serum amyloid proteins (A1, A2, and A3
isoforms), serum amyloid P-component, and fibrinogen components (alpha, beta, and gamma),
shown in Figure 12. Engagement of this pathway of local hepatic inflammatory response is
consistent with histological findings in this animal model, as well as serological findings of
increased IL-6 and liver injury in both the animal model, and in the PCB-exposed population of
Anniston, AL.
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Table 42
Common targets between all PCB exposure levels within diet comparisons
Diseases
p-value
FDR
Pathological Conditions, Signs and Symptoms
6.116E-27
8.706E-24
Pathologic Processes
1.071E-26
8.706E-24
Drug-Related Side Effects and Adverse Reactions
2.676E-24
1.450E-21
In-house Adverse Events
1.478E-23
4.980E-21
Chemically-Induced Disorders
1.531E-23
4.980E-21
Nutritional and Metabolic Diseases
2.480E-23
6.722E-21
Metabolic Diseases
1.164E-22
2.704E-20
Phenomena and Processes
5.832E-22
1.185E-19
Physiological Phenomena
1.705E-21
3.081E-19
Endocrine System Diseases
4.360E-21
7.089E-19
Networks
p-value
FDR
Development_Regulation of angiogenesis
3.424E-07
5.000E-05
Inflammation_IL-6 signaling
5.307E-06
3.874E-04
Development_Blood vessel morphogenesis
3.416E-05
1.662E-03
Translation_Translation initiation
2.444E-04
8.920E-03
Translation_Elongation-Termination
1.509E-03
4.405E-02
Signal Transduction_Cholecystokinin signaling
4.062E-03
8.473E-02
Cell cycle_Meiosis
4.062E-03
8.473E-02
Reproduction_Feeding and Neurohormone signaling
4.882E-03
8.910E-02
Cell cycle_G0-G1
7.245E-03
1.109E-01
Blood coagulation
7.594E-03
1.109E-01
Maps
p-value
FDR
Cholesterol Biosynthesis
7.453E-06
4.636E-03
Cell cycle_Role of Nek in cell cycle regulation
3.880E-05
1.207E-02
IL-6-induced acute-phase response/hepatocytes
7.792E-05
1.616E-02
Effect of H. pylori infection on gastric epithelial cell proliferation
1.643E-04
2.555E-02
Transcription_Sirtuin6 regulation and functions
3.062E-04
3.809E-02
Role of ZNF202 in regulation of expression of genes involved in
7.644E-04
7.149E-02
atherosclerosis
Development_Beta adrenergic receptors in brown adipocyte
8.592E-04
7.149E-02
differentiation
Expression targets of Tissue factor signaling in cancer
9.195E-04
7.149E-02
Signal transduction_mTORC1 downstream signaling
1.456E-03
9.691E-02
Regulation of Tissue factor signaling in cancer
1.719E-03
9.691E-02
Processes
p-value
FDR
lipid metabolic process
1.500E-25
9.695E-22
response to organic cyclic compound
7.688E-24
2.484E-20
response to oxygen-containing compound
1.649E-23
3.553E-20
single-organism metabolic process
4.262E-23
6.635E-20
small molecule metabolic process
5.133E-23
6.635E-20
response to organic substance
8.934E-21
9.623E-18
response to external stimulus
2.110E-20
1.948E-17
response to drug
4.389E-20
3.546E-17
steroid metabolic process
5.788E-20
3.908E-17
single-organism process
6.046E-20
3.908E-17
Top ten enrichments for each grouping, ranked from most to least significant by p-value
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Table 43
Enrichments for liver and metabolic disease endpoints in comparison CVvsC20
Liver Toxicity Endpoint Processes
p-value
FDR
Steatosis, development_liver
4.866E-02 5.422E-01
Fibrosis, development_liver
7.746E-02 5.422E-01
Hypertrophic organ growth_liver
1.679E-01 7.837E-01
Cell cycle, processes involved in G0-phase
3.450E-01 7.870E-01
Cell cycle, processes involved in G1-phase
4.245E-01 7.870E-01
Cholestasis, development_liver
4.409E-01 7.870E-01
Cell cycle, processes involved in G2-phase
4.702E-01 7.870E-01
Peroxisomal proliferation, induction_liver
5.235E-01 7.870E-01
Cell cycle, processes involved in S-phase
5.474E-01 7.870E-01
Apoptosis via Mitochondrial membrane dysfunction
6.746E-01 7.870E-01
Liver-Specific Maps
p-value
FDR
Neurophysiological process_Circadian rhythm
1.030E-04 9.994E-03
DNA damage_ATM/ATR regulation of G1/S checkpoint
6.179E-04 2.997E-02
Development_TGF-beta receptor signaling
2.286E-03 6.552E-02
Development_WNT signaling pathway. Part 2
2.702E-03 6.552E-02
Signal transduction_mTORC2 downstream signaling
5.471E-03 1.061E-01
Development_Signaling of β-adrenergic receptors via Beta-arrestins 7.044E-03 1.125E-01
DNA damage_ATM / ATR regulation of G2 / M checkpoint
8.240E-03 1.125E-01
Development_SSTR1 in regulation of cell proliferation and migration 1.019E-02 1.125E-01
DNA damage_Brca1 as a transcription regulator
1.088E-02 1.125E-01
Regulation of lipid metabolism_FXR-dependent negative-feedback
regulation of bile acids concentration
1.159E-02 1.125E-01
Nutritional and Metabolic Disease Biomarkers
p-value
FDR
Hypokalemia
6.052E-08 3.752E-06
Overnutrition
9.254E-04 1.707E-02
Obesity
9.254E-04 1.707E-02
Water-Electrolyte Imbalance
1.105E-03 1.707E-02
Hypertriglyceridemia
1.377E-03 1.707E-02
Hypercholesterolemia
1.839E-03 1.901E-02
Hypoglycemia
2.258E-03 2.000E-02
Hyperlipidemias
2.774E-03 2.150E-02
Nutrition Disorders
3.774E-03 2.600E-02
Insulin Resistance
7.968E-03 4.448E-02
Nutritional and Metabolic Disease Maps
p-value
FDR
Development_Signaling of β-adrenergic receptors via Beta-arrestins 2.670E-03 9.095E-02
Regulation of lipid metabolism_FXR-dependent negative-feedback
regulation of bile acids concentration
4.437E-03 9.095E-02
Bile acids regulation of glucose and lipid metabolism via FXR
7.673E-03 9.830E-02
Transcription_Androgen Receptor nuclear signaling
9.590E-03 9.830E-02
Development_IGF-1 receptor signaling
1.214E-02 9.958E-02
Unsaturated fatty acid biosynthesis
1.699E-02 1.161E-01
Transcription_Transcription regulation of aminoacid metabolism
7.854E-02 2.751E-01
Triacylglycerol metabolism p.2
8.456E-02 2.751E-01
Role of Diethylhexyl Phthalate and Tributyltin in fat cell
differentiation
9.055E-02 2.751E-01
Vitamin B6 metabolism
9.353E-02 2.751E-01
Enrichment is based on the significantly differentially transcribed genes (p<.05) in a
comparison between control diet/vehicle and control diet/20 mg/kg PCB (CVvsC20). Top ten
enrichments for each grouping, ranked from most to least significant by p-value
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Table 44
Enrichments for liver and metabolic disease endpoints in comparison CVvsC200
Liver Toxicity Endpoint Processes
p-value

FDR

Ischemia-induced cellular changes_liver
Hypoxia, development
Apoptosis via Mitochondrial membrane dysfunction
Fibrosis, development_liver
Steatosis, development_liver
Hypertrophic organ growth_liver
Phospholipidosis, development_liver
Cholestasis, development_liver
Cell cycle, processes involved in G1-phase
Cell cycle, processes involved in G2-phase
Liver-Specific Maps

1.588E-03
2.421E-03
5.073E-02
7.399E-02
8.062E-02
8.403E-02
1.391E-01
1.710E-01
3.839E-01
5.009E-01
p-value

2.179E-02
2.179E-02
2.521E-01
2.521E-01
2.521E-01
2.521E-01
3.576E-01
3.848E-01
7.678E-01
8.667E-01
FDR

Immune response_TLR2 and TLR4 signaling pathways
Apoptosis and survival_p53-dependent apoptosis
G-protein signaling_Proinsulin C-peptide signaling
Signal transduction_mTORC2 upstream signaling
Apoptosis and survival_Endoplasmic reticulum stress response
pathway
Immune response_IL-1 signaling pathway
Immune response_TLR5, TLR7, TLR8,TLR9 signaling pathways
Immune response_IL-18 signaling
Histamine H1 receptor signaling/immune response
Development_ERBB-family signaling
Nutritional and Metabolic Disease Biomarkers

1.658E-05
3.762E-05
5.040E-05
5.539E-05

5.109E-03
5.109E-03
5.109E-03
5.109E-03

9.226E-05
9.229E-05
1.064E-04
1.600E-04
1.749E-04
2.779E-04
p-value

5.608E-03
5.608E-03
5.608E-03
7.170E-03
7.170E-03
9.580E-03
FDR

Obesity
Overnutrition
Nutrition Disorders
Vascular Calcification
Frontotemporal Dementia
Frontotemporal Lobar Degeneration
Hyperinsulinism
Diabetes Mellitus, Type 1
Insulin Resistance
Calcinosis
Nutritional and Metabolic Disease Maps

3.371E-07
3.371E-07
3.925E-06
9.711E-05
5.455E-04
5.455E-04
9.153E-04
1.805E-03
4.129E-03
5.304E-03
p-value

2.174E-05
2.174E-05
1.688E-04
3.132E-03
1.173E-02
1.173E-02
1.687E-02
2.911E-02
5.918E-02
6.842E-02
FDR

G-protein signaling_Proinsulin C-peptide signaling
1.347E-06
Development_Activation of ERK by Alpha-1 adrenergic receptors
4.336E-06
Immune response_IL-18 signaling
4.675E-06
Development_IGF-1 receptor signaling
1.332E-05
Putative pathways for BPA-stimulated fat cell differentiation
5.286E-05
Apoptosis and survival_Ceramides signaling pathway
1.942E-04
Development_β adrenergic receptors in brown adipocyte
differentiation
1.109E-03
Transcription_Transcription regulation of aminoacid metabolism
1.875E-03
Transcription_Sirtuin6 regulation and functions
2.481E-03
Membrane-bound ESR1: interaction with growth factors signaling
2.706E-03
Enrichment is based on the significantly differentially transcribed genes (p<.05) in a
comparison between control diet/vehicle and control diet/20 mg/kg PCB (CVvsC20).
enrichments for each grouping, ranked from most to least significant by p-value
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2.102E-04
2.431E-04
2.431E-04
5.196E-04
1.649E-03
5.049E-03
2.471E-02
3.656E-02
4.221E-02
4.221E-02
Top ten

Table 45
Enrichments for liver and metabolic disease endpoints in comparison HVvsH20
Liver Toxicity Endpoint Processes
p-value

FDR

Cholestasis, development_liver
Steatosis, development_liver
Fibrosis, development_liver
Progression of oxidative stress
Inflammation, development
Hypertrophic organ growth_liver
Hypoxia, development
Apoptosis via Mitochondrial membrane dysfunction
Ischemia-induced cellular changes_liver
Apoptosis via Death Domain receptors cascades
Liver-Specific Maps

6.523E-04
1.053E-03
1.364E-02
1.461E-02
2.248E-02
1.108E-01
4.259E-01
5.346E-01
8.177E-01
8.298E-01
p-value

9.480E-03
9.480E-03
6.576E-02
6.576E-02
8.092E-02
3.323E-01
1.000E+00
1.000E+00
1.000E+00
1.000E+00
FDR

IL-6-induced acute-phase response/hepatocytes
Immune response_IL-6 signaling pathway via JAK/STAT
Signal transduction_mTORC2 downstream signaling
MIF-induced cell adhesion, migration and angiogenesis
Development_Ligand-dependent activation-ESR1/AP-1 pathway
Development_Beta-adrenergic receptors transactivation of EGFR
Transcription_Role of AP-1 in regulation of cellular metabolism
Glutathione metabolism
Development_VEGF signaling and activation
Immune response_IL-1 signaling pathway
Nutritional and Metabolic Disease Biomarkers

4.661E-13
9.310E-07
2.422E-05
4.658E-05
4.793E-05
8.020E-05
9.590E-05
1.810E-04
2.163E-04
2.509E-04
p-value

1.571E-10
1.569E-04
2.721E-03
3.231E-03
3.231E-03
4.505E-03
4.617E-03
7.624E-03
8.100E-03
8.457E-03
FDR

Nutrition Disorders
Obesity
Overnutrition
Diabetes Mellitus, Type 2
Dyslipidemias
Hypokalemia
Hyperinsulinism
Lipid Metabolism Disorders
Colorectal Neoplasms, Hereditary Nonpolyposis
Hyperlipidemias
Nutritional and Metabolic Disease Maps

9.404E-08
1.539E-07
1.539E-07
1.879E-06
6.992E-06
2.684E-05
2.901E-04
4.613E-04
6.567E-04
1.077E-03
p-value

7.284E-06
7.284E-06
7.284E-06
6.669E-05
1.986E-04
6.352E-04
5.885E-03
8.188E-03
1.036E-02
1.472E-02
FDR

Ligand-dependent activation of the ESR1/AP-1 pathway
1.295E-05
β adrenergic receptors/brown adipocyte differentiation
1.397E-05
Transcription_Role of AP-1 in regulation of cellular metabolism
1.681E-05
Glutathione metabolism
2.174E-05
Putative pathways for stimulation of fat cell differentiation by
Bisphenol A
6.243E-05
Immune response_IL-18 signaling
3.418E-04
Transcription_Sirtuin6 regulation and functions
5.104E-04
Development_α-1 adrenergic receptors signaling via Cyclic AMP
7.107E-04
Insulin, IGF-1 and TNF-alpha in brown adipocyte differentiation
9.726E-04
Regulation of metabolism_Bile acids regulation of glucose and lipid
metabolism via FXR
2.027E-03
Enrichment is based on the significantly differentially transcribed genes (p<.05) in a
comparison between control diet/vehicle and control diet/20 mg/kg PCB (CVvsC20).
enrichments for each grouping, ranked from most to least significant by p-value
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7.881E-04
7.881E-04
7.881E-04
7.881E-04
1.811E-03
8.259E-03
1.057E-02
1.288E-02
1.567E-02
2.939E-02
Top ten

Table 46
Enrichments for liver and metabolic disease endpoints in comparison HVvsH200
Liver Toxicity Endpoint Processes
p-value
FDR
Hypertrophic organ growth_liver
1.768E-03 2.109E-02
Fibrosis, development_liver
2.343E-03 2.109E-02
Steatosis, development_liver
5.006E-03 3.004E-02
Cell cycle progression of Mitosis
8.310E-02 3.725E-01
Apoptosis via Mitochondrial membrane dysfunction
1.035E-01 3.725E-01
Cholestasis, development_liver
1.580E-01 4.741E-01
Hypoxia, development
3.809E-01 9.793E-01
Inflammation, development
4.762E-01 9.971E-01
Cell cycle, processes involved in S-phase
5.009E-01 9.971E-01
Cell cycle, processes involved in G1-phase
6.586E-01 9.971E-01
Liver-Specific Maps
p-value
FDR
Development_Regulation of EMT
3.347E-06 8.870E-04
Immune response_IL-6-induced acute-phase response in
hepatocytes
1.092E-05 1.447E-03
Immune response_Oncostatin M signaling via JAK-Stat
2.479E-04 2.190E-02
Signal transduction_mTORC2 downstream signaling
4.219E-04 2.795E-02
Development_IGF-1 receptor signaling
8.743E-04 4.215E-02
Development_WNT signaling pathway. Part 2
9.544E-04 4.215E-02
Development_Ligand-dependent activation - ESR1/AP-1 pathway
1.180E-03 4.469E-02
Cell cycle_ESR1 regulation of G1/S transition
1.376E-03 4.557E-02
Development_Beta-adrenergic receptors transactivation of EGFR
1.895E-03 5.580E-02
Transcription_Sirtuin6 regulation and functions
2.236E-03 5.926E-02
Nutritional and Metabolic Disease Biomarkers
p-value
FDR
Obesity
8.546E-05 2.606E-03
Overnutrition
8.546E-05 2.606E-03
Vascular Calcification
1.017E-04 2.606E-03
Nutrition Disorders
1.032E-04 2.606E-03
Frontotemporal Dementia
1.580E-04 2.659E-03
Frontotemporal Lobar Degeneration
1.580E-04 2.659E-03
Zellweger Syndrome
1.506E-03 2.165E-02
Peroxisome biogenesis disorders
1.715E-03 2.165E-02
Diabetes Mellitus, Type 2
2.031E-03 2.279E-02
Calcinosis
2.557E-03 2.582E-02
Nutritional and Metabolic Disease Maps
p-value
FDR
Development_IGF-1 receptor signaling
2.504E-04 2.165E-02
Development_Ligand-dependent activation - ESR1/AP-1 pathway
5.388E-04 2.165E-02
Transcription_Sirtuin6 regulation and functions
6.629E-04 2.165E-02
Retinol metabolism
1.066E-03 2.612E-02
Unsaturated fatty acid biosynthesis
4.752E-03 9.314E-02
Galactose metabolism
6.265E-03 1.023E-01
Regulation of metabolism_Bile acids regulation of glucose and lipid
metabolism via FXR
1.028E-02 1.439E-01
Transcription_Androgen Receptor nuclear signaling
1.407E-02 1.724E-01
Signal transduction_PTMs in BAFF-induced signaling
1.857E-02 2.022E-01
Amitraz-induced inhibition of Insulin secretion
2.424E-02 2.127E-01
Enrichment is based on the significantly differentially transcribed genes (p<.05) in a
comparison between control diet/vehicle and control diet/20 mg/kg PCB (CVvsC20). Top ten
enrichments for each grouping, ranked from most to least significant by p-value
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Table 47
Targets associated with liver disease enrichments and change vs. vehicle control by comparison
Input IDs

Gene
Symbol

CVvsC20

CVvsC200

HVvsH20

HVvsH200

Liver toxicity: Steatosis
ENSMUSG00000035561
ENSMUSG00000025003
ENSMUSG00000066072
ENSMUSG00000032349
ENSMUSG00000010663
ENSMUSG00000025153
ENSMUSG00000078650
ENSMUSG00000027984
ENSMUSG00000042632
ENSMUSG00000023913
ENSMUSG00000000440
Liver toxicity: fibrosis
ENSMUSG00000000532
ENSMUSG00000041324
ENSMUSG00000039304
ENSMUSG00000029661
ENSMUSG00000021820
ENSMUSG00000029675
ENSMUSG00000026072
ENSMUSG00000017057
ENSMUSG00000030748
ENSMUSG00000027947
ENSMUSG00000029304
ENSMUSG00000024620
ENSMUSG00000028599
ENSMUSG00000021250

Aldh1b1
Cyp2c39
Cyp4a10
Elovl5
Fads1
Fasn
G6pc
Hadh
Pla2g6
Pla2g7
Pparg

‐0.68
‐2.02
‐0.83
‐0.53
‐0.64
‐1.12
1.01
‐0.47
0.98
0.65
0.62
0.97

Acvr1b
Inhba
Tnfsf10
Col1a2
Camk2g
Eln
Il1r1
Il13ra1
Il4ra
Il6ra
Spp1
Pdgfrb
Tnfrsf1b
Fos

1.24
1.10
-0.76
0.80
-0.87
0.58
0.71
0.57
-0.67
0.48
-0.53
0.58
1.27

Liver toxicity analysis for each comparison indicated gene sets associated with liver toxicity
endpoints including steatosis and fibrosis. Differentially regulated gene targets are indicated.
For each target, the fold change vs. control is shown.
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Figure 11. IL-6-mediated acute-phase response in hepatocytes.
PCB exposure and PCB/HFD coexposures induced transcriptional changes in elements of IL-6mediated acute-phase response in hepatocytes. In particular, components of the AP-1 complex
(c-Jun, c-Fos) were differentially regulated in the CVvsC200 comparison (2), the HVvsH20
comparison (3), and the HVvsH200 comparison (4), along with changes in transcription of HNF1alpha targets IBP1, G6PT and Fibrinogen alpha. The HVvsH20 condition was associated with
differential transcription of the most targets associated with this pathway, in particular, targets of
STAT3 transcriptional activation. An increase in local inflammation associated with this condition
is consistent with our histological findings. Image generated using MetaCoreTM from Thomson
Reuters.
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Figure 12. IL-6/STAT-3 signaling pathways.
PCB exposure and PCB/HFD coexposures induced transcriptional changes in elements of IL-6signaling pathways. In particular, components of the AP-1 complex (c-Jun, c-Fos) were differentially
regulated in the CVvsC200 comparison (2), the HVvsH20 comparison (3), and the HVvsH200
comparison (4). Image generated using MetaCoreTM from Thomson Reuters.

108

Both the lack of transcription-level changes in biomarkers of liver disease in the CVvsC20
comparison and the relative abundance of changes in the HVvsH20 comparison vs. either of the
higher PCB exposure groups is in keeping with the histological severity of liver disease in these
groups23. Few common targets were seen in this enrichment, which may suggest pleiotropic
effects on hepatocyte toxicity, as well as complex interactions between nutrition/PCB
coexposures on disease mechanisms.
Among nutritional and metabolic disease enrichments, the pattern presented by the
individual comparisons was far more cohesive, with over-nutrition/obesity in the top enrichments
for every comparison. Fold changes of differentially transcribed genes associated with overnutrition/obesity for each vehicle vs. PCB comparison are listed in Table 48. Other metabolic
diseases that were of interest to us and highly enriched in one or more datasets were type 2
diabetes mellitus (Table 49), metabolic syndrome (Table 50), and insulin resistance (Table 51).
In each of these disease categories, the condition with the most changes vs. vehicle control was
the HVvsH20 condition. These changes included down-regulation of fatty acid synthetase and
beta 2-adrenergic receptor, polymorphisms of which have been associated with metabolic
disease123, 124. Down-regulation of GLUT4 reduces insulin-sensitive glucose uptake in nonhepatocyte liver cells and other insulin-sensitive tissues125. Metabolic disease enrichments for
the CVvsC20 and CVvsC200 group indicated changes to PPAR-alpha and LXR-mediated
glucose and lipid homeostasis, including alterations in expressions of the Tribbles-3
pseudokinase, which contributes to insulin resistance126 and down-regulation of Cyp7a1, which
could lead to cholesterol accumulation.

MetaCoreTM network analysis of dose-within-diet comparisons did not appear to indicate
enrichment in transcriptional targets of the xenobiotic transcription factors AhR, PXR, or CAR
Because xenobiotic receptors AhR, PXR, and CAR are classically associated with
transcriptional response to PCBs and other chemicals, we used MetaCoreTM to evaluate overrepresentation of curated transcriptional targets of these receptors. The direct transcriptional
targets of these receptors as defined by the MetaCoreTM database did not comprise a large
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Table 48
Targets associated with metabolic disease enrichments (overnutrition/obesity) and their
change vs. vehicle control in each comparison
Input IDs
Gene
CVvsC20
CVvsC200
HVvsH20
HVvsH200
Symbol
Metabolic Disease Biomarkers: Obesity
ENSMUSG00000020917
Acly
ENSMUSG00000031278
Acsl4
ENSMUSG00000035783
Acta2
ENSMUSG00000026883
Dab2ip
ENSMUSG00000042429
Adora1
ENSMUSG00000022994
Adcy6
ENSMUSG00000005580
Adcy9
ENSMUSG00000046532
Ar
ENSMUSG00000027792
Bche
ENSMUSG00000055116
Arntl
ENSMUSG00000045730
Adrb2
ENSMUSG00000082361
Btc
ENSMUSG00000002944
Cd36
ENSMUSG00000039804
Ncoa5
ENSMUSG00000029238
Clock
ENSMUSG00000000326
Comt
ENSMUSG00000056054
S100a8
ENSMUSG00000056071
S100a9
ENSMUSG00000019768
Esr1
ENSMUSG00000025153
Fasn
ENSMUSG00000044167
Foxo1
ENSMUSG00000048756
Foxo3
ENSMUSG00000019779
Frk
ENSMUSG00000028001
Fga
ENSMUSG00000033831
Fgb
ENSMUSG00000033860
Fgg
ENSMUSG00000018566
Slc2a4
ENSMUSG00000031451
Gas6
ENSMUSG00000091971
Hspa1a
ENSMUSG00000041798
Gck
ENSMUSG00000020429
Igfbp1
ENSMUSG00000020427
Igfbp3
ENSMUSG00000046070
Igfals
ENSMUSG00000027947
Il6ra
ENSMUSG00000038894
Irs2
ENSMUSG00000025780
Itih5
ENSMUSG00000055148
Klf2
ENSMUSG00000032796
Lama1
ENSMUSG00000053846
Lipg
ENSMUSG00000020593
Lpin1

-0.47
-0.96
0.65
0.81

-0.86
2.19
-1.04
-0.75

-0.72
1.05
-0.71
-0.64
-0.69
-0.92
-1.11
-0.67

-0.66
-0.73

1.04
-1.49
1.10
0.74
-0.65

-0.89

0.77
1.44
1.39

0.62
1.49
1.69
0.57
-1.12
-0.53
-0.79

1.62
1.58
0.69

0.58
1.06
1.02
0.96
-1.78
-0.47
-3.96
-0.98

-1.01
-0.46

-0.63
1.08

0.44
-0.70

0.60
-1.38
-1.08
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-0.78
-0.76

-0.67
0.57
1.01
-0.74
-0.63
-1.66
-1.96

0.83

-0.94
-0.70

Table 48 (continued)
Targets associated with metabolic disease enrichments (overnutrition/obesity) and their
change vs. vehicle control in each comparison
Input IDs
Gene
CVvsC20 CVvsC200
HVvsH20 HVvsH200
Symbol
-0.55
ENSMUSG00000028553
Angptl3
-1.59
ENSMUSG00000061132
Blnk
-0.65
ENSMUSG00000027556
Car1
0.84
1.32
ENSMUSG00000008845
Cd163
0.93
ENSMUSG00000028551
Cdkn2c
0.65
ENSMUSG00000020038
Cry1
0.48
ENSMUSG00000068742
Cry2
2.17
1.23
1.05
ENSMUSG00000015312
Gadd45b
0.69
ENSMUSG00000038039
Gcc2
-1.17
ENSMUSG00000026864
Hspa5
1.13
0.67
ENSMUSG00000074896
Ifit3
1.15
0.62
0.80
ENSMUSG00000052684
Jun
-0.97
ENSMUSG00000049723
Mmp12
0.47
-1.28
ENSMUSG00000003849
Nqo1
1.04
-1.52
ENSMUSG00000020889
Nr1d1
-0.97
ENSMUSG00000020893
Per1
0.85
ENSMUSG00000025509
Pnpla2
-0.53
ENSMUSG00000045038
Prkce
0.89
0.72
ENSMUSG00000020641
Rsad2
-1.37
2.06
2.62
ENSMUSG00000057465
Saa2
-1.04
0.65
ENSMUSG00000041567
Serpina12
0.59
ENSMUSG00000032902
Slc16a1
1.10
0.71
ENSMUSG00000020027
Socs2
0.81
ENSMUSG00000023905
Tnfrsf12a
0.69
ENSMUSG00000034485
Uaca
-0.65
ENSMUSG00000008348
Ubc
-2.54
ENSMUSG00000024924
Vldlr
Metabolic disease analysis for each comparison indicated gene sets associated with endpoints
including obesity/overnutrition. Differentially regulated gene targets are indicated. For each
comparison, fold change vs. control is shown.
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Table 48 (continued)
Targets associated with metabolic disease enrichments (overnutrition/obesity) and their
change vs. vehicle control in each comparison
Input IDs
Gene
CVvsC20 CVvsC200
HVvsH20 HVvsH200
Symbol
-0.73
ENSMUSG00000024052
Lpin2
0.72
0.91
ENSMUSG00000015568
Lpl
-0.73
-0.53
ENSMUSG00000027253
Lrp4
-2.05
ENSMUSG00000040584
Abcb1a
1.14
0.60
0.86
ENSMUSG00000024589
Nedd4l
1.18
1.47
ENSMUSG00000026822
Lcn2
1.21
0.91
-0.59
ENSMUSG00000032715
Trib3
0.68
ENSMUSG00000024413
Npc1
0.82
ENSMUSG00000030659
Nucb2
0.48
ENSMUSG00000029304
Spp1
1.52
1.22
1.08
ENSMUSG00000038508
Gdf15
-1.39
-0.74
ENSMUSG00000055866
Per2
0.86
ENSMUSG00000033871
Ppargc1b
-0.56
-0.48
ENSMUSG00000002289
Angptl4
0.89
ENSMUSG00000032462
Pik3cb
-0.47
ENSMUSG00000041417
Pik3r1
0.62
ENSMUSG00000000440
Pparg
0.61
ENSMUSG00000027540
Ptpn1
0.66
ENSMUSG00000021876
Rnase4
-0.80
-1.82
ENSMUSG00000022883
Robo1
-0.74
0.88
0.53
ENSMUSG00000028150
Rorc
-1.44
2.34
2.41
ENSMUSG00000074115
Saa1
-0.47
ENSMUSG00000075701
Selenos
-0.97
-1.02
ENSMUSG00000060807
Serpina6
1.08
ENSMUSG00000053113
Socs3
0.64
-0.50
ENSMUSG00000025006
Sorbs1
-0.62
1.22
ENSMUSG00000012428
Steap4
0.49
ENSMUSG00000025743
Sdc3
0.57
ENSMUSG00000029174
Tbc1d1
0.58
ENSMUSG00000028599
Tnfrsf1b
1.70
ENSMUSG00000035799
Twist1
-1.28
-2.03
0.72
ENSMUSG00000055254
Ntrk2
0.63
-0.85
ENSMUSG00000027962
Vcam1
0.71
ENSMUSG00000020484
Xbp1
-0.87
ENSMUSG00000028978
Nos3
-1.78
-1.17
ENSMUSG00000041653
Pnpla3
1.52
ENSMUSG00000034853
Acot11
0.80
ENSMUSG00000004730
Adgre1
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Table 49
Targets associated with metabolic disease enrichments (Type 2 Diabetes Mellitus) and their
change vs. vehicle control in each comparison
Input IDs
Gene Symbol CVvsC20 CVvsC200 HVvsH20 HVvsH200
Metabolic Disease Biomarkers: Type 2 Diabetes Mellitus
ENSMUSG00000035783
ENSMUSG00000026883
ENSMUSG00000035561
ENSMUSG00000026289
ENSMUSG00000024391
ENSMUSG00000019947
ENSMUSG00000046532
ENSMUSG00000032066
ENSMUSG00000027792
ENSMUSG00000055116
ENSMUSG00000033863
ENSMUSG00000045730
ENSMUSG00000082361
ENSMUSG00000027381
ENSMUSG00000022637
ENSMUSG00000035042
ENSMUSG00000002944
ENSMUSG00000039804
ENSMUSG00000000326
ENSMUSG00000068742
ENSMUSG00000019997
ENSMUSG00000025003
ENSMUSG00000003053
ENSMUSG00000056054
ENSMUSG00000056071
ENSMUSG00000028914
ENSMUSG00000072082
ENSMUSG00000027533
ENSMUSG00000054191
ENSMUSG00000041112
ENSMUSG00000042787
ENSMUSG00000019768
ENSMUSG00000010663
ENSMUSG00000039529
ENSMUSG00000044167
ENSMUSG00000048756
ENSMUSG00000049721
ENSMUSG00000029992
ENSMUSG00000028645
ENSMUSG00000018566
ENSMUSG00000024978
ENSMUSG00000040562
ENSMUSG00000031451
ENSMUSG00000027984
ENSMUSG00000036594
ENSMUSG00000037025

Acta2
Dab2ip
Aldh1b1
Atg16l1
Apom
Arid5b
Ar
Bco2
Bche
Arntl
Klf9
Adrb2
Btc
Bcl2l11
Cblb
Ccl5
Cd36
Ncoa5
Comt
Cry2
Ctgf
Cyp2c39
Cyp2c29
S100a8
S100a9
Casp9
Ccnf
Fabp5
Klf1
Elmo1
Exog
Esr1
Fads1
Atp8b1
Foxo1
Foxo3
Gal3st1
Gfpt1
Slc2a1
Slc2a4
Gpam
Gstm2
Gas6
Hadh
H2-Aa
Foxa2

-0.96
0.65

-0.71
-0.68

-0.57
0.76
0.51
-0.86
2.19
0.91
-1.04

-1.11
-0.45
-0.67

1.04
0.80
-1.49
1.10
0.91
0.62

-0.75

0.74
-0.65

-0.97
-0.89
0.62

0.48
-0.85
-2.02
2.75
1.44
1.39
0.64

1.49
1.69

-0.63
1.31
1.62
1.58

0.46
0.80
-0.73
-0.92
0.57

0.87
-0.88
0.69
-0.64

0.42
-0.53
-0.79
1.51
-0.75
0.93

-0.56
-1.78
-1.08
-1.48
-0.47
-0.47
-0.42

-0.93

-0.63
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Table 49 (continued)
Targets associated with metabolic disease enrichments (Type 2 Diabetes Mellitus) and their
change vs. vehicle control in each comparison
Input IDs
Gene Symbol CVvsC20 CVvsC200 HVvsH20 HVvsH200
ENSMUSG00000043013
ENSMUSG00000091971
ENSMUSG00000041798
ENSMUSG00000032115
ENSMUSG00000026185
ENSMUSG00000026072
ENSMUSG00000027947
ENSMUSG00000038894
ENSMUSG00000020653
ENSMUSG00000052040
ENSMUSG00000055148
ENSMUSG00000032796
ENSMUSG00000020593
ENSMUSG00000024052
ENSMUSG00000015568
ENSMUSG00000035202
ENSMUSG00000026688
ENSMUSG00000049723
ENSMUSG00000021025
ENSMUSG00000032715
ENSMUSG00000024413
ENSMUSG00000030659
ENSMUSG00000023034
ENSMUSG00000096054
ENSMUSG00000041827
ENSMUSG00000000168
ENSMUSG00000029304
ENSMUSG00000028211
ENSMUSG00000044254
ENSMUSG00000028525
ENSMUSG00000038508
ENSMUSG00000019577
ENSMUSG00000025509
ENSMUSG00000020893
ENSMUSG00000033871
ENSMUSG00000032462
ENSMUSG00000041417
ENSMUSG00000045038
ENSMUSG00000000440
ENSMUSG00000027540
ENSMUSG00000028150
ENSMUSG00000015843
ENSMUSG00000043895
ENSMUSG00000074115
ENSMUSG00000041567
ENSMUSG00000019970
ENSMUSG00000038351

Onecut1
Hspa1a
Gck
Hyou1
Igfbp5
Il1r1
Il6ra
Irs2
Klf11
Klf13
Klf2
Lama1
Lpin1
Lpin2
Lpl
Lars2
Mgst3
Mmp12
Nfkbia
Trib3
Npc1
Nucb2
Nr4a1
Syne1
Oasl1
Dlat
Spp1
Trp53inp1
Pcsk9
Pde4b
Gdf15
Pdk4
Pnpla2
Per1
Ppargc1b
Pik3cb
Pik3r1
Prkce
Pparg
Ptpn1
Rorc
Rxrg
S1pr2
Saa1
Serpina12
Sgk1
Sgsm2

0.96

-1.14

-3.95949
-0.98
-1.35
-1.39

1.13

0.73
-1.38
-0.76
0.73

1.21

-0.51
0.91
0.68

-1.01
0.52
-0.97
0.58
-0.67
0.57
-0.72
-0.74
-0.63
-1.96
-0.73
0.91
-1.38
-1.19
-0.97
-0.46
-0.59

-0.63
-0.75
-0.54
0.83

-0.70
-1.58

0.82
-0.63

0.94

0.62
1.15
-0.76
0.48
-0.99
0.73
1.52
1.04
0.85

1.22

1.08
-1.20
1.08
1.37

-0.97
0.86
0.89
-0.47
-0.53
0.62
0.61
-0.74

0.88
0.83
1.20
-1.44
-1.04

0.53
2.34
0.65

2.41
0.77

0.76
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Table 49 (continued)
Targets associated with metabolic diseases enrichments (Type 2 Diabetes Mellitus) and their
change vs. vehicle control in each comparison
Input IDs
Gene
CVvsC20 CVvsC200 HVvsH20 HVvsH200
Symbol
ENSMUSG00000020027
ENSMUSG00000053113
ENSMUSG00000025006
ENSMUSG00000037465
ENSMUSG00000028599
ENSMUSG00000022797
ENSMUSG00000028128
ENSMUSG00000020123
ENSMUSG00000027962
ENSMUSG00000024924
ENSMUSG00000028978
ENSMUSG00000041653

Socs2
Socs3
Sorbs1
Klf10
Tnfrsf1b
Tfrc
F3
Avpr1a
Vcam1
Vldlr
Nos3
Pnpla3

0.64
0.86

0.98

1.32
-1.29
0.63

1.10
1.08
-0.50
-0.54

0.71
-1.29
0.58

-0.80
0.85
0.72
-0.85
-2.54

-0.87
-1.78

-1.17

Metabolic disease analysis for each comparison indicated gene sets associated with endpoints
including diabetes mellitus. Differentially regulated gene targets are indicated. For each
comparison, fold change vs. control is shown.
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Table 50
Targets associated with metabolic disease enrichments (metabolic syndrome) and their change vs.
vehicle control in each comparison
Input IDs
Gene Symbol CVvsC20
CVvsC200
HVvsH20
HVvsH200
Metabolic Disease Biomarkers: Metabolic Syndrome
-0.47
1.05
ENSMUSG00000031278 Acsl4
0.76
ENSMUSG00000024391 Apom
2.2
1.04
ENSMUSG00000055116 Arntl
-1.04
-1.49
ENSMUSG00000045730 Adrb2
-0.75
0.74
-0.89
ENSMUSG00000002944 Cd36
0.77
ENSMUSG00000029238 Clock
0.48
ENSMUSG00000068742 Cry2
0.46
ENSMUSG00000072082 Ccnf
0.57
0.69
ENSMUSG00000019768 Esr1
-0.64
ENSMUSG00000010663 Fads1
1.06
ENSMUSG00000028001 Fga
1.02
ENSMUSG00000033831 Fgb
0.96
ENSMUSG00000033860 Fgg
-0.46
1.08
ENSMUSG00000020429 Igfbp1
0.44
ENSMUSG00000020427 Igfbp3
-1.14
-1.39
-0.97
-0.54
ENSMUSG00000026185 Igfbp5
-0.674195
ENSMUSG00000027947 Il6ra
-0.76
-1.96
-0.70
ENSMUSG00000020593 Lpin1
0.72
0.91
ENSMUSG00000015568 Lpl
-0.55
ENSMUSG00000059436 Max
1.21
0.91
-0.59
ENSMUSG00000032715 Trib3
0.73
-0.81
ENSMUSG00000027820 Mme
1.04
1.37
ENSMUSG00000019577 Pdk4
-1.39
-0.74
ENSMUSG00000055866 Per2
0.98
ENSMUSG00000042632 Pla2g6
0.65
ENSMUSG00000023913 Pla2g7
0.62
ENSMUSG00000000440 Pparg
0.61
ENSMUSG00000027540 Ptpn1
-1.27
ENSMUSG00000027368 Dusp2
-0.42
ENSMUSG00000020580 Rock2
-1.44
2.34
2.41
ENSMUSG00000074115 Saa1
-1.04
0.65
ENSMUSG00000041567 Serpina12
-0.62
1.22
ENSMUSG00000012428 Steap4
-0.87
ENSMUSG00000028978 Nos3
-1.78
-1.17
ENSMUSG00000041653 Pnpla3
0.63
-0.85
ENSMUSG00000027962 Vcam1
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Table 50 (continued)
Targets associated with metabolic disease enrichments (metabolic syndrome) and their change vs.
vehicle control in each comparison
Input IDs
Gene Symbol CVvsC20
CVvsC200
HVvsH20
HVvsH200
0.44
ENSMUSG00000048376 F2r
0.57
ENSMUSG00000030748 Il4ra
0.61
ENSMUSG00000021871 Pnp
0.56
ENSMUSG00000033220 Rac2
-1.37
2.06
2.62
ENSMUSG00000057465 Saa2
0.58
ENSMUSG00000028599 Tnfrsf1b
Metabolic disease analysis for each comparison indicated gene sets associated with endpoints
including metabolic syndrome. Differentially regulated gene targets are indicated. For each
comparison, fold change vs. control is shown.
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Table 51
Targets associated with metabolic disease enrichments (insulin resistance) and their change
vs. vehicle control in each comparison
Input IDs

Gene
CVvsC20 CVvsC200 HVvsH20 HVvsH200
Symbol
Metabolic Disease Biomarkers: Insulin resistance
ENSMUSG00000031278
ENSMUSG00000035783
ENSMUSG00000024391
ENSMUSG00000027792
ENSMUSG00000055116
ENSMUSG00000045730
ENSMUSG00000036098
ENSMUSG00000035042
ENSMUSG00000002944
ENSMUSG00000029238
ENSMUSG00000068742
ENSMUSG00000072082
ENSMUSG00000041220
ENSMUSG00000019768
ENSMUSG00000010663
ENSMUSG00000024664
ENSMUSG00000044167
ENSMUSG00000048756
ENSMUSG00000028001
ENSMUSG00000033831
ENSMUSG00000033860
ENSMUSG00000049721
ENSMUSG00000029992
ENSMUSG00000018566
ENSMUSG00000021670
ENSMUSG00000043013
ENSMUSG00000041798
ENSMUSG00000020429
ENSMUSG00000020427
ENSMUSG00000026185
ENSMUSG00000027947
ENSMUSG00000038894
ENSMUSG00000020593
ENSMUSG00000024052
ENSMUSG00000015568
ENSMUSG00000054612
ENSMUSG00000059436
ENSMUSG00000054764
ENSMUSG00000021025

Acsl4
Acta2
Apom
Bche
Arntl
Adrb2
Myrf
Ccl5
Cd36
Clock
Cry2
Ccnf
Elovl6
Esr1
Fads1
Fads3
Foxo1
Foxo3
Fga
Fgb
Fgg
Gal3st1
Gfpt1
Slc2a4
Hmgcr
Onecut1
Gck
Igfbp1
Igfbp3
Igfbp5
Il6ra
Irs2
Lpin1
Lpin2
Lpl
Mgmt
Max
Mtnr1a
Nfkbia
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-0.47
-0.96

1.05
-0.71
0.76
-0.67

2.19
-1.04

1.04

-0.75
0.77

0.74

-1.49
0.51
-0.97
-0.89

0.48
0.46
-0.89
0.57
-0.91

-0.56
-0.53
-0.79
1.06
1.02
0.96
1.51
-0.75

-0.53
0.69
-0.64
-0.91

-0.56
-1.78
-0.73

-0.98

-1.14

0.44
-1.39

-0.76
0.72
-0.55
1.51
-0.51

-1.01
-0.46
-0.97
-0.67
0.57
-1.96
-0.73
0.91
-1.03

-0.46

0.96
-0.63
1.08
-0.54
0.83
-0.70

Table 51 (continued)
Targets associated with metabolic disease enrichments (insulin resistance) and their change
vs. vehicle control in each comparison
Input IDs
Gene Symbol CVvsC20 CVvsC200 HVvsH20 HVvsH200
1.21
0.91
-0.59
ENSMUSG00000032715
Trib3
0.73
-0.81
ENSMUSG00000027820
Mme
1.04
1.37
ENSMUSG00000019577
Pdk4
0.85
ENSMUSG00000025509
Pnpla2
-1.39
-0.74
ENSMUSG00000055866
Per2
0.89
ENSMUSG00000032462
Pik3cb
-0.47
ENSMUSG00000041417
Pik3r1
0.98
ENSMUSG00000042632
Pla2g6
0.65
ENSMUSG00000023913
Pla2g7
0.62
ENSMUSG00000000440
Pparg
0.61
ENSMUSG00000027540
Ptpn1
-1.27
ENSMUSG00000027368
Dusp2
-0.42
ENSMUSG00000020580
Rock2
-1.44
2.34
2.41
ENSMUSG00000074115
Saa1
-0.47
ENSMUSG00000075701
Selenos
-1.04
0.65
ENSMUSG00000041567
Serpina12
-0.97
-1.02
ENSMUSG00000060807
Serpina6
1.08
ENSMUSG00000053113
Socs3
-0.62
1.22
ENSMUSG00000012428
Steap4
0.58
ENSMUSG00000028599
Tnfrsf1b
0.63
-0.85
ENSMUSG00000027962
Vcam1
-0.53
ENSMUSG00000044786
Zfp36
-0.87
ENSMUSG00000028978
Nos3
-1.78
-1.17
ENSMUSG00000041653
Pnpla3
0.84
1.32
ENSMUSG00000008845
Cd163
0.44
ENSMUSG00000048376
F2r
0.53
ENSMUSG00000044674
Fzd1
0.57
ENSMUSG00000030748
Il4ra
0.61
ENSMUSG00000021871
Pnp
0.86
ENSMUSG00000033871
Ppargc1b
0.56
ENSMUSG00000033220
Rac2
0.83
ENSMUSG00000015843
Rxrg
-1.37
2.06
2.62
ENSMUSG00000057465
Saa2
Metabolic disease analysis for each comparison indicated gene sets associated with endpoints
including insulin resistance. Differentially regulated gene targets are indicated. For each
comparison, fold change vs. control is shown.
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proportion of the DTG sets. Comparison of these results to outputs of the same network frame
showing DTG sets in vitro primary hepatocyte exposure to prototypical ligands for these
receptors, however, indicates that the sets of direct transcriptional targets as curated by
MetaCoreTM are probably not comprehensive (data not shown). Other software tools may be
needed to further explore these relationships.

Analysis of dose-within-diet comparisons indicated enrichment in disease-associated transcription
factors
Transcription factor analysis for the CVvsC20, CVvsC200, HVvsH20 and HVvsH200 are
shown in Tables 52-55. These analyses are based on gene ontology, therefore the transcription
factors ranked highest in the list of engaged transcription factors were those with the most
literature-based relationships among the DTGs in each dataset. Many of these connections are
based on chromatin immunoprecipitation studies or computational binding site prediction, and are
of unspecified effect, however, when only the defined relationships (activation or inhibition via
transcriptional regulation) were considered, we were able to develop a percent activation for each
listed transcription factor under each condition: the number differentially regulated in a direction
consistent with TF activation/total differentially regulated. These are listed in Tables 56 and 57.
Overall, transcription factors tended to increase in percent activation with increasing PCB
concentration and decrease with HFD exposure. Interestingly, transcription factors which were
targets of PXR regulation by binding showed evidence of increased activation at the 20 mg/kg
exposure, compared to the 200 mg/kg exposure, shown in Figure 13. PXR targets of regulation
by protein-protein interaction.

Specific targets within pathways engaged in these experiments are related to metabolic
syndrome components, including fatty liver disease and diabetes, as well as liver damage and
regeneration pathways.
Several of the targets differentially regulated under one or more of the experimental
conditions have been characterized as potential contributors to metabolic diseases, including
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Table 52
Top ten transcription factor enrichments for condition CVvsC20
Network
GO processes
CREB1
circadian rhythm (36.1%; 6.650e-17), rhythmic process (41.7%; 1.725e-15), single-organism developmental
process (86.1%; 7.277e-11), developmental process (86.1%; 1.097e-10), regulation of circadian rhythm (22.2%;
2.706e-10)
c-Myc
circadian rhythm (35.5%; 2.158e-14), rhythmic process (38.7%; 3.449e-12), circadian regulation of gene
expression (19.4%; 1.757e-09), regulation of transcription from RNA polymerase II promoter (54.8%; 2.296e-09),
regulation of circadian rhythm (22.6%; 3.264e-09)
p53
circadian rhythm (37.5%; 6.220e-16), rhythmic process (40.6%; 2.013e-13), negative regulation of cellular
process (84.4%; 7.367e-12), negative regulation of biological process (84.4%; 5.156e-11), regulation of circadian
rhythm (25.0%; 9.657e-11)
SP1
rhythmic process (45.2%; 3.802e-15), circadian rhythm (35.5%; 2.158e-14), cellular response to chemical
stimulus (71.0%; 2.982e-11), circadian regulation of gene expression (19.4%; 1.757e-09), regulation of
transcription from RNA polymerase II promoter (54.8%; 2.296e-09)
HIF1A
circadian rhythm (37.9%; 8.995e-15), rhythmic process (41.4%; 1.326e-12), cellular response to chemical
stimulus (72.4%; 4.566e-11), regulation of developmental process (69.0%; 5.890e-11), response to oxygencontaining compound (62.1%; 1.198e-10)
RelA (p65
circadian rhythm (36.7%; 1.406e-14), rhythmic process (40.0%; 2.161e-12), cellular response to chemical
NF-kB
stimulus (70.0%; 1.282e-10), regulation of developmental process (66.7%; 1.521e-10), response to oxygensubunit)
containing compound (60.0%; 2.670e-10)
c-Jun
circadian rhythm (42.9%; 8.721e-17), rhythmic process (46.4%; 2.371e-14), cellular response to chemical
stimulus (75.0%; 1.495e-11), response to oxygen-containing compound (60.7%; 6.514e-10), circadian regulation
of gene expression (21.4%; 9.074e-10)
C/EBPbeta circadian rhythm (40.7%; 3.458e-15), rhythmic process (48.1%; 1.299e-14), cellular response to chemical
stimulus (74.1%; 6.790e-11), negative regulation of gene expression (59.3%; 8.863e-11), negative regulation of
cellular macromolecule biosynthetic process (55.6%; 1.788e-10)
circadian rhythm (38.5%; 1.298e-13), rhythmic process (46.2%; 2.637e-13), circadian regulation of gene
expression (23.1%; 5.579e-10), negative regulation of gene expression (57.7%; 5.891e-10), regulation of
circadian rhythm (26.9%; 8.435e-10)
ESR1
(nuclear)

30

31

31

Nodes
37

2.400E-94

1.100E-97

4.960E-101

1.550E-102

p-Value
3.100E-121

1.100E-87

29

27

2.310E-84

2.400E-94

26

2.310E-84

29

26

GCR
circadian rhythm (44.4%; 5.034e-17), rhythmic process (51.9%; 3.145e-16), cellular response to chemical
26
2.310E-84
stimulus (81.5%; 2.376e-13), response to oxygen-containing compound (66.7%; 2.040e-11), response to organic
substance (77.8%; 6.517e-11)
Other significantly enriched transcription factors included Androgen receptor, C/EBPalpha, PPAR-gamma, HNF4-alpha, SMAD3, Oct-3/4, TCF7L2
(TCF4), c-Fos, YY1, FKHR, PPAR-alpha, IRF8, SMAD2, NRF2, SP3, STAT3, AP-2A, SRF, NRSF, and SMAD4.
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Table 53

Top ten transcription factor enrichments for condition CVvsC200
Network
GO processes
Nodes p-Value
CREB1
negative regulation of biological process (49.1%; 3.269e-14), negative regulation of cellular process (46.7%;
300 0.000E+00
3.566e-14), positive regulation of biological process (50.9%; 1.600e-12), positive regulation of macromolecule
metabolic process (32.6%; 4.023e-11), positive regulation of metabolic process (34.0%; 6.487e-11)
c-Myc
negative regulation of biological process (59.8%; 2.064e-18), negative regulation of cellular process (56.3%;
179 0.000E+00
1.927e-17), regulation of apoptotic process (32.2%; 4.137e-17), regulation of programmed cell death (32.2%;
6.263e-17), regulation of cell death (33.3%; 8.005e-17)
SP1
response to organic substance (59.6%; 2.008e-26), single-multicellular organism process (75.2%; 8.820e-24),
143 0.000E+00
regulation of apoptotic process (41.1%; 9.997e-24), regulation of programmed cell death (41.1%; 1.594e-23),
negative regulation of biological process (68.1%; 5.543e-23)
p53
regulation of apoptotic process (46.2%; 9.045e-28), regulation of programmed cell death (46.2%; 1.488e-27),
133 0.000E+00
regulation of cell death (46.9%; 9.259e-27), regulation of cell communication (57.7%; 7.792e-24), regulation of
signaling (57.7%; 1.761e-23)
ESR1
regulation of cell death (42.0%; 1.379e-19), regulation of apoptotic process (40.3%; 1.898e-19), regulation of
121 2.410E-279
(nuclear)
programmed cell death (40.3%; 2.785e-19), negative regulation of biological process (66.4%; 3.771e-18),
negative regulation of cellular process (63.9%; 3.980e-18)
RelA (p65
regulation of apoptotic process (50.0%; 2.902e-28), regulation of programmed cell death (50.0%; 4.657e-28),
113 1.400E-260
NF-kB
regulation of cell death (50.9%; 2.054e-27), negative regulation of biological process (76.8%; 1.145e-26),
subunit)
positive regulation of macromolecule metabolic process (61.6%; 2.046e-26)
Oct-3/4
positive regulation of macromolecule metabolic process (56.5%; 9.314e-21), positive regulation of metabolic
110 1.500E-253
process (57.4%; 6.092e-20), regulation of macromolecule biosynthetic process (63.0%; 6.818e-19), regulation of
cellular biosynthetic process (63.9%; 1.872e-18), positive regulation of cellular metabolic process (53.7%;
2.444e-18)
Androgen
positive regulation of macromolecule metabolic process (58.1%; 1.262e-21), positive regulation of metabolic
107 1.470E-248
receptor
process (59.0%; 8.077e-21), positive regulation of biological process (72.4%; 2.877e-18), developmental
process (73.3%; 9.619e-17), single-organism developmental process (72.4%; 2.108e-16)
HIF1A
regulation of apoptotic process (47.1%; 1.991e-23), regulation of programmed cell death (47.1%; 2.993e-23),
103 3.570E-237
regulation of cell death (48.1%; 8.857e-23), positive regulation of metabolic process (60.6%; 5.779e-22), positive
regulation of macromolecule metabolic process (57.7%; 4.422e-21)
c-Jun
response to organic substance (62.4%; 1.132e-21), positive regulation of metabolic process (59.4%; 2.226e-20),
101 1.660E-234
positive regulation of macromolecule metabolic process (55.4%; 1.163e-18), response to lipid (37.6%; 3.606e18), regulation of primary metabolic process (74.3%; 1.951e-17)
Other significantly enriched transcription factors included STAT3, YY1, GCR, NANOG, E2F1, C/EBPbeta, PPAR-gamma, SRF, GATA-3, HNF4-alpha,
SP3, FKHR, SOX2, C/EBPalpha, NF-kB, KLF4, p63, NF-kB1 (p50), HSF1, PU.1
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Table 54

Top ten transcription factor enrichments for condition HVvsH20
Network
GO processes
Nodes p-Value
CREB1
response to organic substance (47.0%; 3.429e-19), response to oxygen-containing compound (35.4%; 1.098e199 1.150E-299
18), response to organonitrogen compound (26.3%; 4.006e-17), response to extracellular stimulus (19.7%;
7.007e-17), response to nitrogen compound (26.8%; 2.991e-16)
c-Myc
regulation of apoptotic process (45.3%; 1.557e-28), regulation of cell death (46.8%; 2.561e-28), regulation of
141 5.530E-290
programmed cell death (45.3%; 2.621e-28), negative regulation of cell death (36.0%; 6.566e-25), negative
regulation of apoptotic process (33.1%; 3.790e-23)
SP1
response to organic substance (66.7%; 1.091e-33), cellular response to chemical stimulus (61.5%; 9.303e-32),
135 1.890E-284
regulation of cell death (49.6%; 3.956e-31), response to oxygen-containing compound (51.9%; 1.154e-30),
regulation of apoptotic process (46.7%; 1.956e-29)
Androgen
regulation of cell death (43.7%; 2.988e-21), regulation of apoptotic process (42.0%; 3.922e-21), regulation of
120 3.290E-264
receptor
programmed cell death (42.0%; 5.874e-21), response to organic substance (57.1%; 2.958e-20), response to
chemical (66.4%; 4.642e-19)
p53
regulation of cell death (50.0%; 8.565e-28), regulation of apoptotic process (46.6%; 7.797e-26), regulation of
117 1.410E-249
programmed cell death (46.6%; 1.231e-25), positive regulation of biological process (77.1%; 5.883e-25), positive
regulation of macromolecule metabolic process (57.6%; 1.154e-23)
ESR1
response to organic substance (66.4%; 4.157e-28), cellular response to chemical stimulus (61.9%; 2.760e-27),
114 5.010E-242
(nuclear)
response to oxygen-containing compound (51.3%; 2.433e-25), response to chemical (73.5%; 1.489e-24),
regulation of cell death (47.8%; 2.494e-24)
c-Jun
response to organic substance (68.6%; 2.067e-28), response to oxygen-containing compound (54.3%; 1.411e106 5.370E-237
26), regulation of cell death (51.4%; 2.464e-26), regulation of apoptotic process (49.5%; 4.376e-26), regulation
of programmed cell death (49.5%; 6.780e-26)
HIF1A
regulation of cell death (54.9%; 3.336e-29), regulation of apoptotic process (52.0%; 6.901e-28), regulation of
101 1.150E-299
programmed cell death (52.0%; 1.084e-27), response to organic substance (67.6%; 9.912e-27), cellular
response to chemical stimulus (63.7%; 1.848e-26)
RelA (p65
regulation of cell death (55.1%; 2.578e-28), regulation of apoptotic process (53.1%; 5.735e-28), regulation of
98 5.530E-290
NF-kB
programmed cell death (53.1%; 8.944e-28), response to oxygen-containing compound (56.1%; 1.138e-26),
subunit)
response to organic substance (68.4%; 2.053e-26)
GCR
cellular response to chemical stimulus (68.8%; 8.421e-30), response to organic substance (71.9%; 2.788e-29),
96 1.890E-284
response to organic cyclic compound (51.0%; 6.592e-29), response to oxygen-containing compound (57.3%;
2.736e-27), regulation of cell death (54.2%; 7.799e-27)
Other significantly enriched transcription factors included Oct-3/4, C/EBPbeta, STAT3, HNF4-alpha, C/EBPalpha, PPAR-gamma, NANOG, SP3,
TCF7L2 (TCF4), c-Fos, AHR, E2F1, HNF3-beta, YY1, KLF4, FOXO3A, GATA-3, NF-kB, EGR1, VDR
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Table 55

Top ten transcription factor enrichments for condition HVvsH200
Network
GO processes
Nodes p-Value
CREB1
negative regulation of cellular process (66.4%; 7.735e-20), negative regulation of biological process (66.4%;
116 0.000E+00
1.009e-17), regulation of cell death (39.7%; 6.005e-17), response to hormone (31.9%; 3.075e-16), negative
regulation of metabolic process (47.4%; 3.775e-16)
c-Myc
positive regulation of macromolecule metabolic process (60.5%; 9.952e-20), positive regulation of metabolic
87 4.730E-245
process (60.5%; 2.515e-18), response to organic substance (61.6%; 4.053e-18), regulation of cell death
(46.5%; 7.414e-18), regulation of apoptotic process (44.2%; 2.690e-17)
SP1
response to endogenous stimulus (52.4%; 8.326e-21), negative regulation of cellular process (73.8%;
83 1.280E-231
6.342e-20), response to organic substance (64.3%; 1.169e-19), negative regulation of biological process
(75.0%; 5.559e-19), response to hormone (40.5%; 9.947e-19)
p53
regulation of cell death (50.6%; 5.417e-20), response to organic substance (64.2%; 6.069e-19), response to
80 5.070E-223
endogenous stimulus (50.6%; 9.129e-19), positive regulation of macromolecule metabolic process (60.5%;
1.103e-18), regulation of apoptotic process (46.9%; 2.117e-18)
ESR1 (nuclear) response to organic substance (68.0%; 2.838e-20), response to endogenous stimulus (53.3%; 2.041e-19),
77 2.480E-216
negative regulation of cell death (42.7%; 4.796e-19), cellular response to chemical stimulus (61.3%; 3.687e18), regulation of cell death (49.3%; 1.071e-17)
RelA (p65 NFresponse to organic substance (69.2%; 5.822e-22), cellular response to chemical stimulus (64.1%; 7.683e77 1.930E-214
kB subunit)
21), positive regulation of metabolic process (65.4%; 3.572e-20), response to chemical (76.9%; 7.676e-20),
regulation of cell death (51.3%; 8.300e-20)
C/EBPbeta
response to organic substance (70.1%; 2.198e-22), cellular response to chemical stimulus (63.6%; 2.997e76 1.390E-211
20), regulation of cell death (51.9%; 4.482e-20), response to chemical (76.6%; 2.190e-19), response to
oxygen-containing compound (53.2%; 4.302e-19)
HIF1A
regulation of cell death (53.9%; 2.327e-21), response to organic substance (67.1%; 7.032e-20), regulation
75 9.920E-209
of apoptotic process (50.0%; 1.274e-19), regulation of programmed cell death (50.0%; 1.753e-19), positive
regulation of macromolecule metabolic process (63.2%; 1.858e-19)
GCR
response to organic substance (76.0%; 1.606e-26), cellular response to chemical stimulus (70.7%; 4.137e74 7.060E-206
25), response to endogenous stimulus (58.7%; 1.692e-23), response to hormone (48.0%; 7.672e-23),
response to oxygen-containing compound (58.7%; 1.099e-22)
STAT3
positive regulation of macromolecule metabolic process (68.1%; 5.873e-22), positive regulation of metabolic
71 2.490E-197
process (68.1%; 1.405e-20), response to organic substance (69.4%; 1.574e-20), regulation of cell death
(54.2%; 1.805e-20), regulation of apoptotic process (51.4%; 1.144e-19)
Other significantly enriched transcription factors included Androgen receptor, c-Jun, C/EBPalpha, Oct-3/4, HNF4-alpha, STAT1, FOXO3A, SOX2, cFos, NANOG, STAT6, PPAR-gamma, PPAR-alpha, SREBP1 (nuclear), FKHR, VDR, YY1, IRF4, AHR, EGR1
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Table 56
Percent activation for engaged transcription factors identified in all conditions
CVvsC20

31
25
19
23
21

%
CWA
16%
32%
37%
30%
38%

48
72
68
69
54

%
CWA
52%
32%
60%
59%
63%

16

25%

53

14
14
18
16

50%
64%
33%
56%

13
13
9
14
12
7
7
10

Total
CREB1
c-Myc
p53
SP1
HIF1A
RelA (p65 NFkB subunit)
c-Jun
C/EBPbeta
ESR1 (nuclear)
GCR
Androgen
receptor
C/EBPalpha
PPAR-gamma
HNF4-alpha
Oct-3/4
YY1
FKHR
STAT3

CVvsC200

HVvsH20

168
116
92
109
62

%
CWA
13%
28%
34%
32%
34%

64%

69

37
34
52
47

73%
56%
54%
43%

15%

37

46%
78%
50%
42%
29%
43%
50%

25
30
29
54
19
24
44

Total

HVvsH200

93
62
50
58
44

%
CWA
24%
18%
46%
43%
48%

38%

43

56%

71
58
84
60

38%
47%
33%
27%

35
41
50
37

49%
61%
50%
68%

54%

89

25%

33

24%

60%
57%
62%
50%
42%
63%
45%

47
36
45
56
33
24
62

38%
28%
33%
39%
15%
21%
48%

33
15
30
31
15
18
37

39%
47%
53%
39%
27%
50%
57%

Total

Total

Relative activation of the most enriched transcription factors (second column for each
comparison) was determined by comparing the proportion of differentially transcribed targets in
which the direction of transcription was concordant with activation of the transcription factor,
based on the MetaCore curated TFtarget relationship and normalized to the total number of
targets for that TF differentially transcribed in our experiment (first column for each comparison).
This table shows % engagement for TFs which were enriched in all group 1-2 comparisons.
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Table 57
Percent activation for engaged transcription factors identified in 1-3 conditions

SP3
TCF7L2 (TCF4)
c-Fos
SMAD3
PPAR-alpha
IRF8
SMAD2
NRF2
AP-2A
SRF
NRSF
SMAD4
NANOG
E2F1
GATA-3
SOX2
NF-kB
KLF4
p63
NF-kB1 (p50)
HSF1
PU.1
AHR
HNF3-beta
FOXO3A
EGR1
VDR
STAT1
STAT6
SREBP1 (nuclear)
IRF4

CVvsC20
%
Total
CWA
6
33%
7
43%
9
33%
8
38%
8
50%
8
13%
5
20%
6
83%
8
25%
5
40%
4
25%
5
100%
0
0
0
0
0
0
0
0
0
0
0
0
0
10
50%
0
0
0
0
0
-

CVvsC200
%
Total
CWA
25
52%
0
0
0
0
0
0
0
0
26
42%
0
0
27
48%
21
81%
9
33%
18
39%
27
70%
20
55%
25
52%
13
62%
27
26%
26
65%
0
0
0
0
0
0
0
0
0
-

HVvsH20
%
Total
CWA
38
37%
41
34%
35
49%
0
0
45
31%
37
35%
26
15%
0
28
32%
29
62%
0
0
0
0
33
12%
26
15%
29
28%
32
47%
26
27%
0
0
0
0
-

HVvsH200
%
Total
CWA
0
0
22
55%
0
14
43%
0
23
26%
0
0
24
33%
0
0
18
22%
19
47%
23
57%
21
43%
16
50%
20
70%
16
0%
14
7%
16
38%

Relative activation of the most enriched transcription factors (second column for each
comparison) was determined by comparing the proportion of differentially transcribed targets in
which the direction of transcription was concordant with activation of the transcription factor,
based on the MetaCore curated TFtarget relationship and normalized to the total number of
targets for that TF differentially transcribed in our experiment (first column for each comparison).
This table shows % engagement for TFs which were enriched in 1, 2, or 3 of the group 1-2
comparisons.
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Figure 13. Transcription factors regulated by PXR or PXR/RXR via protein-protein interactions.

Targets of inhibition shown in the blue boxes and targets of activation shown in the red box. The pie charts represent the proportion of targets

differentially transcribed in a direction concordant with activation (red) or inhibition/inactivation (blue) of the TF in each of the group 1-2

comparisons. PPARα, a target of PXR activation, is shown in the red box, while targets of PXR or PXR/RXR protein-protein inhibition are shown

in the blue boxes. The apparent status of activation of CREB-1, HNF3β, AR, HNF4α, and FKHR (FOXO1) is more indicative of inhibition
(concordant with PXR activity) in the moderate-exposure conditions compared with the high-exposure conditions.
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Trib3/NIPK, Arntl, and claudin-1. Associated pathway maps are shown in Figures 14-16,
respectively.
The Tribbles 3 pseudokinase (NIPK or TRIB3) interrupts insulin signaling by binding and
preventing phosphorylation of AKT, thereby promoting gluconeogenic down-stream targets such
as PEPCK and diminishing the activity of GSK3B and associated glycogen synthesis127, 128
(Figure 14). TRIB3 can also dephosphorylate several MAP kinases and AMPK. TRIB3 is
activated by PPARα and by endoplasmic reticulum stress (PERK-eIF2alpha-ATF4-CHOP arm of
the unfolded protein response),129 thereby providing a mechanism by which ER stress can
modulate the transduction energy and growth factor signaling to intermediary metabolic and
developmental transcriptional outputs. The human TRIB3 polymorphism Q84R, which enhances
its inhibition of AKT, has been linked to increased prevalence of insulin resistance and associated
cardiovascular risk130. TRIB3 is up-regulated in obesity and metabolic syndrome.
The arylhydrocarbon receptor nuclear translocator-like (Arntl) forms a heterodimer with
CLOCK, an active complex driving transcription of circadian output genes such as the Period
(Per1, 2, etc.) and Cryptochrome (Cry1, 2, etc.) genes (Figure 15). Another target up-regulated in
all four comparisons was nuclear factor interleukin-3 (Nfil-3, or E4BP4), which encodes a protein
that represses expression of the Period genes131, 132. Processes related to circadian rhythm and
control of rhythmic processes were enriched with moderate PCB exposure in our model. Again,
disruption of normal circadian rhythm may be both cause and effect in metabolic disease133, 134.
The oscillatory patterns of circadian clock output genes (BMAL/CLOCK target genes) are
disrupted in response to nutritional challenges135, 136. Disrupted sleep patterns due to sleep
apnea137 or shift work138 are also associated with metabolic disease progression. Another target
of circadian rhythm circuitry is Kruppel-like factor 9 (KLF9), a transcription factor which expressed
in epithelial cells and regulates daytime-specific expression of differentiation-related targets (Ell3)
as well as targets related to glucocorticoid signaling (Fkbp5)139.
Other targets associated with cell differentiation/identity, epithelial-to-mesenchymal
transition and regenerative processes were differentially regulated, particularly within the
moderate exposure models. These included up-regulated cell adhesion proteins such as claudin-
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Figure 14. Nipk/Trib3 signaling pathway downstream of PPAR-alpha.
PCB exposure and PCB/HFD coexposures induced transcriptional changes in elements of
signaling pathways downstream of PPAR-alpha.

In particular, the tribbles pseudokinase

(Nipk/Trib3) differentially regulated in all comparisons: CVvsC20 (1), CVvsC200 (2), HVvsH20 (3),
HVvsH200 (4), C20vsH20 (5), C200vsH200 (6), and CVvsHV (7). Notably, transcription was
upregulated in both control diet comparisons and in CVvsHV and downregulated in other
comparisons. Image generated using MetaCoreTM from Thomson Reuters.
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Figure 15. Arntl/Bmal1 pathway related to circadian signaling.
PCB exposure and PCB/HFD coexposures induced transcriptional changes in elements of
signaling pathways related to circadian signaling. In particular, the arylhydrocarbon receptor
nuclear translocator-like (Arntl/Bmal1) was differentially regulated in comparison CVvsC20 (1),
CVvsC200 (2), and C20vsH20 (5).

Clock output targets such as Per1/2, and Cry1/2 were

differentially regulated in comparisons HVvsH20 (3), HVvsH200 (4), and CVvsHV (7), as well as
comparison 5. Image generated using MetaCoreTM from Thomson Reuters.
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1, endothelin-1, and vimentin, changes in which signal epithelial-to-mesenchymal or
mesenchymal-to-epithelial transitions in hepatocytes140 (Figure 16). Other differentially regulated
targets in this category, including Frizzled, bone morphogenic protein 2 (BMP-2, a TGFβ-family
member), Kruppel-like factors 10/11 (KLF-10, KLF-11: TGFβ-inducible growth regulators) and ID1/2 (inhibitor of DNA binding) are components of multiple development and differentiation
pathways such as WNT (Frizzled), Hedgehog (BMP2), TGFβ (BMP2, TIEG), and Hippo (ID-1/2).
Alterations in cell identity that accompany EMT are classically associated with neoplastic liver
disease141, however there is evidence to link alterations in Hedgehog142, 143, TGFβ144, WNT145, 146,
and Hippo147 signaling to the progression of steatohepatitis and fibrosis.
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Figure 16. Claudin-1 and e-cadherin pathways related to EMT.
PCB exposure and PCB/HFD coexposures induced transcriptional changes in elements of
signaling pathways related to epithelial to mesenchymal transition. The cell adhesion molecules
claudin-1 and e-cadherin were differentially regulated in all or most conditions CVvsC20 (1),
CVvsC200 (2), a HVvsH20 (3), HVvsH200 (4), C20vsH20 (5), C200vsH200 (6) and CVvsHV (7).
Image generated using MetaCoreTM from Thomson Reuters.
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CHAPTER TWO: DISCUSSION

PCB exposure induced transcriptional changes in mouse liver, and higher PCB exposure
substantially increased the number of genes differentially transcribed compared to lower PCB
exposure in the absence of dietary coexposure, the pathway characteristics of which are
summarized in Figure 17. The addition of HFD as a coexposure greatly affected the number of
differentially transcribed genes produced by PCB exposure: increasing the number and changing
the distribution of engaged pathways. HFD itself produces many transcriptional changes in
mouse liver, as have previously been described. PCB exposure modulates this effect, resulting in
sets of differentially transcribed genes which overlap substantially. In the CVvsC20 comparison,
nutritional and metabolic disease biomarkers were over-represented, and along with
cardiovascular and vascular disease categories (also metabolic syndrome components),
occupied five of the top ten most enriched categories in this group. It is interesting that these
indicators were enriched in regular defined diet-fed animals exposed to PCBs, and that the
difference between vehicle and moderate PCB exposure was lost in HFD coexposure. This
suggests that PCB and HFD exposure may converge on pathways regulating nutritional
homeostasis, and that PCBs may contribute to metabolic dysregulation even in the absence of
HFD.
With or without HFD coexposure, exposure to PCBs at 200 mg/kg increases enrichment
in biomarkers of neoplastic disease. This is consistent with findings in previously reported rodent
toxicity studies. Cancer outcomes have been a historic focus of PCB research, mainly due to the
presence of dioxins and dioxin-like PCBs and dibenzofurans within the exposure mixture. Dioxins
are potent carcinogens in mice, and have been classified as human carcinogens. Other than a
recently reported increased prevalence of liver cancer among male Yusho (but not Yucheng)
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Figure 17. Summary of transcriptional differences between groups.
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victims, however, the evidence linking PCB to cancer in humans has been underwhelming110.
Interestingly, other than ovarian neoplasms in the HVvsH20 comparison, neoplastic disease
categories were not in the top 10 disease enrichments by biomarker for either of the moderate
exposure groups.
Our 20 mg/kg PCB exposure was based on the highest serum PCB level reported in the
Anniston population23, 79, which itself has a mean several times higher than that of the US
average148. The moderate PCB dose, therefore, is more representative of environmentallyrelevant human exposures, and we find that the distribution of diseases in these enrichments
reflects this. Our analysis of the differential transcriptomes produced by liver tissue in these
experiments in some ways recapitulated the proteomic and metabolic phenotype assessments.
Within the HVvsH20 comparison, however, the most highly enriched disease category was IL-6
signaling (Table 45 and Figures 11-12). This is consistent with the findings of Wahlang et al.,
which indicated that the increased liver injury observed in the HVvsH20 model was not due to
increased steatosis, but due to increased inflammation23. Increases in serum IL6 and tPAI1
protein were observed in the HFD/moderate exposure. In our transcriptomic analysis of liver
tissue, pathways involving hepatocyte acute-phase response triggered by IL6 were observed in
the moderate exposure (comparison HVvsH20).
We also saw enrichment in pathways and processes associated with control of circadian
rhythm and rhythmic processes with moderate PCB exposure. Interestingly, in a 2015 report
using metabolic cages to carry out metabolic phenotyping on PCB-exposed mice, our laboratory
showed increased movement during the light (typical sleep) cycle in transgenic mice chronically
exposed to 20mg/kg Aroclor 1260. These differences were observed only in mice with ablated
constitutive androstane receptor (CAR) or pregnane and xenobiotic receptor (PXR), with a
nonsignificant increase in wild-type mice. HFD feeding alone has been reported to alter the
oscillatory patterns of circadian rhythm output genes in wild-type mice (Nampt, Acss2/ACSAdownreg in all CDvsHFD comparisons, Cyp2a5)136, but not the core clock genes, which are more
resistant to reprogramming by nutritional challenge135, 136. We also found differences in the
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transcription of clock output genes with HFD and HFD/PCB coexposure, but with moderate PCB
exposure alone, we saw differences in transcription of the core clock genes as well, suggesting
that PCB exposure and nutritional coexposures may impact these systems by different and
potentially interacting mechanisms.
Although neoplastic disease biomarkers may not be captured by enrichment analysis in
more realistic models of human environmental exposure, processes such as cell adhesion, cellcell communication, and pathways dictating cell identity changes through the processes of
development and remodeling are over-represented in these models. The liver has extraordinary
regenerative potential requiring plasticity in development and differentiation pathways even in
adult hepatic tissue. Multiple pathways involved in development as well as repair were engaged
in these models, including TGF-beta signaling, Wnt/β-Catenin signaling, Hedgehog signaling, and
Hippo signaling. Because these pathways are involved in development and regeneration, they
also share common processes related to cell identity, orientation, and cell-cell recognition.
Although pathway analysis shows engagement of these pathways in our animal model of
environmental liver disease, it is unclear whether this engagement indicates regenerative
response to ongoing PCB/HFD-dependent liver damage or modulation of basal or HFD-driven
liver regeneration through xenobiotic receptor mediated PCB effect.
Responses to endogenous and exogenous organic compounds were over-represented
among engaged processes both in the presence and absence of HFD coexposure. Responses
to xenobiotics are thought to be mediated by xenobiotic receptors, of which AhR, PXR, and CAR
are the prototypical example. In addition, xenobiotic receptors may also be activated by
endogenous molecules, and crosstalk at multiple levels with receptors transducing hormone and
metabolite sensing to control of intermediary metabolic processes. Among the direct
transcriptional targets of these receptors with defined relationships curated by MetaCoreTM, few
were differentially regulated, however, MetaCoreTM software does not offer a comprehensive
database of interactions for these receptors, and even some prototypical transcriptional effects of
receptor-target interactions, such as Mus musculus PXR transcriptional activation of Cyp3a11,
are not among the curated dataset. Canonical prototypical targets of PXR, including Cyp3a11,
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were up-regulated in the CVvsC20 condition. Alternative pathway analysis tools may offer more
insight into the direct transcriptional effects of xenobiotic receptors in this model. It is interesting
to note, however, that transcription factors which directly interact with and are inhibited by PXR
showed a pattern consistent with increased engagement in the moderate exposure compared to
the high exposures. Since these protein-protein interactions are ligand-dependent, it suggests
that PXR (and potentially other xenobiotic receptors) may indeed be engaged, and that the
mechanism of their effect in PCB-associated liver injury requires further study.
In summary, our RNAseq and subsequent pathway analysis of liver tissue from an animal
model of PCB/HFD coexposure revealed several transcriptional changes which may be related to
the observed phenotypic differences between groups. In particular, the enrichments in nutritional
disease terms observed in the control diet animals exposed to PCBs may explain some of the
differences in glucose handling which were previously reported for this experiment.23
Enrichments in IL-6 signaling with the moderate PCB/HFD coexposure may explain the increased
histological evidence of liver injury observed only in this condition, while differential transcription
affecting pathways involved in development and regeneration, as well as cell adhesion and cellcell recognition may provide some insight into differences in regenerative/fibrotic processes
observed in the animal model.
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CHAPTER THREE
PCB EXPOSURE INDUCES A DIFFERENTIAL TRANSCRIPTOME WHICH PARTIALLY
OVERLAPS WITH THAT OF PROTOTYPICAL XENOBIOTIC RECEPTOR LIGANDS IN A
MOUSE PRIMARY HEPATOCYTE MODEL

Xenobiotic receptors are transcription factors which allow an organism to respond to
chemical changes in the environment with appropriate metabolic adaptations. Although these
changes are often circumscribed in the literature as encounters with environmental toxicants, it is
important to recognize that xenobiotic receptors often respond to endobiotic signals as well, and
are intimately involved in intermediary metabolism and inter-tissue communication along with the
metabolism of xenobiotics. Even the arylhydrocarbon receptor (AhR), a classic focus of
xenobiotic and toxicant research, affects149 and is affected by150, hormonal signaling pathways
and the metabolic products of gut commensals. It is not surprising, therefore, that AhR and other
xenobiotic receptors such as the pregnane and xenobiotic receptor (PXR) and the constitutive
androstane receptor (CAR), have been implicated in metabolic derangements associated with
toxicant exposures. Such derangements may manifest clinically and experimentally as
components of metabolic syndrome, including steatohepatitis.
Nuclear receptors including PXR, CAR, farnesoid X receptor (FXR) and the liver X
receptor (LXR) are known to cross-talk at multiple levels, from common ligands151, binding
partners, and cofactors152 to conserved response elements characterized by a DR4153 or other
shared motifs. This last intersection is most intriguing because while PXR and CAR are known to
be sensors and effectors in xenobiotic metabolism, induction of the sterol-sensor LXR and the
bile acid receptor FXR directly induce lipogenic gene targets, a phenomenon which is known to
be modulated by CAR, PXR, and AhR. LXR induction, particularly as an off-target effect of
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pharmacotherapy, has been shown to lead to nonalcoholic fatty liver disease (NAFLD)154.
Considering the interplay of these factors, it is not surprising that PXR, CAR, and LXR have been
implicated along with the AhR in toxicant-associated steatohepatitis.

A further degree of complexity arises when we consider the effects of toxicant mixtures such as
PCBs, which can be expected to affect several of these sensors simultaneously. PCBs are
always encountered and bioaccumulated as mixtures of congeners, and persist at detectable
levels in the serum of every adult in the United States37. The distribution of congeners found in
the adipose tissue and serum of humans contains species which are known to modulate the
activity of AhR, PXR, CAR19, 34, 35, 155 and other receptors, and may, through crosstalking
pathways, affect the transcriptional function of LXR. Because each of these receptors modulates
gene targets related to steatohepatitis, an understanding of the contribution of each of these
transcription factors to the overall PCB-modified transcriptome would assist with both risk
assessment and the rational development of therapies.
Other groups have elucidated the subsets of the transcriptome modulated by AhR, PXR,
and CAR individually in response to prototypical ligands. Findings have been intriguing for
several reasons. Both in vivo and in vitro experiments suggest that for both AhR and PXR,
differential transcription of target genes appears to be ligand-specific156. Additionally, for primary
hepatocytes, variations in cell isolation and culture techniques including culture time and plating
substrate may drastically affect the expression levels of prototypical targets of AhR, CAR and
PXR. In light of this, we sought to consolidate our assessment into a single primary murine
hepatocyte model, examining the relationships between prototypical ligand responses and
response to PCBs using RNAseq. We further sought to evaluate the PCB-dependent
transcriptional output of this model for components of metabolic pathways related to steatosis and
for gene ontology (GO) term enrichments within hepatic and metabolic disease categories.
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CHAPTER THREE: MATERIALS AND METHODS

Animals and primary cell isolation procedure

Male C57BL6 mice 8-10 weeks of age were purchased from Jackson Labs and allowed to
acclimate for 1 week on a defined control diet (Harlan Teklad Cat TD.06416). Mice were deeply
anesthetized with ketamine/xylazine, and the liver was flushed by retrograde perfusion first with a
washing solution for 6 minutes, then with a buffered collagenase solution for 10 minutes. After
perfusion, the liver was isolated and the gallbladder removed in a dish of ice-cold FBSsupplemented Waymouth’s media. The liver was finely minced and the resulting suspension
filtered through a 70 µm cell strainer. Cells were immediately centrifuged, washed twice with ice
cold HBSS, and selected by densitiy gradient centrifugation. The cell pellet was then
resuspended in cold, supplemented Waymouth’s media, and viability and cell count were
determined. Cells were plated on collagen-coated 12-well plates and allowed to adhere.
Adherent cells were exposed for 6 hours to 4 µl/well vehicle (DMSO) or test substance solubilized
in DMSO: Aroclor 1260 at 5 µg/ml or a prototypical ligand for mPXR – summarized in Table 58
(10 µM pregnane carboxynitrile, PCN), mCAR (10 µM, TCPOBOP), LXR (1 µM GW3965
hydrochloride, GW) or AhR (50 µM benzathracene, BA). After exposure, media was removed and
RNA was isolated by the RNAStat60 manufacturer’s protocol.

RNAseq and gene transcription analysis

RNA samples were multiplexed using sequence barcoding, and sequenced single ended to 75
base pair reads using a NextSeq500 to an approximate read count of 40 million reads per
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Table 58
Treatment summary
Exposure
DMSO
Benzanthracene (BA), 50 µM
Pregnane Carboxynitrile (PCN), 10µM
GW3965 1µM
TCPOBOP µM
Aroclor 1260 (PCB) 5µg/ml

Anticipated Target
Control
AhR
mPXR
LXR
mCAR
--

Isolated primary mouse hepatocytes were exposed to Aroclor 1260 (a representative PCB
mixture) or prototypical ligand for the above anticipated targets for 6h.
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sample. The bcl files produced were basecalled using Illumina’s bcl2fastq software. All
sequences produced were aligned to the mouse reference genome (GRCm38.83) using the
alignment software TopHat, and transcript expression levels were calculated in FPKM units using
Cufflinks122. The quantification was guided by transcriptome annotation for the mouse
downloaded from NCBI. Records corresponding to both mitochondrial and ribosomal RNA were
removed (annotated as transcript_biotype rRNA or Mt_tRNA) to improve the accuracy of the
transcriptome quantification. Differential analyses (FPKM units averaged from 4 replicates of
each test vs. DMSO-treated controls) were performed using CuffDiff.

Pathway and GO enrichment term analysis

For each treatment, the fold changes and p-values for each differentially transcribed gene
(indexed by Ensembl ID) were uploaded into MetaCoreTM (Thompson Reuters) and recognized
genes were associated with one or more MetaCoreTM-curated network objects. Experiments
were analyzed using the MetaCoreTM Enrichment Analysis Workflow tool, using a species (M.
musculus) and tissue (liver) prefilter. With prefilters, the number of tags/genes was reduced to 87
targets (from 119).

qPCR validation of selected targets:
Targets for validation were selected based on RNAseq-indicated up-regulation and
relevance to implicated transcription factors, pathways and disease processes. cDNA was
generated using the QuantiTect Reverse Transcription kit (Qiagen #205313) according to
manufacturer recommendations. Multiplexed qPCR (target and GAPDH) was carried out on
BioRad CFX384 system using the following TaqMan Gene Expression Array probes: Cyp1a2
(Applied Biosystems Mm00487224_m1/FAM), Cyp3a11 (Applied Biosystems
Mm00731567_m1/FAM), Cyp2b10 (Applied Biosystems Mm01972453_s1/FAM) and GAPDH
(Applied Biosystems, Mm99999915_g1/VIC).
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CHAPTER THREE: RESULTS

Aroclor1260 exposure at 5 ug/mL for 6h induced differential transcription in primary mouse
hepatocytes
Under these conditions, 123 targets were significantly differentially transcribed with
Aroclor 1260 treatment vs. DMSO control (Figure 18 and Table 59). Among these, 68 were
down-regulated (FC > 0.5), with 13 genes showing greater than 1-fold reduction in transcription.
Aroclor 1260 exposure resulted in up-regulation (FC < 0.5) of 55 genes, with 3 genes upregulated more than 1-fold.

In this model, the Aroclor 1260-dependent DTG sets partially overlapped with DTG sets produced
by exposure to ligands for AhR, PXR, CAR, and LXR
Of the 123 targets within the PCB-DTG set, 41 (33%) were not shared with the DTG sets
produced by the prototypical ligands investigated, as shown in Figure 19. Most (67.5%) of the
genes within the PCB-DTG set overlapped with DTG sets produced by prototypical ligands for
murine AhR, PXR, CAR, and/or LXR, as shown in Figure 20. The largest areas of overlap as a
proportion of the total PCB-DTG set occurred with the PXR agonist PCN (65 targets in common
with PCB exposure) and the AhR agonist BA (64 targets in common with PCB exposure). These
two prototypical ligands produced by far the largest differential transcriptomes: 672 and 720 total
DTGs, respectively, and the proportion of these transcriptomes which were also modulated by
PCBs was relatively small (9.7% and 8.9%, respectively). The smallest area of overlap occurred
between PCB and GW3960, a specific inducer of LXR, with only 14 targets differentially
transcribed under both conditions. Although the direct murine CAR agonist TCPOBOP produced
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Figure 18. Histograms of differential transcriptomes produced by PCB/prototypical ligand exposure.
The differential transcriptome produced by Aroclor 1260 exposure in this model included both upregulated and downregulated targets, with fold changes ranging from -3.73 to +1.3 (Panel A).
Differential transcriptome FC ranges for prototypical ligands are shown in Panels B-E.
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Table 59
Targets differentially regulated with Aroclor 1260 Exposure
Ensembl ID
Name
FC
Ensembl ID
ENSMUSG00000026442 Nfasc
-3.73
ENSMUSG00000035171
ENSMUSG00000002489 Tiam1
-2.51
ENSMUSG00000011305
ENSMUSG00000076434 Wfdc3
-2.45
ENSMUSG00000100798
ENSMUSG00000034780 B3galt1
-1.81
ENSMUSG00000036941
ENSMUSG00000032315 Cyp1a1
-1.78
ENSMUSG00000045502
ENSMUSG00000084923 Gm15611 -1.57
ENSMUSG00000028088
ENSMUSG00000069919 Hba-a1
-1.47
ENSMUSG00000035202
ENSMUSG00000038156 Spon1
-1.43
ENSMUSG00000032310
ENSMUSG00000050097 Ces2b
-1.41
ENSMUSG00000059325
ENSMUSG00000097461 Gm26735 -1.20
ENSMUSG00000030643
ENSMUSG00000076431 Sox4
-1.17
ENSMUSG00000019832
ENSMUSG00000004038 Gstm3
-1.10
ENSMUSG00000019726
ENSMUSG00000050069 Grem2
-1.00
ENSMUSG00000039270
ENSMUSG00000041992 Rapgef5
-0.99
ENSMUSG00000049404
ENSMUSG00000030909 Anks4b
-0.97
ENSMUSG00000019866
ENSMUSG00000053168
-0.96
ENSMUSG00000012428
ENSMUSG00000052305 Hbb-bs
-0.96
ENSMUSG00000023073
ENSMUSG00000101206 Gm5266
-0.95
ENSMUSG00000018102
ENSMUSG00000064128 Cenpj
-0.92
ENSMUSG00000038332
ENSMUSG00000091572 Vmn2r3
-0.92
ENSMUSG00000021190
ENSMUSG00000052131 Akr1b7
-0.90
ENSMUSG00000056204
ENSMUSG00000031169 Porcn
-0.89
ENSMUSG00000000303
ENSMUSG00000057068 Fam47e
-0.86
ENSMUSG00000041483
ENSMUSG00000021260 Hhipl1
-0.84
ENSMUSG00000022512
ENSMUSG00000041132 N4bp2l1
-0.84
ENSMUSG00000037260
ENSMUSG00000055312 Them7
-0.84
ENSMUSG00000016382
ENSMUSG00000038403 Hfe2
-0.83
ENSMUSG00000024773
ENSMUSG00000078612
-0.81
ENSMUSG00000021998
ENSMUSG00000020000 Moxd1
-0.80
ENSMUSG00000035671
ENSMUSG00000030107 Usp18
-0.79
ENSMUSG00000030790
ENSMUSG00000061540 Orm2
-0.76
ENSMUSG00000047777
ENSMUSG00000030089 Slc41a3
-0.75
ENSMUSG00000024042
ENSMUSG00000057425 Ugt2b37
-0.75
ENSMUSG00000068876
ENSMUSG00000028359 Orm3
-0.74
ENSMUSG00000024014
ENSMUSG00000022032 Scara5
-0.72
ENSMUSG00000032350
ENSMUSG00000063659 Zbtb18
-0.71
ENSMUSG00000019854
ENSMUSG00000046027 Stard5
-0.71
ENSMUSG00000020034
ENSMUSG00000032715 Trib3
-0.69
ENSMUSG00000025351
ENSMUSG00000022244 Amacr
-0.67
ENSMUSG00000078866
ENSMUSG00000020553 Pctp
-0.67
ENSMUSG00000000957
ENSMUSG00000046794 Ppp1r3b
-0.66
ENSMUSG00000024486
ENSMUSG00000003762 Adck4
-0.65
ENSMUSG00000019960
ENSMUSG00000056148 Rdh9
-0.65
ENSMUSG00000028381
ENSMUSG00000073565 Prr16
-0.65
ENSMUSG00000025779
ENSMUSG00000036181 Hist1h1c
-0.64
ENSMUSG00000052609
ENSMUSG00000030827 Fgf21
-0.63
ENSMUSG00000027954
ENSMUSG00000031482 Slc25a15 -0.63
ENSMUSG00000021765
ENSMUSG00000107198 Gm19619 -0.63
ENSMUSG00000024810
ENSMUSG00000022946 Dopey2
-0.62
ENSMUSG00000040152
ENSMUSG00000040562 Gstm2
-0.61
ENSMUSG00000079427
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Name
Plin5
Gm19589
Elac1
Hcar2
Fmo5
Lars2
Cyp1a2
Hopx
Rab30
Rab32
Lyst
Megf9
Rarres1
Aim1
Steap4
Slc10a2
Hist1h2bc
Sesn1
Lgmn
Pgpep1
Cdh1
Zfp281
Cldn1
Hgsnat
Pls3
Atg2a
Lcp1
Zswim4
Adm
Phf13
Sik1
Cgn
Pim1
Gclc
Reps1
Tcp11l2
Cd63
Gm14420
Mmp14
Hbegf
Dusp6
Ugcg
Ly96
Plekhg3
Efna1
Fst
Il33
Thbs1
Mthfsl

FC
-0.61
-0.59
-0.59
-0.56
-0.53
-0.53
-0.52
-0.52
-0.51
-0.51
-0.49
-0.49
-0.47
-0.46
-0.46
-0.45
-0.43
-0.42
0.42
0.45
0.45
0.46
0.46
0.49
0.50
0.50
0.51
0.51
0.51
0.51
0.52
0.52
0.52
0.53
0.54
0.54
0.55
0.56
0.56
0.57
0.58
0.59
0.60
0.61
0.61
0.61
0.61
0.62
0.64
0.65

Table 59 (Continued)
Targets differentially regulated with Aroclor 1260 Exposure
Ensembl ID
Name
FC
ENSMUSG00000078952 Lincenc1
0.65
ENSMUSG00000044134 Fam109a
0.65
ENSMUSG00000024912 Fosl1
0.66
ENSMUSG00000068299 1700019G17Rik 0.67
ENSMUSG00000078650 G6pc
0.68
ENSMUSG00000051439 Cd14
0.70
ENSMUSG00000022218 Tgm1
0.71
ENSMUSG00000017002 Slpi
0.71
ENSMUSG00000018774 Cd68
0.75
ENSMUSG00000020607 Fam84a
0.76
ENSMUSG00000041836 Ptpre
0.77
ENSMUSG00000026728 Vim
0.77
ENSMUSG00000063531 Sema3e
0.77
ENSMUSG00000056515 Rab31
0.84
ENSMUSG00000097073 9430037G07Rik 0.85
ENSMUSG00000097879 Gm26869
0.85
ENSMUSG00000046733 Gprc5a
0.89
ENSMUSG00000032643 Fhl3
0.91
ENSMUSG00000075707 Dio3
0.92
ENSMUSG00000029304 Spp1
0.93
ENSMUSG00000024803 Ankrd1
1.09
ENSMUSG00000037239 Spred3
1.31
ENSMUSG00000029188 Slc34a2
1.34
Gene targets differentially regulated with Aroclor 1260
exposure are shown. FC = fold change compared to DMSO
control.
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Figure 19. Venn diagram showing the overlapping differentially transcribed gene sets
between PCB and prototypical ligand exposures.
Aroclor 1260 (PCB) exposure resulted in differential transcription of 41 (33.3%) targets not
attributable to ligand‐activated transcription by any of the other four transcription factors
investigated.

This uniquely regulated section of the PCB‐dependent transcriptome

included unique of CREB1, SP1, and c‐Myc. Several of the differentially transcribed targets,
including SOX‐4, Ptpre (Receptor‐type Protein Tyrosine Phosphatase epsilon) and Sik‐1
(salt‐inducible kinase 1) are implicated in regulation of hepatic intermediary metabolism.
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Figure 20. A portion of the PCB-DTG overlapped with DTGs for AhR, PXR, CAR, and LXR
prototypical ligands. The differential transcriptome produced by Aroclor 1260 (PCB) exposure in
this model overlapped with the differential transcriptome produced by each of the 4 prototypical
ligands studied. The largest differentially-transcribed gene (DTG) sets were produced by A.
pregnane carboxynitrile (PCN), a pregnane and xenobiotic receptor agonist and B.
Benzanthracene (BA), an arylhydrocarbon receptor agonist. These two prototypical ligands also
produced the largest areas of overlap with PCB exposure (65 and 64 common DTGs, respectively).
Two other prototypical ligands produced smaller total DTG sets. C. GW3965, a LXR agonist,
produced a total differential transcriptome of 78 genes, 14 of which were also affected by PCB
exposure.

D. TCPOBOP, a direct constitutive androstane receptor (CAR) agonist, caused

differential transcription of the smallest number of total genes (56), 20 of which were shared with
PCB exposure.

PCB exposure regulated a larger proportion of the total CAR differential

transcriptome, however, than any other prototypical ligand studied (36%, vs 8% of BA-DTGs, 9%
of PCN-DTGs, and 18% of LXR-DTGs).
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the smallest differential transcriptome (56 targets), 20 targets within this set were also targets of
differential regulation by Aroclor 1260 exposure.
The direction of change in these common DTGs varied between treatment with Aroclor
and prototypical ligands, but agreed with the direction of PXR and AhR differential transcription in
most cases, as expected (Table 60), with more shared targets down-regulated than up-regulated.
Of the 65 targets shared between PCB and PCN, 87.7% agreed in direction. Exceptions included
the gene target Usp18, which was moderately up-regulated in the PXR prototypical ligand
condition and down-regulated with both Aroclor 1260 treatment and CAR prototypical ligand
treatment. Of the 64 targets shared between PCB and BA, 85.9% agreed in direction. The six
genes up-regulated with BA and down-regulated with Aroclor 1260 were all differentially regulated
by at least one other transcription factor, and in fact, two of the three DTGs common to all 5
conditions were represented in this group (Cyp1a1 and Lars2). DTGs shared between
GW3965/PCB and TCPOBOP/PCB included both up-regulated and down-regulated targets. In
both cases, the up-regulated target sets were entirely concordant (6/6 for GW3965 and 10/10 for
TCPOBOP, concurrently up-regulated/shared). 87.5% of genes were concordantly downregulated between GW3965 and PCB, while only half of the shared targets of TCPOBOP downregulated with PCB exposure agreed in direction. Although a tremendous amount of overlap
existed between the conditions investigated, we were surprised to find that 41 DTGs (33.3%)
were unique to Aroclor exposure and are not shared with other prototypical ligand treatment
(Figure 19 and Appendix Table 1), with 21 up-regulated and 20 down-regulated.
As expected, exposure to each of the prototypical ligands resulted in up-regulation of the
corresponding prototypical target (Table 61). With Aroclor 1260 exposure, however, no
significantly different transcription occurred (vs. DMSO control) in any prototypical target other
than Cyp1a2, which was significantly down-regulated. This finding validates previous reports that
while PCB exposure leads to induction of CAR, PXR, AhR and LXR prototypical targets in vivo23,
these effects are not recapitulated in vitro.

149

3

87.0%
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87.5%
92.9%
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7
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1
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8
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TCPOBOP

0

100%

10

50.0%
75.0%

20
10

5

down

5

up
10
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Table 60

64
23
35

6

Total

Concordance in direction of differential transcription between PCB-DTGs and Prototypical Ligand DTGs
Prototypical
BA
PCN
GW3965
ligand:

shared
Upregulated
41

Targets in
PCB-DTG
Dataset

Downregulated
Total
concordance
(%)

down

ligands. Of the targets shared between PCB exposure and each prototypical ligand, most showed concordance in direction of regulation.

Numerically, the largest gap in concordance existed between the 25 shared targets of Aroclor 1260 and PCN which were upregulated by Aroclor

1260 exposure, 18 of these were also upregulated by PCN and 7 were downregulated by PCN, resulting in an overall concordance of 72%. As

a percentage, the largest gap in concordance existed between the 10 shared targets of Aroclor 1260 and TCPOBOP and downregulated by
Aroclor 1260 exposure. Only half these targets (5) were also upregulated by TCPOBOP.
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up

Concordance in direction between targets differentially regulated by Aroclor 1260 (PCB-DTG) and targets differentially regulated by prototypical

Total

Table 61
Fold induction of prototypical targets for AhR, PXR, and CAR with prototypical ligand exposure
BA
PCN
TCPOBOP
Aroclor 1260
Cyp1a2
1.25
‐1.10
0.89
‐0.52
Cyp3a11
0.41
0.970
Cyp2b10
2.54

Fold change in each of the prototypical targets with exposure to prototypical ligands is shown.
As expected, exposure to each prototypical ligand induced upregulation of the corresponding
prototypical targets (shown in bold). Exposure to Aroclor 1260 did not result in significant
change in any prototypical target except for Cyp1a2 (AhR target), which was downregulated.
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Aroclor1260 differentially transcribed genes are significantly enriched in pathway maps involved
in cell identity and development, and in GO terms related to liver, endocrine, and metabolic
disease
Initial output of in silico analysis using the MetaCoreTM Enrichment analysis workflow
identified 9 pathway maps significantly (FDR < .05) over-represented in the Aroclor1260
differentially transcribed gene set, shown in Table 62. Within these pathways, network objects
related to differentiation or epithelial to mesenchymal transition (EMT) were enriched, particularly
E-cadherin, vimentin, and claudin-1, which appeared separately or together in half of the top 10
enriched pathways. Pathways related to EMT were enriched for the PCB-DTG members. Figure
21 illustrates elements of this pathway.
Components of the PCB-DTG set were enriched in GO terms related to liver (31/4260
curated network objects, p = 6.0 E-05, FDR = 4.7 E-04), pancreatic (27/3463 curated network
objects, p = 6.8e-5, FDR = 5.2 e-4) and metabolic (29/3584 curated network objects, p = 1.6 e-5,
FDR = 2.0 e-4) disease biomarkers. Within these sets, E-cadherin, vimentin and claudin-1
figured prominently, as did HB-EGF, AMACR, and osteopontin.
Aroclor1260 DTGs contain known or putative targets of transcription factors with known
involvement in fatty liver disease and metabolic dysfunction. Transcription factor analysis of
Aroclor 1260 indicated that large subsets of the PCB-DTGs set were predicted to be influenced
by specific transcription factors including CREB-1, SP-1 and cMyc. Nuclear receptors such as
HNF4-α and PPAR-γ, with known roles in steatosis and steatohepatitis, were also found to
modulate the transcription of targets within this set. Significantly overconnected transcription
factors are listed in Table 63. Notably, several of these transcription factors are direct or downstream targets of EGFR activation.
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Table 62
Enriched pathways for PCB-DTG set

1.524E-04
2.544E-02

2.544E-02

3/30

3/26

4/53

Histone H2, Histone H1.2, Histone H1

Histone H2B, CD63, Histone H1

Vimentin, Claudin-1, Cingulin

E-cadherin, Vimentin, Claudin-1, Fra-1

Targets

Development_WNT signaling pathway. Part 2
3.090E-04
2.544E-02

3/31

E-cadherin, Vimentin, Claudin-1

Targets
in-network/total

Cell adhesion_Endothelial cell contacts by
junctional mechanisms
4.755E-04
2.544E-02

3/35

CD63, Thrombospondin 1, CD14

FDR

Apoptosis and survival_Granzyme A signaling
5.246E-04

2.921E-02

3/43

p-value

NETosis in SLE
7.528E-04

3.849E-02

Pathway

Development_TGF-beta-dependent induction of
EMT via SMADs
1.379E-03

E-cadherin, Vimentin, Claudin-1

Role of cell adhesion in vaso-occlusion in Sickle
cell disease

3/46

E-cadherin, Vimentin, Claudin-1

HB-EGF, Tiam1, Ephrin-A
3.849E-02

3/47

E-cadherin, Vimentin, Claudin-1

3/45
1.678E-03

3.849E-02

3/64

3.849E-02

Development_TGF-beta-dependent induction of
EMT via RhoA, PI3K and ILK.

1.786E-03

8.237E-02

1.574E-03

Development_TGF-beta-dependent induction of
EMT via MAPK

4.315E-03

Neurophysiological process_Receptor-mediated
axon growth repulsion

Development_Regulation of epithelial-tomesenchymal transition (EMT)

MetacoreTM pathway analysis of the differentially transcribed gene set produced by Aroclor 1260 exposure (PCB-DTG) identified 9 significantly

enriched pathways (FDR < .05). Targets E-cadherin, Vimentin, and/or Claudin-1 were associated with more than half of the top ten pathways.
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Figure 21. Pathways related to EMT were enriched in genes in the PCB-DTG set. The cell
adhesion molecules claudin-1 and E-cadherin, as well as vimentin were important components of
this pathway as well as others related to cell differentiation and tissue regeneration pathways.
Image generated using MetaCoreTM from Thomson Reuters.
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Table 63
Transcription factors with targets in the PCB-dependent differentially-transcribed gene set

Network

Seed
nodes

p-Value

zScore

CREB1
SP1
c-Myc
p53
C/EBPbeta
Androgen receptor
c-Jun
ESR1 (nuclear)
PPAR-gamma
HNF4-alpha
NANOG
C/EBPalpha
STAT3
HIF1A
GATA-3
ATF-4
c-Fos
RelA (p65 NF-kB subunit)
Bcl-6
SMAD3
VDR
IRF1
SMAD2
Oct-3/4
JunD
GCR
FKHR
PPAR-alpha
TCF7L2 (TCF4)
p63

33
23
21
20
19
17
15
14
14
14
13
13
12
12
12
12
11
11
10
10
10
10
10
10
9
9
9
8
8
8

3.050E-105
8.940E-73
2.420E-66
3.910E-63
6.230E-60
1.530E-53
3.570E-47
5.360E-44
5.360E-44
5.360E-44
7.920E-41
7.920E-41
1.150E-37
1.150E-37
1.150E-37
1.150E-37
1.660E-34
1.660E-34
2.340E-31
2.340E-31
2.340E-31
2.340E-31
2.340E-31
2.340E-31
3.250E-28
3.250E-28
3.250E-28
4.430E-25
4.430E-25
4.430E-25

212.83
176.55
168.36
164.12
159.76
150.68
141.01
135.93
135.93
135.93
130.65
130.65
125.15
125.15
125.15
125.15
119.4
119.4
113.37
113.37
113.37
113.37
113.37
113.37
107.02
107.02
107.02
100.27
100.27
100.27

Transcription regulation pathway analysis was performed on the PCB-DTG
dataset without prefilters.
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CHAPTER THREE: DISCUSSION

Classically, the transcriptional effects of PCB exposure have been attributed entirely to
ligand-dependent activation of AhR, PXR and CAR. We expected that the subset of genes
differentially transcribed with Aroclor1260 exposure in this acute primary hepatocyte model would
overlap almost entirely with the transcriptional output of prototypical ligands for these three
receptors. We were therefore surprised to discover that fully 1/3 of DTGs were unique to
Aroclor1260 in this system, possibly due to the transcriptional effects of another xenobiotic
receptor or by an indirect mechanism. Our laboratory has recently reported that EGFR is also a
target of inhibition by both Aroclor1260 and individual PCB congeners. PCBs therefore would be
expected to function as an indirect CAR activator in both mice and humans by the same
mechanism as phenobarbital21.
The canonical cytochrome P450 targets of CAR and PXR activation cyp2b10 and
cyp3a11 did not appear among the RNA-seq derived PCB-DTG gene set, while cyp1a1 and
cyp1a2 (prototypical targets of AhR induction) were both down-regulated in the PCB-DTG set.
Interestingly, cyp1a1 and cyp1a2 were also down-regulated by PCN treatment in this model.
Regulation of cyp1a1 was particularly complex: up-regulated by inducers of CAR and LXR as well
as AhR and down-regulated by PXR induction. We conclude that differential regulation of the
proportion of PCB-DTGs overlapping with targets of the evaluated receptors is complex and may
be influenced by the combined effects of these and other xenobiotic receptors.
The targets most strongly up-regulated with Aroclor 1260 exposure, slc34a2 (+1.34-fold
vs. control) and spred3 (+1.31-fold vs. control) were uniquely up-regulated by PCBs in this model.
Although slc34a2 was also a target differentially regulated by PCN exposure, it was downregulated in that condition and unchanged with exposure to other prototypical ligands. The targets
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most strongly down-regulated with Aroclor 1260 exposure, nfasc (-3.73-fold vs. control) Tiam1(0.51-fold vs. control) and wfdc3 (-2.45-fold vs. control) were also strongly down-regulated by PCN
treatment (-4.20, -2.73, and -2.13-fold vs. control, respectively). PXR is involved in differential
regulation of transcription related to PCB exposure, however, it seems more involved in inhibition
of these targets than induction.
Several of the genes differentially transcribed with PCB exposure in this model are
differentially transcribed in the incidence or progression of liver disease or liver disease
biomarkers. Osteopontin (Spp), which was up-regulated with PCB (+0.93-fold vs. control) is upregulated in NASH fibrosis has been shown to oppose EMT in liver progenitor cells157. Four And
A Half LIM Domains 3 (FHL3), which was up-regulated with PCB (+0.91-fold vs. control) affects
transcription of tPAI1, a fibrosis biomarker up-regulated in PCB-exposed humans. RAB31, a
member RAS Oncogene Family, which was up-regulated with PCB (+0.84-fold vs. control), is
associated with invasive/metastatic characteristics and worse prognosis in HCC.158. Semaphorin
3E (Sema3e), which was up-regulated in PCB exposure (+0.77 vs. control) is expressed by
damaged hepatocytes and secreted, inducing contraction of sinusoidal epithelial cells and
activation of stellate cells. Chronic exposure to Semaphorin 3E in a mouse model of CCl4-induced
chronic heptatitis lead to disorganized sinusoidal regeneration and exacerbated fibrosis.159
Cytochrome P450 1a1 (Cyp1a1), which was down-regulated (-1.78-fold vs. control) is a
prototypical target of the arylhydrocarbon receptor and is up-regulated in animal models of
TCDD-induced nonalcoholic steatohepatitis.160 Interestingly, in this model, although it was upregulated by prototypical ligands of LXR and CAR in addition to AhR, it was strongly downregulated by PXR ligand exposure. Carboxyesterase 2 (Ces2b), which was down-regulated in our
model (-1.41-fold vs. control), and in the livers of NASH patients. Experimental ablation of Ces2b
in a mouse model causes ER stress in hepatocytes and stimulates lipogenesis in an SREBP-1dependent manner.161 Aldo-keto reductase family 1, member B7 (Akr1b7), which was downregulated in our model (-0.90-fold vs. control) is enriched in adipose stromal vascular fraction, but
not in mature adipocytes. In a mouse model, Akr1b7 KO increased basal adiposity (adipocyte
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hyperplasia and hypertrophy) with diet-independent development of liver steatosis and insulin
resistance.162 Hemochromatosis, type 2 (Hfe2), which was down-regulated in our model (-0.83 vs.
control), is expressed at significantly lower levels in NAFLD patients vs. those with no disease.
Because Hfe2 is involved in iron-sensing pathways, it is hypothesized that lower levels of Hfe2
are related to the dysregulated iron-sensing pathways leading to iron overload in NAFLD.163
Thrombospondin-1 (Thbs1), was up-regulated in our model (+0.64 vs. control). Transcription of
Thrombospondin-1 is increased in individuals with chronic liver disease and in mouse models of
liver fibrosis.164 Interleukin 33 (Il33) was up-regulated in our model (+0.62 vs. control), and is
elevated in the serum of NASH patients, increasing with increasing histologic severity.165
Several of the genes differentially transcribed with PCB exposure in this model affect
pathways of interest. Sprouty-related protein with EVH-domain 3 (Spred-3), which was upregulated with PCB (+1.31-fold vs. control) potently inhibits ERK1/2 signaling166, 167. Four And A
Half LIM Domains 3 (FHL3) physically interacts with SMAD proteins (TGFβ) pathway.168 RAB31
is associated with modulation of EGFR trafficking. It physically interacts with EGFR and its
overexpression increases early-late endosome trafficking and degradation of EGFR.169, 170 T
lymphoma invasion and metastasis 1 (Tiam1), which is strongly down-regulated with PCB (-2.51fold vs. control) is differentially regulated in hepatocellular carcinoma and pancreatic cancer
tissues.171, 172 In pancreatic cancers, the Par3 interacts with Tiam1 to affect tight junctions by
downregulating Claudin-1 and Occludin.172 Tiam1 is also a target suppressed by several
miRNAs.173, 174 Sustained ectopic exposure to Sema3E (up-regulated by PCB exposure in this
model) has been found to result in disorganized regeneration of liver sinusoids, contributing to
fibrosis, in a mouse model of liver regeneration.159 SRY (sex determining region Y)-box 4 (Sox-4),
was down-regulated with PCB exposure in our model (-1.17-fold vs. control). In HepG2 cells,
inhibition of Sox-4 blocks caspase-1-dependent apoptosis.175 Glutathione S-transferase, mu 3
(Gstm3), which was down-regulated with PCB exposure in our model (-1.10-fold vs. control) is
involved in glutathione-dependent clearance of xenobiotics (Phase II metabolism).176 Protein
Tyrosine Phosphatase, Receptor Type E (Ptpre) was up-regulated with PCB exposure, and
functions to modulate insulin signaling in hepatocytes and skeletal muscle by suppressing
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phosphorylation of targets down-stream of insulin signaling such as Akt, ERK and GSK3.177
Porcupine homologue (Porcn), which was down-regulated (-0.89-fold vs. control) is an ER protein
essential for the processing of Wnt proteins, and its inhibition inhibits Wnt signaling.178
Lastly, several of the genes differentially transcribed with PCB exposure in this model are
affected by pathways of interest. Na+-Pi Cotransporter NaPi-IIb is regulated by glucocorticoid,
estrogen, EGF, aging,179 dietary phosphate status, hormones like parathyroid hormone, 1,25OH2 vitamin D3 or FGF23180. Expression of Gstm is induced by wnt/β-catenin activation and
inhibited with Ras activation.181 Aldo-keto reductase family 1, member B7 (Akr1b7) is induced in
the liver by activation of FXR182 CAR, PXR, and LXR via direct interaction with DR4 elements in
the promoter, and that the influence of PXR/LXR is additive.183
The MetaCoreTM curated GO processes most significantly enriched in genes affected by
Aroclor 1260 exposure included several recurring objects with roles in Wnt signaling, cell
adhesion and/or EMT: pathways which are altered in the progression of fatty liver disease184. Of
these, up-regulation of Claudin-1 was unique to Aroclor 1260 exposure and although more than
one prototypical ligand induced differential expression of E-cadherin (PCN and BA), it was upregulated only with PCB exposure. Vimentin, in contrast, was up-regulated with PCN and
TCPOBOP as well as PCB exposure. Importantly, EMT in hepatocytes is characterized by a
decrease in E-cadherin and claudin-1, corresponding to increased inhibition by SNAIL/SLUG
signaling down-stream of TGFβ. EMT in hepatocytes is characterized by decreases in Ecadherin and claudin-1, and increased Vimentin, however, with PCB exposure, we saw increases
in expression of both epithelial (E-cadherin and Claudin-1) biomarkers, along with increased
Vimentin (a mesenchymal biomarker). Although decreases in expression are associated with
mesenchymal change, exogenously expressed Claudin-1 promotes the acquisition of
mesenchymal characteristics in hepatocellular carcinoma185. Decreased Claudin-1 and Ecadherin in Increases in Claudin-1 expression characterize HUVEC cells undergoing
differentiation to endodermal and hepatic stages.186
In the context of liver damage and regeneration, the designation of “epithelial” or
“mesenchymal” refers not to the inflexible characteristic of lineage (origin) but rather, the plastic
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cellular organization and metabolic commitments underlying tissue-level function187. Epithelial
cells are characterized by tight cell-cell contacts and apico-basal polarity. In epithelioid adult liver
parenchymal cells, (hepatocytes and cholangiocytes), these characteristics are critical to their
function as a selectively permeable, transformative metabolic layer receiving input from
enterohepatic circulation (sinusoidal/basolateral) and contributing modified output to systemic
circulation and the biliary system (cannalicular/apical). The levels, ratio, and distribution of
claudins, members of the main transmembrane protein family forming hepatocyte intercellular
tight junctions form the structural underpinning of this polarity/permeability, and so define specific
identity and function of the cell.
In contrast, traits associated with mesenchymal cells include a lack or loss of polarity and
loss or differential organization of the protein architecture required to maintain cell-cell and cellECM contacts. A transition from epithelial to mesenchymal or mesenchymal to epithelial qualities
involves the gradual loss of characteristic markers of one state and gain of markers characteristic
of the other, with transitioning cells often expressing some of each. In this case, high E-cadherin
and claudin would be indicative of epithelioid character, while Vimentin is typically a
mesenchymal marker140.
In summary, in primary hepatocytes, differential transcription induced by PCB exposure
cannot be completely explained by direct ligand-induced transcriptional activity of the AhR, PXR,
or CAR by congeners within the Aroclor 1260 mixture. This is surprising, considering the vast
amount of research that has focused on these three receptors as mediators of PCB effect. AhR
and PXR had the largest areas of overlap, however, the direction of differential transcription was
often opposite between Aroclor 1260 DTGs and the DTGs produced by treatment with these
prototypical ligands, particularly PXR. LXR, which is unlikely to be bound by congeners within the
mixture, is likely to crosstalk with PXR and CAR at the level of chromatin binding, as it recognizes
the same DR-4 motif response element. LXR is often implicated as a key transcription factor
involved in the development of steatosis leading to steatohepatitis, however, transcriptional
changes due to direct ligand activation of LXR did not have a large overlap with the Aroclor 1260dependent differential transcriptome either. We conclude from the information in this model that
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other transcription factors are likely responsible for a large portion of the transcriptional changes
observed with PCB exposure.
Transcription factors that appear to be involved in PCB-dependent transcription are often
directly or indirectly influenced by EGFR-mediated cell signaling via phosphorylation, consistent
with our recent report that PCBs inhibit EGFR signaling20. MetaCoreTM pathway analysis of the
PCB-DTG set indicated enrichment in biomarkers associated with liver disease, and components
pathways known to be involved in the progression of fatty liver disease. Targets uniquely
modified by PCB exposure in this model include markers of epithelioid character and hepatocyte
polarity, as well as ECM modifiers. Together, these suggest that at least some of the diseases
associated with PCB exposure are due to differential transcription mediated by one or more
receptors. More work is needed to determine the relevance of engaged pathways suggested by
this preliminary investigation.
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CONCLUSIONS

The study of human disease related to environmental exposures requires a
multidisciplinary approach unique in biomedical research. It requires a balance between overly
reductionist approaches that ignore poorly understood pathways and massive, non-mechanistic
association studies which muddy the waters and yield unapproachable data. The experimental
approaches to PCB research suffer from both problems, resulting in a body of literature that is
measured “by the pound, not by the page”39: a massive body of exposure data with mechanistic
assumptions based on changes to one or two transcriptional targets of one or two xenobiotic
receptors. The overall result of this status is that even 80 years after publication of the first paper
linking PCB exposure to human disease, the mechanisms of PCB-related diseases are poorly
understood.
The Cave laboratory began with a study of the people exposed to PCBs – every adult in
the US population, represented by the massive, cross-sectional National Health and Nutrition
Evaluation Survey, or NHANES. That study demonstrated that PCBs are ubiquitous and
associated with liver injury in the general population37. A logical next step was then an
epidemiological evaluation of liver disease in a population with a relatively high exposure to
environmental PCBs – that of Anniston, Alabama, already under investigation to determine
whether PCB exposure was associated with multiple metabolic diseases.
Both the positive and negative findings of our study were striking and novel – although
nonalcoholic fatty liver disease in Anniston was clearly elevated compared to expected
prevalence in the general US and worldwide population, the mechanistic biomarkers employed
showed that the overall level of the PCB exposure represented by the sum of all congeners was

162

not correlated with the severity of liver injury or inclusion in a liver disease category in the overall
population.
We considered two potential reasons for this observation which were not mutually
exclusive. First, the Anniston population represents a complex, but not atypical, exposure
situation, which was one of the acknowledged limitations of the study. Chemical exposures alone
included not only PCBs, but also heavy metals and pesticides, many of which are associated with
liver or metabolic disease37, 121, 188, while nutritional coexposures inferred from the high
prevalence of obesity/overweight in this population could contribute independently to fatty liver
disease. A second possibility is that, like other endocrine/metabolism-disrupting chemical
exposures189, increasing PCB dose could result in a nonmonotonic dose-response (NMDR) with
respect to damage biomarkers – not steadily increasing or decreasing with increasing exposure
concentration. At the cellular level, differential engagement of crosstalking mechanisms may
result in different output at different exposures. At the organismal level, PCB effects on multiple
systems must be considered: suppressive effects on inflammatory pathways could lead to higher
overall liver damage indicators at a lower exposure level, interference with circadian control could
contribute to hyperphagy and decreased energy expenditure, while effects on hormonal signaling
could communication between concerted systems. For this last consideration, nutritional
coexposures play a role as well: direct effects of PCBs to reduce insulin output could limit the
compensatory role of the pancreas in glucose allostasis, putting more stress on connected
systems including the liver.
The animal study previously reported by Wahlang et al.23 was an attempt to
disambiguate the effects of PCB exposure level and nutritional coexposure in an animal model of
chronic PCB/HFD coexposure. We integrated our epidemiological study with our animal model
by comparing serology and phenotype in both studies. The condition represented by animals
coexposed to HFD and moderate PCBs (20 mg/kg) was designed to most closely model the
Anniston exposure, and, indeed, the phenotype of animals within this condition approximated the
findings in Anniston with respect to physical characteristics of metabolic syndrome and
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serological evidence of liver injury, inflammation, and metabolic dysfunction. The exposure to
higher levels of PCBs in this animal model did not result in additional histological evidence of liver
injury, suggesting that it was possible to observe nonmontonic dose responses to PCBs with
respect to serological biomarkers of liver injury.
One of the major findings of the Wahlang et al. study was that Aroclor 1260 exposure
contributed to liver injury not by exacerbating steatosis, but by increasing inflammation,
particularly in the HVvsH20 model. Our original hypothesis was that, at higher levels of Aroclor
1260 exposure, the concentration of trace dioxin-like PCBs within the mixture would reach a
“tipping point” that would quell immune response in our inflammation-primed HFD-fed mice.
Previous reports suggested that the ED50 for Aroclor 1260 immunotoxicity (in mice) was 360
mg/kg190, still higher than our highest in vivo dose. We saw differences in the moderate vs. high
dose with regards to transcriptional output of IL-6JAKSTAT-3 signaling, which plays a role in
chronic inflammation.
Inflammatory response is a process that is both context-modulated and dynamic,
involving initiation and resolution processes that confound a simple understanding of “proinflammatory” and “anti-inflammatory” signaling molecules. IL-6, which is produced by many cell
types, including hepatocytes and Kupffer cells (liver-resident macrophages), is often categorized
as a “pro-inflammatory” cytokine, and was elevated in both the ACHS cohort and in the in vivo
moderate dose + HFD. Certainly, IL-6 is elevated in inflammation and has down-stream effects
that promote inflammation; on the other hand, IL-6 has distinctly “anti-inflammatory” effects in the
liver as well, particularly to oppose exaggerated cytokine release from neighboring Kupffer cells.
Components of IL-6 signaling pathways were more enriched in the moderate PCB/HFD
model (Figure 22). IL-6 signaling mediators down-stream of STAT-3 transcriptional regulation
leading to cell differentiation pathways (cFos and cJun – 1.23-fold and 0.64-fold increased,
respectively), were also affected with the high PCB exposures (cJun only: 0.80-fold, p=0.00005
and 1.15-fold, p=0.00005 in the high PCB exposure with HFD and CD, respectively). Another
group of STAT-3 targets with PCB-dependent transcriptional changes were the suppressors of
cytokine signaling (SOCS2 and SOCS3 – 1.10-fold and 0.71-fold increased, respectively in the
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Figure 22. Exposure to PCB with or without HFD coexposure alters transcription of multiple
components of IL‐6 signaling. The red circles correspond to targets differentially regulated in a
comparison between 0 and 20mg/kg Aroclor 1260 within the control diet group while the black
circles correspond to targets differentially regulated in a comparison between control and HFD
within the Aroclor 1260 20mg/kg group.
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moderate PCB/HFD exposure). SOCS3 is an important player in the attenuation of IL-6-mediated
STAT-3 signaling. Potently up-regulated by active STAT-3, SOCS3 binds to and inhibits
JAK2/gp130 kinases, which couple IL-6 to STAT-3 signaling. SOCS3 also independently
contributes to hepatic insulin resistance and metabolic dysfunction by binding to and inhibiting
both insulin receptor and its down-stream mediator IRS-1191 and well as leptin receptor192.
SOCS3 was only up-regulated in the moderate PCB/HFD exposure, while in the high PCB/HFD
exposure, SOCS2 was up-regulated as well (0.71-fold, p=0.00005).
In addition to transcriptional changes down-stream of STAT-3 signaling, the
HFD/moderate exposure animals had decreased transcription of IL-6 receptor alpha (IL-6Rα: 0.67-fold, p=0.0000). IL-6Rα plays an important role in mechanisms contributing to chronic
STAT-3 activation and related metabolic dysfunction and chronic inflammation. Of interest is the
relationship between IL-6Rα and EGFR. Independent of EGF activation, EGFR forms a complex
with both IL6Rα and STAT-3 in a mechanism which potentiates STAT-3 phosphorylation even in
the presence of SOCS-3193. EGFR/IL-6Rα-mediated STAT-3 activation contributes to chronic IL6 expression by hepatocytes193. Expression of EGFR itself was down-regulated in HFD alone (0.85-fold, p=0.0027), but was up-regulated in both the moderate and high PCB + HFD exposures
(1.15-fold, p=0.00005 and 0.78-fold, p=0.0011, respectively). If protein levels were similarly
affected, this might represent a mechanism by which PCBs and HFD contribute to chronic IL-6
release. Alternatively, liver-specific knockout of IL-6Rα has been shown to enhance the release
of IL-6 and TNFα from Kupffer cells (liver-specific tissue-resident macrophages), preventing the
IL-6-mediated down-regulation of these cytokines. Abrogation of this receptor in liver
parenchymal cells also reduces insulin-stimulated glucose uptake in white adipose tissue and
skeletal muscle, contributing to systemic insulin resistance194. Therefore, by altering IL-6 signaling
within hepatocytes, PCBs may affect not only the transduction of inflammatory signals in the liver,
but also signals coordinating metabolic response between tissues. Future studies may be able to
pinpoint whether PCB-mediated EGFR/IL-6Rα/STAT-3 perpetuation of STAT-3 signaling and/or
IL-6Rα inhibition contribute to systemic IL-6 elevation, which has been associated with T2DM and
many other metabolic diseases.
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Another factor contributing to increased systemic IL-6 may be hyaluronic acid, an
extracellular matrix protein which was significantly increased with PCB exposure in sera from the
ACHS-II cohort. Hyaluronic acid binds and stabilizes extracellular IL-6, resulting in increased
serum protein levels without affecting IL-6 mRNA transcription195. Multiple factors contributing to
high chronic systemic IL-6 may therefore represent a self-sustaining system by which PCBs
exacerbate pre-existing metabolic dysfunction. Chronic IL-6 elevation may also represent a point
of convergence for liver injury mechanisms, agreeing well with the “multiple-hits hypothesis”.
PCB exposure did not contribute to increased steatosis in our animal model beyond the
effects of HFD, nevertheless, genes encoding elements of hepatic lipid processing were
differentially transcribed in the exposure models relative to vehicle-treated controls on the same
diet. Key events regulating the development of steatosis include increased fatty acid uptake,
increased lipid synthesis, decreased fatty acid oxidation, and decreased lipid efflux.56
Transcription of CD36, a FA uptake receptor, was up-regulated in high-exposure/control diet
(0.74, p=0.0004) and with HFD alone (CVvsHV: 0.57-fold, p=0.00185), and was down-regulated
in both moderate exposure models (CVvsC20: -0.75-fold, p=0.00045, and HVvsH20: -0.89-fold,
p=0.00005). Transcription of long-chain acyl-CoA synthetase 4 (ACSL4), involved in lipid
synthesis, was down-regulated in high-exposure/control diet (-0.47-fold, p=0.00315) as in HFD
alone (-0.91-fold, p=0.00005), but was up-regulated in moderate exposure/HFD (1.05-fold,
p=0.00005). These patterns do not suggest a consistent increase in pro-steatotic molecular
changes, which would be consistent with the observation that Aroclor 1260 exposure (particularly
at the moderate dose) did not worsen steatosis. They do, however, suggest that PCB exposure
at both high and low levels affects cellular events which can alter hepatocellular lipid flux, and,
moreover, PCB exposure affects the components of those events which are known to be
influenced by nuclear receptor-driven transcriptional changes.56
The classically understood function of xenobiotic receptors is to respond to the presence
of chemical ligands by heterodimerizing with RXR (nuclear receptors) or ARNT (AhR),
translocating to the nucleus, and binding response elements in the promoters of their respective
cytochrome p450 oxidase targets. A more nuanced understanding includes the association of
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unliganded receptors with specific binding partners in a corepressor complex and liganded
receptors with coactivators. In addition to ligand-binding, post-translational modifications such as
phosphorylation, acetylation, and sumoylation can change the receptor’s protein-protein
associations, adding tremendous range to both the direct and indirect transcriptional targets
affected by xenobiotic sensing. This provides a compelling mechanism by which the changing
chemical environment can shape the pattern of physiological metabolism.
Just as multiple systems create a dynamic balance by shifting chemical pressures,
rhythmic metabolic processes affected by the central or peripheral circadian clock alter metabolic
tides in response to temporal cues. An exploration of PCB effects on the suprachiasmatic nucleus
(SCN) which regulates the central clock is beyond the scope of this work, however, the behavioral
changes in our mouse model described in Chapter 2 (anachronistically increased movement
during typical sleep cycles in transgenic mice chronically exposed to 20mg/kg Aroclor 1260) are
most likely a manifestation of central clock alterations. In peripheral tissues including the liver,
however, oscillations in the transcription of specific gene sets create feedback loops which
reinforce the periodic cycling within those tissues. Importantly, the challenge of nutritional stress –
HFD136 or time-restricted135 feeding – can uncouple the peripheral circadian clock from the
central, leading to differential temporal expression of targets of timekeeping transcription factors
(CLOCK and BMAL1) as well as new oscillations of previously non-cycling gene targets of
transcription factors such as PPARγ136.
It is not now known whether the behavioral changes seen in our transgenic mouse model
were a direct effect of PCBs on the SCN neurons or a product of peripheral PCB effect feeding
back by some mechanism to reprogram the central clock. Studies investigating the effects of
dietary stresses on circadian cycling have indicated that while peripheral tissues are
reprogrammed by nutritional challenge, the SCN central pacemaker remains unaffected.
However, these studies have also reported changes to the clock output genes (Per1/2 and Cry1/2
isoforms) without changes to expression of the core clock genes (Clock and Bmal1). In our in
vivo experiment, we observed changes in both clock output and core clock genes under multiple
conditions (Table 64). Differential transcription of Clock, however, was unique to the moderate
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Table 64
Differentially transcribed circadian-rhythm related targets from in vivo and in vitro experiments
HFD vs CD

In vivo
FC vs. CD/V
C20
C200

Core Clock Genes
Clock
0.77
Bmal1
2.19
Clock output Genes
-0.73
Cry1
Cry2
Per1
Per2
-1.39
Selected Clock-associated genes
Melatonin
2.80
receptor
1A
ROR-g
-0.74
TrkB
0.66
-1.28

FC vs. HFD/V
H20
H200

1.04

In vitro
FC vs. DMSO
PCN
BA
-0.81

-0.73

0.65
0.48

-0.47
-0.97

-0.74
1.51
0.88
-2.03

0.53
0.72

Table 64 shows fold changes for the comparisons listed above. Targets are grouped by their
relationship to circadian rhythm control machinery (core clock genes, clock output genes, or
clock-associated genes). Numbers are fold change vs. the indicated control, p<.05. Blank
fields were not significantly different in the listed comparison.
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PCB/control diet condition, however, where it was up-regulated compared to vehicle/control diet
(0.77-fold, p=0.00005). Our in vitro experiment did not indicate differential regulation of clockrelated genes with Aroclor 1260 exposure, but did indicate down-regulation of one core clock
gene (Bmal1) with PCN or BA, and down-regulation of one clock output gene (Cry2) with PCN
exposure. The direction of fold change was again opposite from any of the in vivo conditions in
which these genes were differentially transcribed.
The mechanism by which PCBs affect the transcription of peripheral circadian rhythm
machinery is unclear from our in vivo or in vitro experiments, although there exists no shortage of
potential interactions between elements of these processes and xenobiotic receptors. BMALl1,
also known as the arylhydrocarbon receptor nuclear translocator-like (ARNTL), and CLOCK are
PAS-domain proteins which readily associate with AhR, and their regulation of Per1 has been
shown to be disrupted by AhR activity in response to TCDD196. In addition, the hepatocytespecific cyclic AMP responsive element-binding protein (CREBH) is a transcription factor with
transcriptional activity controlling the rhythmic expression of hepatic triglyceride and fatty acid
metabolic targets via its associations with PPARα and LXRα131, which crosstalk with xenobiotic
nuclear receptors as previously described. The processes leading to circadian activation of
CREBH are controlled by BMAL1 via GSK3β/AKT pathways131. Other isoforms of CREB
physically interact with and are inhibited by PXR (Figure 13).197
A clear limitation of the experiment in this area is the lack of tissue harvest timepoints
designed to capture oscillations in transcription at multiple timepoints. Harvest was carried out
only during the light cycle and over a period of approximately 8 hours. Future studies to explore
PCB effect in this area could be modeled on the methods of Eckel-Mahan et al.136, to capture
potential PCB exposure-related shifts in the temporal expression of normally cyclic or normally
acyclic hepatic genes.
A final pattern observed in the enrichment analyses of both the in vivo and in vitro study
was that of cell adhesion and related cell-cell communications apparatus. Components of ephrin
signaling were highly differentially expressed between conditions. Ephrin receptors are part of a
large class of receptor tyrosine kinases which form bi-directional communication complexes
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between cells. Ephrins and ephrin receptors are well-studied in the context of cytoskeletal
remodeling during neuronal path-finding and development, and, importantly, play a role in
adhesion and communication between cells of the same or different types, including monocytes
and endothelial cells198. The ephrin signaling system consists of two classes of receptor (A and
B, based on sequence homology and corresponding to structural characteristics) which respond
to ligands produced by neighboring cells199. Both receptor and ligand are generally membranebound, facilitating communication between cells that are in physical contact, however, there is
evidence that some ligands, specifically Ephrin A1, can be shed as soluble ligands to affect cells
over longer distances200. In the ephrin signaling system, signal transduction in the direction of the
receptor is described as forward-signaling and signal transduction in the direction of the ligand is
described as reverse signaling. Ephrin-A/EphA forward signaling affects many of the pathways
activated by other RTKs, including IGF-1-activated Ras-Erk, and may inhibit or activate these
cascades in a cell-type specific manner201.
In our experimental models, both ephrin receptors and ephrin ligands were differentially
regulated under some or all conditions (Figures 23-25). Interestingly, Ephrin A1 (Efna1) was
significantly up-regulated in every in vivo comparison except moderate PCB/control diet exposure
as well as in vitro PCB exposure, and was one of the targets which was uniquely regulated in
PCB exposure (Figure 23). Ephrin A5 (Efna5), another ligand, was also up-regulated in all HFDexposed groups and and upon exposure to 200 mg/kg PCB with CD (Figure 24). Ephrin A3
(Efna3) was strongly up-regulated only in the moderate PCB/HFD coexposure (3.85-fold,
p=0.00095), and was otherwise not significantly different from vehicle/CD. Ephrin receptor B2
was differentially regulated under all conditions (Figure 25).
Differential expression of ephrin receptors and ligands is associated with proinflammatory states and changes in inflammatory cytokines in multiple tissue. Expression of
EphA2 (receptor) and Ephrin A1 (ligand) have been shown to increase in lung tissue after LPS
exposure, and posttreatment with mAb against EphA2 receptor reduces lung injury and
permeability in LPS-exposed animals, as well as the production of pro-inflammatory cytokines
(IL1β, MIP-2)202.
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Figure 23. Ephrin ligand A1 (Efna1) was differentially regulated in multiple comparisons. The
vertical axis shows aggregate fragments per kilobase of transcript per million mapped reads
(FPKM) for each condition, with significant differences indicated by bridging lines. Panel A shows
the respective aggregate FPKM for six in vivo conditions, while Panel B shows the same for the in
vitro experiment, with exposure to Aroclor 1260 and PCN shown. Treatment with prototypical
ligands for AhR, CAR, and LXR did not induce significant changes in Efna1 expression.
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Figure 24. Ephrin ligand A5 (Efna5) was differentially regulated in multiple comparisons. The
vertical axis shows aggregate fragments per kilobase of transcript per million mapped reads
(FPKM) for each condition, with significant differences indicated by bridging lines.
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Figure 25. Ephrin receptor B2 (EphB2) was differentially regulated in multiple comparisons. The
vertical axis shows aggregate fragments per kilobase of transcript per million mapped reads
(FPKM) for each condition, with significant differences indicated by bridging lines.
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Differential expression of ephrin receptors and ligands is also associated with transitions
between differentiated (epithelial) and undifferentiated (mesenchymal) cell characteristics. In the
context of cancer, it has been observed that overexpression of ephrin receptors tends to favor
metastatic characteristics (loss of adhesion), while overexpression of ligand tends to favor
increased cell adhesion203. To that effect, EphA2 was found to be overexpressed in neoplastic
cells, and the distribution changed from clustered localization of EphA2 at sites of cell-cell
contacts to either a diffuse pattern or concentration in the leading edge of migrating cells204. This
loss of localization at sites of stable cell-cell contacts led to decreased ligand-dependent
phosphorylation of EphA2, because the membrane-bound Ephrin-A ligands also localize at these
sites. E-cadherin forms homodimers with E-cadherin in adjacent cells to mediate highly stable
calcium-dependent cell adhesion foci, and E-cadherin function in these cell-cell junctions is
necessary to prevent decreased phosphorylation of EphA2. Given the role of ephrin receptors
and ligands in cytoskeletal remodeling during growth and development as well as regeneration,
development, especially with the sequential events necessary for cells to form properly oriented
relationships with one another. In all PCB exposures, both in vivo and in vitro, the expression of
adhesion proteins such as Claudin-1 and E-Cadherin was up-regulated vs. untreated control.
Most literature describing changes to these proteins in the context of liver disease deals with their
importance as biomarkers of cell identity during periods of physiological or pathological change:
development, regeneration, and neoplasia. Up-regulation of these proteins is associated with a
more terminally differentiated, epithelioid cell, but in the larger context, expression of these
proteins is necessary for proper orientation of cells relative to one another within the larger tissue
structure.
Ephrin signaling is important in other tissues which participate in metabolic allostasis.
For instance, pancreatic beta cells employ ephrin signaling to synchronize release of insulin in
response to glucose, using engagement of EphA forward signaling to inhibit insulin secretion and
ephrin-A reverse signaling to stimulate insulin secretion205. If expression of Ephrin-A1 is similarly
up-regulated in the pancreas as it is in the liver, this may represent another mechanism by which
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PCBs and PCB+HFD contribute to the phenotype of reduced serum insulin observed in both
Anniston and our mouse model.
Xenobiotic receptors are known to crosstalk with signaling cascades down-stream of
tyrosine kinase signaling. Ephrin receptor signaling may crosstalk with regulation of the
constitutive androstane receptor in a similar way to EGFR. The receptor for activated c-kinase 1
(RACK-1) associates with ligand-bound, autophosphorylated and active EphB3, forming a
complex with PP2A and AKT and promoting the dephosphorylation of AKT at S473203. an event
which leads to reduced cell migration as well as apoptosis. Active (dephosphorylated) RACK-1
also facilitates the interaction of CAR with PP2A, an event which is necessary for the nuclear
translocation of CAR, the indirect or ligand-independent pathway for CAR activation described by
Mutoh et al.21 This pathway is critical to PCB research, because it activates CAR via EGFR
inhibition, a mechanism which is shared by phenobarbital and PCB congeners20. Input into CAR
transcriptional activity via ephrin signaling represents a mechanism by which inflammatory status
and cell-cell communication status can crosstalk with the output of xenobiotic receptors, providing
more nuanced control over adaptive metabolic control. Our in vitro experiment, however,
indicated that only one target related to ephrin signaling was differentially regulated by Aroclor
1260 exposure: the Ephrin A ligand Efna1 (Figure 26, Panel B). Interestingly, Efna1 was also
differentially regulated in hepatocytes cells exposed to PCN, although in an opposite direction (0.66-fold, p=0.00005), which may be another example of the trend of PCB-dependent upregulation of targets in vivo which are negatively regulated by PCN exposure, and presumably
PXR activation, in vitro.
Our combined approach of epidemiological assessment followed by in vivo and in vitro
mechanistic exploration has uncovered many interesting relationships between environmental
PCB exposure and human disease. While the question of the roles of xenobiotic receptors in
PCB-associated fatty liver disease is far from resolved, we have at least pushed the
understanding of those roles beyond direct, ligand-activated transcriptional activity of a few (or
worse, one), xenobiotic-responsive transcription factor. It is likely that a great many of the effects
of PCB-associated TASH are independent of direct effects of CAR, PXR, or AhR. It is equally
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likely that input from these receptors is indirectly involved in the pathways and processes
modulated by PCB effects. We have described three groups of effects which are related to effects
seen in all three of our models: systemic inflammatory dysregulation via IL-6 signalling,
disruption of circadian rhythm processes, and modulation of cell adhesion and cell-cell
communication via differential expression of E-cadherin/claudin-1 and related ephrin signaling
pathways. These effects appear to be directly related to PCB exposure, are strongly involved in
and modulated by dietary coexposures, and are likely to affect multiple systems involved in
metabolic disease. Simultaneous dysregulation of these systems during PCB exposure could
explain the “2-hit” phenomenon, providing a mechanism by which PCB/HFD coexposures could
accelerate allostatic overload – crippling the normal adaptive response to metabolic challenge.
Future studies will likely focus on individual components of these effects, and may involve
analysis of tissues other than liver. It remains to be determined whether PCB-dependent changes
to IL-6 signaling lead to failure of feedback inhibition from hepatocytes to Kupffer cells and
subsequent uncontrolled inflammation, or whether the systemic IL-6 elevations seen in Anniston
arise from a different tissue – adipose, for instance. Likewise, an assessment of the PCBdependent changes to circadian signaling require evaluation of PCB-dependent changes to clock
output and, more intriguingly, core clock gene transcription not only in peripheral tissues, but in
the SCN as well. Exploring the mechanism and effects of the PCB-dependent transcriptional
changes to ephrin signaling components and cell adhesion molecules may allow us to determine
whether cell-cell communication between hepatocytes, endothelial cells, and/or Kupffer cells are
dysregulated in PCB exposure, and whether changes to cell adhesion mediators is indicative of
failed regenerative processes which could explain the apparent “chronic necrosis” observed in the
Anniston population as well as the increased biomarkers of fibrosis.
As for the activities of the xenobiotic receptors themselves, our in vitro model was
interesting from the standpoint that it showed that a substantial portion of the targets differentially
transcribed with Aroclor 1260 exposure were not attributable to activation of AhR, PXR, CAR, or
LXR. Targets within the set differentially transcribed with Aroclor 1260 exposure were associated
with many liver and metabolic disease states, however, in a direct comparison between targets
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differentially transcribed with Aroclor 1260 exposure in vitro and in vivo, there were very few
shared between the in vitro (Figure 27) and moderate exposure, with far more shared between
the in vitro and high exposure. Although the in vitro experiment used 5 µg/ml Aroclor 1260, a
concentration lower than the concentration used to induce activity of human PXR, CAR, and AhR
transfected into a HepG2 model luciferase reporter system19, there were more DTGs shared
between the in vitro and the two high-dose in vivo models than the in vitro and two moderatedose in vivo models. It is possible, therefore, that 5 µg/ml is still too high to accurately model a
relevant environmental exposure in primary hepatocytes. With that in mind, however, targets
such as Claudin-1, E-Cadherin, Ephrin-A, and Tribbles-3 pseudokinase were conserved across
more than one of the comparisons, suggesting that they may be part of common mechanisms for
PCB effect. Because the raw data from the in vitro work will be available for further interrogation,
it is likely that alternative bioinformatics tools may bring some clarity to the specific roles of these
receptors in the observed transcriptional changes. If, instead of direct transactivation PXR, CAR,
and/or AhR are involved via protein-protein interactions with other transcription factors, this may
be due to a PCB-dependent intracellular milieu that favors specific post-translational
modifications and corresponding specific protein associations.
This laboratory set out to investigate the relationship between exposure to PCBs a
widespread class of persistent organic pollutant, and steatohepatitis, a widespread manifestation
of metabolic disease. Because xenobiotic receptors drive the metabolic machinery responsible
for recognizing and detoxifying foreign chemicals, and because of historic attention to the role of
one part of this machinery, the cytochrome p450s, in generating carcinogenic metabolites from
polycyclic aromatic hydrocarbons206 including PCBs, we and others expected to find a central role
for these receptors which placed down-stream transcriptional targets as effectors in disease.
Although some targets of these receptors are undoubtedly involved in steatohepatitis and other
disease states, I find that the evidence from this study suggests a more peripheral role for these
xenobiotic receptors in PCB-associated TASH: modulating metabolic responses with the
additional information about the presence of toxicants. This makes sense from a standpoint of
phenotype: moderate-dose PCBs alone did not induce steatohepatitis in our mouse model, and
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Figure 26. In vivo comparison diagrams. Venn diagrams show the overlapping region between
in vitro study (white), 20 mg/kg Aroclor 1260 in vivo (red) and 200 mg/kg in vivo (black) on in
vivo datasets grouped by diet. Panel A, control diet, shows a larger proportion of DTGs
overlapping between the in vivo and high Aroclor. Shared targets include Gstm3, Cldn1, Pim1,
Orm3, Trib3, and Akr1b7. In Panel B, which shows the overlap with the HFD in vivo expsoures,
a larger proportion of the DTGs identified in the in vitro Aroclor 1260 exposure overlapped with
the moderate in vivo exposure + high fat diet. Shared targets include Cdh1, Moxd1, Slc10a2,
Efna1, Orm3, Rab30, Cyp1a2, Hist1h1c, Rarres1, Ces2b, Akr1b7, Ugt2b37, Orm2, and G6pc.
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there is not a clear dose-response relationship between total PCB load or the concentration of a
defined PCB functional grouping and TASH in Anniston. The requirement for co-occurring
metabolic stress would also explain the convergence in phenotype seen in both human
NASH/TASH and in mouse models. PCB exposure appears to change elements of the response
to this metabolic pressure – hepatocyte death mechanism, and inflammatory response, for
instance, or elements of cell-cell signaling and adhesion important in regeneration. Lastly, the
extrahepatic effects of PCBs on the liver cannot be overemphasized. Our human population
showed inappropriate insulin production in response to hyperglycemia, strongly suggesting direct
PCB effects in the pancreas, and a transgenic mouse (CAR-/-) in our laboratory demonstrated
altered circadian patterns in response to PCB. One or both of these effects may involve the
activity of xenobiotic receptors – their role in mediation of PCB effect in extrahepatic tissues is
beyond the scope of this project – however, both effects have the potential to impact the
development of steatohepatitis through effects on other metabolic allostasis machinery. These
studies have strengthened the body of evidence connecting environmental PCB exposures to
toxicant-associated steatohepatitis, have shifted the focus of mechanism from strictly xenobioticreceptor-mediated effects, and have pointed to new areas of inquiry we can explore to address
the health effects of PCB exposure in the Anniston population and in all PCB-exposed humans.
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Appendix Table 1

Gene ID

FC_A

FC_G

FC_P

-1.60

-2.14

-2.13

FC_B

-4.20

-1.83

1.77

FC_T

hemoglobin alpha, adult chain 1

predicted gene 15611, known lincRNA

Neurofascin is an L1 family immunoglobulin
cell adhesion molecule with multiple IGcam
and fibronectin domains.
T lymphoma invasion and metastasis 1 is
upregulated in hepatocellular carcinoma
with highly invasive and metastatic
character171, 212, 213 and pancreatic cancer
tissues secondary to loss of Par3 (binding
partner).172 In pancreatic cancers, Par3 and
Tiam1 affect the expression of Claudin1
and ZO-1 to reduce tight junction
function.172 Tiam1 is a target of suppression
for miRNA 141173 and miRNA 377.174
Protein structure with four disulfide cores
(shared with SLPI and elafin/Trappin-2),
allows the proteins in this family to function
as protease inhibitors, antimicrobials, and to
regulate calcium.214
Beta-1,3-galactosyltransferase expressed
exclusively in the brain. Functions to
transfer galactose from UDP-galactose to
substrates with a terminal beta-Nacetylglucosamine (beta-GlcNAc) residue.
A drug-metabolizing enzyme of the p450
family, classic target of arylhydrocarbon
receptor.

References and summary

Fold change and summary information for 123 targets differentially transcribed with Aroclor 1260 exposure, compared to fold change with
prototypical ligand exposure
ENSEMBL ID

-3.23

-2.94

-3.73

-2.45

3.82

Nfasc

-1.81

-2.09

ENSMUSG00000026442

Wfdc3

-1.78

-2.73

B3galt1

-1.57

-2.51

ENSMUSG00000076434

Cyp1a1

Tiam1

ENSMUSG00000034780

Gm15611

ENSMUSG00000002489

ENSMUSG00000032315

-1.47

-3.43

ENSMUSG00000084923

Hba-a1

1.53

ENSMUSG00000069919
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FC_G

FC_P

FC_T

-1.03

FC_B

-1.43

-1.46

-1.12

FC_A

Spon1

-1.41
-1.48

-1.64

Gene ID

ENSMUSG00000038156

Ces2b

-1.20

-1.46

ENSEMBL ID

ENSMUSG00000050097
Gm26735

-1.17

-0.67

-1.31

ENSMUSG00000097461
Sox4

-1.10

0.66

ENSMUSG00000076431

Gstm3

-1.56

0.81

ENSMUSG00000004038

-1.00

-1.56

Grem2

0.99

ENSMUSG00000050069
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Carboxyesterase 2 is downregulated in the
livers of NASH patients. Experimental
ablation of Ces2b in a mouse model causes
ER stress in hepatocytes and stimulates
lipogenesis in an SREBP-1-dependent
manner.161 Pro-inflammatory cytokine
signaling can affect expression of
carboxyesterases: LPS treatment reduces
the expression of human Ces2 (and
Ces1)215 as does IL-6.216 Because Ces2
induces enzyme systems responsible for
the metabolism of some xenobiotic esters
both in the liver and in the intestine,
reductions in expression can also affect
drug metabolism.217

Predicted gene, known lincRNA
SRY (sex determining region Y)-box 4,
stimulates apoptosis in response to Ca++
ionophores or A23187 in HepG2 cells.175
glutathione S-transferase, mu 3 is involved
in glutathione-dependent clearance of
xenobiotics (Phase II metabolism).176
Expression of Gstm is inhibited with Ras
activation.181
Gremlin 2, DAN Family BMP Antagonist,
inhibits BMP2 and BMP4. Upregulated
during mucosal regeneration, opposes cell
migration in (primary airway) epithelial cells
during regeneration in a model of disrupted
epithelium.218 In mouse lung after asbestos
exposure, Grem2 upregulation was
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-0.99

-0.51

FC_B

0.55

FC_G

FC_A

Rapgef5

-0.97

Gene ID

ENSMUSG00000041992

Anks4b

ENSEMBL ID

ENSMUSG00000030909

FC_P

-1.14

-1.24

-0.96
-1.74

-1.42
-1.21

-1.02

Hbb-bs

-0.95

-1.38
-0.72

-0.96

ENSMUSG00000052305
Gm5266

-0.92
-0.92

9030619P08Rik

ENSMUSG00000101206

Cenpj or CPAP
Vmn2r3

ENSMUSG00000053168

ENSMUSG00000064128
ENSMUSG00000091572

FC_T

-0.96
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associated with decreased SMAD1/5/8
protein and increased SMAD2
phosphorylation.219 Antagonizes BMP4 to
affect proximal-distal patterning of the lung
during development.220
Rap Guanine Nucleotide Exchange Factor
5
Ankyrin Repeat And Sterile Alpha Motif
Domain Containing 4B is a target of HNF4a
in pancreatic beta cells, and is decreased in
the β-cells of an HNF4a KO mouse model
and during HNF4a KD in cell line. HNF4a
KD also . It binds to glucose-related protein
78 (GRP78) – an ER chaperone – and
enhances ER stress/ER stress-related
apoptosis.221
A known transcribed unprocessed
pseudogene
Hemoglobin Subunit Beta was elevated in
the serum of patients with NASH, and
increased with increasing severity of
disease.222

Centromere Protein J is a transcriptional
coactivator of NFKB, via synergistic
CREB1/p300/NFKB interaction. CENPJ
associates with the p65 (RelA) subunit of
NFKB.223 In HCC, CENPJ contributes to
TNFa-induced NFKB activation by
increasing phosphorylation of p65 and
phosphorylation/degradation of IKBa
(involved in recruitment of IKK to inactive
cytoplasmic NFKB complexes).224
vomeronasal 2, receptor 3
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ENSEMBL ID

Gene ID

FC_A

-1.46

FC_B

0.74

FC_G

-0.58

FC_P

1.16

FC_T

-0.89

-0.90

Porcn

-0.86

-0.48

Akr1b7

ENSMUSG00000031169

Fam47e

-0.84

-0.73

ENSMUSG00000052131

ENSMUSG00000057068

Hhipl1

-0.84

-0.71

ENSMUSG00000021260

N4bp2l1

-1.17

ENSMUSG00000041132
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Aldo-keto reductase family 1, member B7 is
enriched in adipose stromal vascular
fraction, but not in mature adipocytes. In a
mouse model, Akr1b7 KO increases basal
adiposity (adipocyte hyperplasia and
hypertrophy) with diet-independent
development of liver steatosis and insulin
resistance.162 In the liver, Akr1b7
expression is induced by FXR activation
(direct binding to FXRE in promoter).182
Porcupine homologue is an ER protein
catalyzes the palmitoylation of Wnt proteins,
allowing secretion and activity. Inhibition of
Porcn (by LGK974, IWP-1/2,
ETC/A*STAR1/2, synthetic Porcn inhibitors)
used as a chemotherapeutic strategy
because it inhibits aberrant Wnt signaling,
which is often dysregulated in cancer.178
Loss of macrophage-derived Wnt ligands in
Porcn-null mice prevents recovery after
radiation-induced damage to the
intestine.225
Family with sequence similarity 47, member
E expression is significantly positively
correlated with CKD (is a CKD-risk
associated candidate gene).226
Hedgehog interacting protein-like 1, like
Hhip1, is a secreted protein with an Nterminal signal peptide, and is expressed in
trabecular bone.227 A SNP in Hhip1 is
linked to coronary artery disease by
GWAS.228
NEDD4 binding protein 2-like 1 is highly
expressed in oral squamous cell carcinoma,
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ENSEMBL ID

Gene ID

FC_A

FC_B

ENSMUSG00000038403

1700024P16Rik

Hfe2

-0.80

-0.81

-0.83

-6.65

-0.63

-0.57

-0.61

ENSMUSG00000078612

Moxd1

-0.79

-0.84

ENSMUSG00000020000

Usp18

-0.76

Them7

ENSMUSG00000030107

Orm2

ENSMUSG00000055312

ENSMUSG00000061540

FC_G

FC_P

-0.64

-0.54

-5.84
0.47

FC_T

-0.73

References and summary

and knockdown of this protein significantly
inhibits metastasis.229
Thioesterase superfamily member 7 is a
member of the Acyl-CoA thioesterase
(ACOT) family – enzymes which catalyze
the hydrolysis of fatty acyl-CoA molecules
and other substrates. This family has roles
in control of intracellular FFA (vs fatty acylCoA), as well as the production of
inflammatory metabolites. Another member
of this family, Them1/ACOT11 is
differentially regulated in vivo, and contains
a C-terminal START domain and binds to
StarD14.230
Hemochromatosis type 2 is associated with
hepcidin function, and is downregulated in
NAFLD possibly as a consequence of
impaired hepatic iron sensing, which may
contribute to iron accumulation in NAFLD.
Hfe expression is also negatively correlated
with TNF α expression in patients with
NAFLD. 163
RIKEN cDNA 1700024P16 gene is proteincoding and of unknown function.
Monooxygenase, DBH-like 1, is a widely
expressed ER protein with copper-binding
capabilities.231 Its expression has been
reported to be influenced by insulin
signaling in the liver.232

Ubiquitin specific peptidase 18
Oromuscoid 2 is an acute-phase protein
mainly synthesized and secreted by
hepatocytes. Its ectopic expression
opposes HCC metastasis. ORM
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-0.75

-1.90

FC_B

Slc41a3

-0.75

-0.64

FC_A

ENSMUSG00000030089

Ugt2b37

-0.74

Gene ID

ENSMUSG00000057425

Orm3

ENSEMBL ID

ENSMUSG00000028359

FC_G

FC_P

-1.58

FC_T

References and summary

transcription is promoted by the activity of
C/EBPβ, particularly the LAP1/2
isoforms.233 Mine this reference for
supporting primary literature for statements:
it is anti-inflammatory (opposes neutrophils,
depresses cytokine secretion). Upregulated
by IL-6, glucocorticoids.
Solute Carrier Family 41 Member 3 plays a
role in magnesium homeostasis in the
kidney (distal convoluted tubule) and
intestine by functioning as a cation
transporter and regulating basolateral Mg2+
extrusion (into the blood)234. Expression is
increased by low-Mg2+ diet. Mice with loss
of function mutation in this transporter suffer
from severe hypomagnesemia (cannot
extrude recovered magnesium to blood)234.
Interestingly, individuals on EGFR inhibitors
often suffer from hypomagnesemia235.
In two mouse models of kidney injury, UDP
Glucuronosyltransferase Family 2 Member
B37 was a target of SMAD3-dependent
transcription inhibition. Ugt2b37 is involved
in the metabolism of endogenous
compounds (bilirubin, bile acids, fatty acids,
steroid hormones, thyroid hormones and fat
soluble vitamins)236.
Oromuscoid 3, like Orm2, is an acute-phase
protein of the immunocalin subfamily: smallmolecule-binding proteins that function to
modify immune response. Unlike Orm2,
Orm3 transcription was not induced in
astrocytes after systemic LPS challenge.237
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FC_T

FC_G

-0.62

FC_B

-1.34

FC_A

-1.97

Gene ID

-0.72

ENSEMBL ID

Scara5

-0.50

ENSMUSG00000022032

-0.61

-0.85

-0.90

-0.71

-0.77

-1.10

Stard5

-0.69

-0.62

-0.71

ENSMUSG00000046027

Trib3

-0.67

Zbtb18

ENSMUSG00000032715

Amacr

ENSMUSG00000063659

ENSMUSG00000022244

References and summary

Scavenger Receptor Class A Member 5
binds to extracelluar ferritin and controls its
endocytosis and the capture of its iron.238
In a human renal cell carcinoma model
(Rock2 overexpression), knockdown of
Rock2 increases Scara5 through betacatenin/TCF4 signaling and suppresses
migration239.
Zinc Finger And BTB Domain Containing 18
encodes a C2H2-type zinc finger protein, a
transcriptional repressor of genes involved
in neuronal development.240
Steroidogenic Acute Regulatory - Related
Lipid Transfer Domain Containing 5
encodes a cytosolic cholesterol transport
protein241 which is additionally able to bind
and transport other sterol-derived lipids
such as primary bile acids and 25hydroxycholesterol242-244. Its mRNA is
stabilized by ER stress245.
The tribbles pseudokinase 3 gene (TRIB3)
which is associated with insulin
resistance/T2DM46, 47, cardiovascular risk46,
and polycystic ovary syndrome in various
human populations.
The protein encoded by Alpha-MethylacylCoA Racemase (p504s) interconverts
pristanoyl-CoA and C27-bile acylCoAs from
(R)- to (S)-stereoisomers, a necessary step
in the degradation of these substrates by
peroxisomal beta-oxidation. It is a putative
target of beta-catenin, and is overexpressed
in individuals with CTNNB1 mutations
(related to Mg++ sensing)246. It is a putative
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ENSEMBL ID

Gene ID

FC_A

-0.66

-1.33

-1.59

FC_B

Ppp1r3b

-0.65

-0.67

ENSMUSG00000046794

Adck4/COQ8B

-0.65

Pctp

ENSMUSG00000003762

Rdh9

ENSMUSG00000020553

ENSMUSG00000056148

FC_G

0.60

FC_P

-1.31

-1.02

FC_T

References and summary

target of C/EBP via a non-classic binding
site247.
Phosphatidylcholine Transfer Protein is also
called Stard2. It facilitates the import of
phosphatidylcholine into the
mitochondria248. Pctp interacts with
Them2/Acot13 to increase hepatic glucose
production during fasting249, 250. It has a role
in the development of atherosclerosis, most
likely by modulating blood lipid levels251. It
regulates the hepatic uptake and clearance
of HDL particles in a diet-dependent
manner252. Pctp inhibits thermogenesis in
brown adipose tissue253.
Protein Phosphatase 1 Regulatory Subunit
3B . SNPs in this gene (rs4240624) are
associated with higher incidence of liver
injury in obese Mexican-Americans254.
Polymorphisms are also associated with
higher hepatic triglycerides255. Depletes the
phosphorylated form of glycogen
phosphorylase, removing the inhibition on
glycogen synthase – defects in this pathway
lead to dysregulation of hepatic glucose
production in T2DM256. It is a target of FXR
activation257.
Coenzyme Q8B mutations are associated
with steroid-resistant nephrotic
syndrome/chronic kidney disease of
unknown origin258-260.
Retinoid dehydrogenase 9 encodes a shortchain dehydrogenase/reductase important
in steroid/retinoid metabolism. It converts
9-cis-retinol into 9-cis-retinal and 3α-
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Gene ID

FC_A

-0.65

ENSEMBL ID

Prr16

FC_B

-0.82

FC_G

FC_P

-0.52

-2.77

ENSMUSG00000073565

-2.31

-0.46

-0.64

-0.63

-0.90

-0.64

Fgf21

-0.63

Hist1h1c

ENSMUSG00000030827

Slc25a15

ENSMUSG00000036181

ENSMUSG00000031482

FC_T
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androstanediol into dihydrotestosterone. It
is highly expressed in adult hepatocytes.
Knockout causes an increase in
xenobiotic/steroid metabolic enzymes
(Cyp2, Cyp3, 11β-hydroxysteroid
dehydrogenase type 2, and 17βhydroxsteroid dehydrogenases types 4 and
5) and a decrease in Cyp17A1261.
Proline Rich 16 encodes the protein Largen,
a factor affecting the translation of specific
mRNA. Overexpression causes increased
cell size and increased mitochondrial mass.
Largen controls cell size independent of
Hippo and mTOR pathways262.
Histone Cluster 1 H1 Family Member C
encodes a protein which interacts with DNA
between nucleosomes to regulate the
higher order structure of chromatin263.
Fibroblast Growth Factor 21 encodes a
starvation-induced hepatokine which
functions to increase hepatic insulin
sensitivity and upregulate β-oxidation
pathways264 . Serum levels of FGF21 can
be used as a biomarker to distinguish
simple steatosis from NASH265, 266. Mice
lacking Fgf21 were more likely to develop
NASH in an experimental model of
metabolic fatty liver disease267.
The protein encoded by Solute Carrier
Family 25 Member 15 transports ornithine
from the cytosol to the mitochondrial matrix
(across the mitochondrial inner membrane).
Mutation can cause human
hyperornithinemia-hyperammonemia-
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-0.63

ENSEMBL ID

Gm19619

-0.61

ENSMUSG00000107198

Gstm2

-0.61

-0.62

ENSMUSG00000040562

1110059E24Rik

-0.59

Dopey2

ENSMUSG00000035171

Plin5

ENSMUSG00000022946

ENSMUSG00000011305

FC_B

0.46

FC_G

0.73

FC_P

FC_T
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homocitrullinuria (HHH) syndrome, an urea
cycle defectc268, 269.

Predicted gene
Dopey Family Member 2 encodes a protein
involved in morphogenesis and embryonic
patterning, which is overexpressed in
Downs Syndrome and may contribute to
developmental defects in the brains of
those affected270, 271. May be a susceptibility
gene in Alzheimers Syndrome272, 273.
Glutathione S-Transferase Mu 2 encodes a
protein in the class of enzymes responsible
for the detoxification of xenobiotic and
endobiotic compounds by conjugation with
glutathione. It is differentially expressed in
the livers of African-American NASH
patients (upregulated) vs. Caucasian NASH
patients274 and also shows age- and sexspecific patterns of expression275, 276. Gstm2
is overexpressed in (mouse) hepatoma
cells with activating CTNNB (beta-catenin)
mutations, and its perivenous expression
preference is driven by beta-catenin181.
Expression of this GST subunit is
specifically upregulated with
epigallocatechin gallate (green tea
polyphenol) exposure277.

A protein-coding gene
Perilipin 5 encodes a protein involved in
hepatic lipid accumulation. It is upregulated
in Notch1 KO mice, contributing to
metabolic dysfunction, and ablation of Plin5
is protective in MCD-diet-induced steatosis
via compensatory changes in phospholipid
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remodeling, inflammation and ER stress278,
279
. Induction of perilipin 5 is pronounced in
hepatocytes of livers with chronic (vs acute)
steatosis and the protein localizes to large
(macrovesicular) lipid droplets280, 281.

Known lincRNA
Encodes a cytosolic endonuclease involved
in tRNA processing282
Hydroxycarboxylic Acid Receptor 2 is one
of a family G-protein-coupled receptors that
sense endogenous intermediates of
metabolism283. It is a high-affinity receptor
for nicotinic acid and β-hydroxybutarate284,
285
. It is stimulated by LPS, and has antiinflammatory effects283, 286. This is a good
candidate for exploring the machinery
coupling diet to immunomodulation287.
Not the one that keeps you from smelling
like fish. Flavin Containing Monooxygenase
5 is a component of xenobiotic
detoxification processes. It positively
regulates cholesterol biosynthesis. Fmo3
KO mice maintain a lean phenotype during
aging with carbohydrate oxidation during
the active period. Transcription differed in
KO mice - upregulated: HMG-CoA
reductase, squalene synthase, and sterol
regulatory element-binding protein-2
(SREBP-2) and downregulated: aldolase B,
glycerol 3-phosphate dehydrogenase
(GPD1), b-hydroxy-b-methylglutaryl-CoA
(HMG-CoA), and cytosolic malic enzyme
(ME1)288.
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Mitochondrial Leucyl-TRNA Synthetase 2 is
a target gene of c-Myc. Genetic variants of
Lars2 are associated with Perrault
syndrome289, 290 severe multisystem
metabolic disorder (hydrops, sideroblastic
anemia, lactic acidosis)291 and
(controversially) T2DM292, 293.
Cytochrome P450 Family 1 Subfamily A
Member 2 encodes a p450 enzyme which
catalyzes the oxidation of some polycyclic
aromatic hydrocarbons as well as other
xenobiotics such as caffeine, aflatoxin B1,
and acetaminophen294. It is induced by
TCDD/BA and considered a prototypical
target of AhR. Its expression is attenuated
in NAFLD progression295, 296.
Encodes the HOP Homeobox protein,
which lacks DNA binding capabilities. It is a
stem cell marker in intestinal epithelial cells,
and is downregulated by FGF10 (during
differentiation)297. Along with Klf4, it
controls one pathway of specific claudin
(4,7,15) upregulation during colonic
epithelium differentiation (The other is
Tcf7l2/Hnf4a  Cldn23)298
The protein encoded by RAB30, Member
RAS Oncogene Family is one of a family of
small GTPases with roles in intracellular
membrane trafficking. It is necessary for
maintaining Golgi apparatus morphology299.
Rab30 may interact with IKB kinase in the
Golgi.
RAB32, Member RAS Oncogene Family
encodes a small GTPase, involved in
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vesicle trafficking and localized to the
mitochondria and the mitochondrial
associated membrane of the ER. Rab32
anchors the type II regulatory subunit of
protein kinase A to the mitochondrion and
aids in mitochondrial fission. In a mouse
model, Rab32 KO resulted in decreased
lipid accumulation within the liver. Rab 32
affects lipid accumulation via lipolysis by
promoting the transcription of ATGL300.
Lysosomal Trafficking Regulator encodes a
protein which regulates intracellular protein
trafficking in endosomes. Dysfunction in
this gene leads to Chediak-Higashi
Syndrome: a failure of phagocytosis leading
to recurrent pyogenic infections301, 302. It
also is responsible for some cases of
congenital neutropenia301.
Multiple EGF Like Domains 9 encodes a
transmembrane protein with multiple EGFlike repeats303. It is progressively
downregulated in monoclonal gammopathy
of undetermined origin, but not in multiple
myeloma304. It is stimulated by
dexamethasone by a GR-dependent
mechanism, which is blocked by RU-486 in
primary mouse hepatocytes305.
Retinoic Acid Receptor Responder 1 is
overexpressed in CCl4-induced mouse liver
fibrosis and TGF-β-induced rat lung fibrosis,
and appears to be an early marker of
fibrosis in multiple tissues306.
Absent In Melanoma 1 encodes a
betagamma crystalline family protein which
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functions in melanin transport and is one of
the genes responsible for human skin color
variation in several populations as well as
oculocutaneous albinism307-309.
Six-Transmembrane Epithelial Antigen Of
Prostate 4 variants are associated with
metabolic syndrome in several human
populations310-312 Its expression is
regulated by STAT3 and C/EBPα313 and is
synergistically induced by TNFα/IL17314.
Solute Carrier Family 10 Member 2
encodes a bile acid transporter with a role
in cholesterol homeostasis315. Its
expression is regulated by AP-1 and
HNF1α316, 317

Claudin-1, a structural component of
intercellular tight junctions. In kidney cells,
(overexpressed) Cldn1 is downregulated by
EGFR signaling, resulting in an overall
increase in TJ function.

Autophagy-related protein 2 homolog A

lymphocyte cytosolic protein 1
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Salt-inducible kinase 1 (Ser/Thr kinase) is a
member of the AMP-activated protein
kinase family. It inhibits CREB1 function
independently of CREB1 localization,
probably by inhibiting nuclear translocation
of the CREB1 cofactor TORC2
(pSer171).318 The overall effect of Sik1
overexpression on CREB1 is to inhibit
expression of TORC2-dependent (ACTHinduced) CREB1 targets, including
steroidogenic genes (such as Cyp11a and
STAR).319
Cingulin is regulatory protein localizing to
tight junctions (cytoplasmic side) and
regulates RhoA signaling.320 At the apical
cell membrane, microtubule ends are
anchored the tight junction via cingulin, an
interaction which is controlled by AMPK
phosphorylation of cingulin.321, 322
Pim-1 Proto-Oncogene, Serine/Threonine
Kinase phosphorylates a set of targets
involved in cell survival and proliferation. Its
targets partially overlap with those of
mTOR, and suppression of mTOR
increases Pim1 protein levels.323 It is often
overexpressed in hepatocellular carcinoma,
particularly under hypoxic conditions, where
its action promotes tumor growth and
invasion.324 It phosphorylates and stabilizes
Myc325, as well as phosphorylating and
activating the apoptosis stimulating kinase
(ASK1), which phosphorylates MKK4/7 and
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MKK3/6 upstream of JNK/p38.326 Pim1 is
involved in diamond blackfan anemia,
where it binds and phosphorylates RPS19
(the mutated protein) as well as interacting
with ribosomes.327
Glutamate-Cysteine Ligase Catalytic
Subunit forms part of the protein complex
Glutamate-cysteine ligase, the rate-limiting
enzyme of GSH synthesis.328 In a mouse
model, loss of GSH secondary to Gclc KO
causes rapid-onset steatosis and
mitochondrial dysfunction progressing to
liver failure.329
RALBP1 Associated Eps Domain
Containing 1 forms an endocytic complex
with Numb, which has been shown to
regulate the endocytosis and trafficking of
Notch, E-Cadherin, and integrins.330 The
association of Reps1 with Rab11-FIP2 and
alpha-adaptin to regulate the endocytosis
and trafficking of EGFR.331
T-Complex 11 Like 2 encodes a basic
leucine zipper protein.
CD63 is a cell surface protein which acts as
a receptor for TIMP (metallopeptidase
inhibitor). Expression of CD63 is altered in
the liver under high glucose conditions.332
CD63 can be found on the surface of
microsomes released by hepatocytes.333

Encodes Zinc Finger Protein 970
Matrix metalloproteinase 14 is a cell-surface
MMP with activity against ECM
components. It is overexpressed in HCC,
and is associated with worse prognosis.334
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Heparin-binding EGF-like growth factor
binds to and activates both EGFR and
ErbB4, and its overexpression can lead to
pancreatic fibrosis.335 During liver
regeneration in a 1/3 hepatectomy model,
which does not induce upregulation of HBEGF, low levels of exogenous HB-EGF
were required for quiescent hepatocytes to
enter the cell cycle (priming). HB-EGF
expression preceded EGF and TNFa
expression.336
Dual specificity phosphatase 6 encodes a
phosphatase (DUSP6, MKP3 or PYST1)
which acts as a negative regulator of MAPK
signaling. DUSP6 is increased in mouse
DIO models, and interacts with and
dephosphorylates FOXO1, preventing its
nuclear export and promoting induction of
gluconeogenic gene targets (Pepck and
G6pase).337 Dusp6 is upregulated in
cancers with aberrant RTK/Ras/Raf
signaling as a negative feedback inhibitor of
mitogenic processes, but it is
downregulated in pancreatic cancer
because of promoter hypermethylation.338
Activation of ERK downstream of FGF
signaling causes increased Dusp6
expression, and DUSP6 inhibits ERK
signaling through dephosphorylation.339
UDP-glucose ceramide glucosyltransferase
catalyzes the first step of the
glucosylceramide-based GSL-synthesis
pathway.340 Ugcg expression declined in
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individuals with NASH reversal due to
lifestyle (weight-loss) intervention.341
Lymphocyte antigen 96 (MD2) expresses
functional domains that facilitate the
assembly of TLR2/4 and regulate in TLRs
activation. Blocking Ly96 reduced TLR4mediated lung injury after orthotopic
autologous liver transplant in a rat model.342
MD expression is significantly higher with
ethanol feeding (Lieber-De-Carli diet) in a
mouse model of alcohol-induced liver
injury.343
Plekhg3 encodes the protein pleckstrin
homology domain containing, family G (with
RhoGef domain) member 3, which is
regulated by PI3K and acts as a guanine
nucleotide exchange factor for Rac1 and
CD42. Its localization at the leading edge of
migrating fibroblasts and recruitment of
actin (which in turn recruits more
PLEKHG3) forms a positive feedback loop
driving cell polarization and directed
migration.344
Ephrin A1 is a membrane-bound ligand for
the Ephrin receptor tyrosine kinase.
Ephrins bind promiscuously to receptors on
adjacent cells, leading to contact
dependent, bidirectional cell-cell signaling
(Uniquely, both receptors and ligands
transmit signals toward the interior of the
cell).345 In a rat model of HFD-dependent
steatohepatitis, Ephrin A1 was markedly
decreased with HFD vs. control-fed
animals.346 Ephrin A1 antagonizes HGF-
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driven cell protrusions in developing kidney
epithelia through a Raf/MAPK-independent
but RhoA/Raf1-dependent mechanism,
involving inhibition of ROCK (Raf1
competitor).345
Follistatin is a natural antagonist of
members of the TGFβ superfamily, primarily
Activin. In primary human hepatocytes, Fst
transcription is inhibited by adiponectin, but
this effect is impaired with free fatty acid
loading.347
Interleukin 33 is an IL-1 family member
which drives production of Th2 cytokines
(↑IL4, IL5, IL13) and M2 polarization of
macrophages. It is upregulated in both
MCD and HFD mouse models of
steatohepatitis. In these models, exogenous
IL33 ameliorated IR and glucose
intolerance but exacerbated hepatic
fibrosis, and increased transcription of
TGFB and Col1A1. Serum IL33 is
increased in NASH patients and levels are
positively associated with NASH severity.165
Thrombospondin 1 inhibits MMPs,
preventing the release of VEGF. It can also
bind directly to VEGF and mediate its
uptake and clearance. THBS1 is therefore
anti-angiogenic.348 THBS1 binds to
adiponectin in serum.349 Transcription of
Thrombospondin-1 is increased in
individuals with chronic liver disease and in
mouse models of liver fibrosis (CCl4 and
DDC).164
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The gene 5, 10-methenyltetrahydrofolate
synthetase-like encodes a protein which
catalyzes the transformation of 5formyltetrahydrofolate to 5,10methenyltetrahydrofolate.350
Long non-coding RNA, embryonic stem
cells expressed 1, is a known lincRNA.
Family with sequence similarity 109,
member A (IPIPA, Ses1) encode a protein
which binds the 5-phosphatase Inpp5b to
affect receptor recycling from endosomes.
This protein is implicated in the pathology of
Lowe syndrome and Dent disease.351
Fos-like antigen 1 is a modular constituent
of the Activator Protein-1 (AP1) complex.
The inclusion of Fra1 as part of the AP1
(hetero) dimer confers resistance to
acetaminophen toxicity and inhibits PPARγ
expression/lipid synthesis in hepatocytes.352
N-acetyltransferase 8 (GCN5-related) family
member 4, encodes an ER protein
expressed in the liver and kidney. Nat8 is a
catalytic enzyme in the mercapturic
pathway of xenobiotic metabolism,
acetylating the free amino group of cysteine
S-conjugates to form more water-soluble
mercapturic acids, which can be excreted to
bile by MRP-family transporters.353 This
pathway metabolizes PCB epoxides such
as those formed from 2-4’-5trichlorobiphenyl.354
Glucose-6-phosphatase catalytic subunit
localizes to the ER and functions to
catalyze the hydrolysis of D-glucose 6-
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phosphate to D-glucose.355 G6pc
transcription is increased during periods of
fasting by glucagon stimulation and
proceeds via cAMP-pCREB pathway.356
CD14 antigen is a receptor for TLR4343
predominantly expressed in myeloid cells
such as kupffer cells, and is upregulated in
animal models of alcoholic
steatohepatitis357, 358 Individuals with a
polymorphism in the CD14 promoter
leading to increased expression are at
higher risk for NASH.359
Transglutaminase 1, K polypeptide crosslinks proteins in the epidermis during the
formation of the stratum corneum. Its
transcription is induced by TCDD treatment
in cultured skin keratinocytes.360
Chloracne?
Secretory leukocyte peptidase inhibitor – is
a protease inhibitor with antibacterial,
antiviral, and immunomodulatory functions.
It inhibits activation of NFKB by preventing
degradation of its inhibitors and opposes
the transcription of NFKB, IL8 and TNFa by
competing with p65 for binding sites in the
promoters of these genes.361
Although Cd68 is a prototypical M1
macrophage marker, it is also expressed in
other cell types.362
Family With Sequence Similarity 84
Member A is a known target of CAR
(phenobarbital/indirect) activation which is
overexpressed in phenobarbital-promoted
liver tumors363
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Protein Tyrosine Phosphatase, Receptor
Type E suppressed phosphorylation of Akt,
ERK and GSK3 and suppressed. It
modulates insulin signaling, suppressing
insulin-induced glycogen synthesis and
inhibiting insulin-induced suppression of
PEPCK expression in rat primary
hepatocytes.177 An elevated differential
correlation exists between leptin and
PTPRE in a cross-tissue coexpression
study between metabolically unhealthy
obese individuals vs. metabolically healthy
obese individuals. PTPRE shows altered
co-expression with genes that are coming
from white adipose tissue depots (ISL1 and
LEP), suggesting that PTPRE may act as a
link between tissues in obesity related
diseases.364
Vimentin is an intermediate filament protein
associated with epithelial cells. Loss of
Vimentin is associated with EMT. Vimentin
was upregulated by LPS treatment but not
lipid filling.365
Semaphorin 3E is expressed by damaged
hepatocytes and secreted, inducing
contraction of sinusoidal epithelial cells and
activation of stellate cells. Continuous
exposure to (exogenous) Sema3e postCCl4-induced hepatic damage causes
disoriented sinusoidal regeneration and
activates hepatic stellate cells, leading to
fibrosis. 159
A member of the Ras superfamily of GTPbinding proteins. Overexpressed HCC, and
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is associated with invasive and metastatic
character and worse prognosis in HCC.158
An oncogene, its overexpression is antiapoptotic via PI3K/AKT/Bcl-2/Bax axis.158
Rab31 physically interacts with EGFR and
overexpression increases EGFR
endocytosis and trafficking to late
endosomes, while loss of Rab31 inhibits
EGFR endocytosis.169
Known lincRNA

Predicted gene, known lincRNA

Four And A Half LIM Domains 3 interacts
with SMAD proteins to affect transcription of
targets.168
Iodothyronine 5-deiodinase type III,
catalyzes the inactivation of thyroid
hormone to inactive metabolites
Osteopontin, which is induced by the
hedgehog signaling pathway, is implicated
in fibrogenesis during liver repair366.
Notably, Spp1 was not affected by EGFR
activation in kidney cell model with claudin
overexpression367.
A nuclear protein gene which is induced by
pro-inflammatory cytokines in endothelial
cells as part of the immediate early
response.368
Sprouty-related protein with an EVH1
domain. EVE-1 is the isoform expressed in
the liver166. Membrane-associated
substrates of tyrosine kinases, regulated by
phosphorylation. Feeds back to potently
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inhibit Ras/MAPK signaling.369 Spred
proteins are associated with liver disease.
Decreased Spred-1 and -2 are associated
with increased invasiveness/malignant
features in HCC.167 ↑Spred1 is associated
with ↓MMP2 and MMP9.167
Na+-Pi Cotransporter NaPi-IIb, regulated by
glucocorticoid, estrogen, EGF, aging.179
dietary phosphate status, hormones
like parathyroid hormone, 1,25-OH2 vitamin
D3 or FGF23.180 Transport byNaPi-IIb of the
phosphatemimetic arsenate has been
demonstrated, and given its intestinal
localization, this may have relevance for
providing a potential route for arsenate
accumulation. Although the levels of 1,25OH2 vitamin D3 seem unaffected
in PXR−/− mice, these animals have low
serum phosphate
levels associated with reduced intestinal
expression of NaPi-IIb (reference 84 from
180
).
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